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Abstract 
Leptin is an adipocyte-derived hormone that regulates energy balance, 
metabolism, and the neuroendocrine response to altered nutrition. Mice lacking leptin 
(ob/ob) or its receptor (db/db) are massively obese and hyperphagic. They also have 
increased triglyceride deposits in multiple peripheral organs, including the liver, which is 
massively enlarged and steatotic. Leptin elicits a metabolic response that cannot be 
explained by its anorectic effects alone. This response is characterized by weight loss, the 
depletion of lipid from peripheral tissues, and enhanced insulin sensitivity. The 
mechanisms underlying these actions were largely unknown. This thesis addressed 
leptin's metabolic effects on the liver, an organ with a critical role in lipid metabolism 
and glucose homeostasis. 
The relative contribution of central vs. peripheral leptin action on body weight, 
neuroendocrine function, and lipid metabolism had not been tested genetically. To 
address this question, mice with either neuronal (ObRSynIKO) or hepatocyte-specific 
(ObRAlbKO) deletion of the leptin receptor were studied. ObRSynIKO mice were 
massively obese and had neuroendocrine abnormalities resembling those of db/db mice, 
whereas ObRAlbKO mice displayed normal body weight. ObRAlbKO mice had normal 
liver triglyceride levels, while ObRSynIKO mice had enlarged fatty livers, indicating that 
the liver abnormalities of ob/ob and db/db mice are secondary to defective leptin action in 
the brain. 
Microarrays were used to explore the basis for leptin's unique effects on the liver. 
Genes with altered expression in ob/ob liver were identified, and gene expression was 
profiled following a time course of weight loss induced by either leptin treatment or food 
1 
restriction. Cluster analysis demonstrated a unique transcriptional response to leptin, 
distinct from pair-feeding. Based on these findings, an algorithm was developed to 
identify and rank leptin-regulated genes for further functional analysis. The two most 
strongly leptin-regulated genes were stearoyl-CoA desaturase-1 (SCD-1) and insulin-like 
growth factor binding protein-2 (IGFBP-2). SCD-1 was specifically repressed during 
leptin-mediated weight loss, and mice lacking SCD-1 showed markedly reduced 
adiposity on both a lean (abJ/abJ) and ob/ob background (abJ/abJ; ob/ob), despite higher 
food intake. abJ/abJ; ob/ob mice also showed a complete correction of the hypometabolic 
phenotype and hepatic steatosis of ob/ob mice, suggesting that fatty acid oxidation is 
enhanced in the absence of SCD-1. Furthermore, both alcoholic and nonalcoholic fatty 
liver disease secondary to lipodystrophy were markedly attenuated in SCD-1 deficient 
mice. IGFBP-2 was specifically induced during leptin treatment. Double mutant IGFBP-
2~/~;ob/ob mice were partially resistant to leptin, suggesting that IGFBP-2 induction may 
be necessary for the full spectrum of leptin's metabolic effects. 
Thus, central leptin action coordinates a specific transcriptional response in the 
liver, which mediates the metabolic effects of leptin. SCD-1 and IGFBP-2 both have a 
role in leptin-mediated weight loss. Further study of these and other leptin-regulated 
genes may further elucidate the molecular basis for leptin's unique effects on 
metabolism. 
Chapter 1: Introduction 
Obesity as a health problem 
Medical and psychological effects of obesity 
Obesity is an increasingly urgent medical and public health concern. The effects 
of obesity and overweight have now permeated society. The diet industry generates 
billions of dollars of revenue each year, with over 30% of adults in the United States 
reporting that they are attempting to lose weight (Serdula et al. 1999; Friedman 2000a). 
Obesity has been estimated to cost citizens over $70 billion annually in both health care 
costs and lost productivity (Wickelgren 1998). As further evidence of the far-reaching 
effects of obesity, recent news stories have described a class action lawsuit against fast 
food chains by a morbidly obese man (Reaves 2002), an expanding market in oversized 
children's clothing (Erman 2002), and the banning of soda sales by the Los Angeles 
school board in order to combat childhood obesity (Lota 2002). While these stories can 
be viewed with a mixture of pessimism and alarm, an examination of the health 
consequences and incidence of obesity illustrates the staggering scope of this issue. 
Obesity is associated with increased morbidity and mortality due to type 2 
diabetes mellitus, coronary heart disease, cancer, hypertension, osteoarthritis, 
cholelithiasis, and sleep apnea (Kopelman 2000). Actuarial studies have shown that 
mortality and body weight are highly related. When smokers were removed from the 
analysis, lowest mortality was found in those who are slightly underweight, with 
mortality rising in parallel with body weight (Lew 1985). Results from the Nurses Health 
Study of ~115,000 w o m e n s h o w e d a direct relationship between b o d y weight and overall 
mortality, as well as mortality specifically 















_ 4 ~ 4 
CN tor trend -9.02 
P<0.001 
>N' > * ,<*>" >*' > V 
Body-Mass Index 
from cardiovascular disease (Figure 1.1) 
(Manson et al. 1995). In a 26-year follow-
up of over 5000 participants in the 
Framingham Heart Study, obesity, 
independent of other risk factors, was 
Figure 1.1 Relative risk of death vs. body mass index. 
Association between relative risk of death and BMI in women 
found tO be a predictor Of Cardiovascular who never smoked. Relative risk is directly related to BMI 
(Taken from Manson et al.. 1995V 
disease (Hubert et al. 1983). Further analysis of this population found that men with body 
weight even 20% greater than normal showed elevated mortality (Garrison et al. 1983). 
Obesity not only contributes to illness, but also carries with it a painful social 
stigma in modern society. Overweight people are more likely to be thought of as unhappy 
and as possessing negative personality traits (Hiller 1981). Studies have shown that obese 
people are the victims of discriminatory attitudes and behavior in three major facets of 
life: education, employment, and health care (Puhl and Brownell 2001). This 
stigmatization contributes to psychological distress, poor self-esteem, and perhaps 
worsening obesity (Myers and Rosen 1999). 
Defining overweight and obesity 
The most widely used metric for assessing overweight and obesity is body mass 
index (BMI), which is equal to weight in kilograms, divided by the square of height in 
meters. Other measures for defining obesity include waist circumference, skin fold 
thickness, and bioimpedance (Kopelman 2000). BMI is highly correlated with body fat, 
which is in turn, associated with adverse effects of obesity. When analyzing BMI, 
however, a few caveats need to be considered. BMI does not distinguish lean mass from 
fat mass, nor does it describe the distribution of body fat, or take into account differences 
in body proportions. The World Health Organization classifies a BMI from 18.5-24.9 as 
normal and healthy. Individuals with BMI from 25.0-29.9, 30.0-39.9, and >40 are 
respectively classified as overweight, obese, and morbidly obese (Committee 1995; 
Organization 1997). BMI is closely associated with the incidence of type 2 diabetes, 
cholelithiasis, coronary heart disease, and hypertension, showing a linear relationship for 
BMI < 30, but more of an exponential relationship for BMI above 30 (Willett et al. 
1999). Data on women from the Nurses' Health Study and on men from the Health 
Professionals Follow-up Study indicate that individuals with a BMI > 35 have a 20-fold 
increased risk of developing diabetes, relative to individuals with BMI between 18.5 and 
24.9 (Field et al. 2001). 
Rising incidence of obesity 
By any criteria, the incidence of obesity (BMI > 30) and overweight (BMI 25-
29.9) in the United States, other industrialized nations, and even in the developing world 
is increasing rapidly (Taubes 1998). The most recent data indicate that the prevalence of 
overweight and obesity is 34% and 27% respectively in American adults (Yanovski and 
Yanovski 2002). By comparison, according to the National Health and Nutrition 
Examination Surveys (NHANES), only 12.8% of American adults met the criteria for 
obesity in 1962 (Kuczmarski et al. 1994). Certain minority populations are affected at 
much greater levels, with more than 10% of African-American women meeting the cutoff 
for morbid obesity (BMI > 40) (Flegal et al. 1998). Similar, but less severe trends have 
also been observed throughout Europe, where recent estimates cite 15% of men and 22% 
of women as obese (Project 1988). Among Pacific Islanders, rates of obesity are 
markedly higher reaching a prevalence of greater than 60% in certain populations (Hodge 
et al. 1995; Shmulewitz et al. 2001). Rates of obesity have also risen in Japan, Korea, 
China, and Thailand, countries where obesity has not traditionally been a concern 
(Popkin 1994). 
Obesity is not only affecting adults in greater numbers, but is an increasing 
concern in children and adolescents as well. Since 1976, the prevalence of overweight, 
among children and adolescents in the US, has more than doubled (Troiano et al. 1995) 
(Yanovski and Yanovski 2002). This trend has been linked to a rise in the incidence of 
Type 2 diabetes and other sequellae of increased body weight in this age group (Sinha et 
al. 2002). In addition, early infancy, 5-7 years of age, and adolescence are critical periods 
where the presence of obesity markedly increases the risk for obesity in adult life (Dietz 
1994). Thus, obesity not only impacts on health in children, but also predisposes them to 
a lifetime of health problems. 
Causes of obesity 
A consequence of environment or biology? 
In basic terms, obesity, a disorder of energy homeostasis, develops when energy 
intake exceeds energy expenditure. One view, popular among the public, is that obesity is 
the result of a lack of willpower and gluttony, coupled with extreme laziness. In today's 
consumer-driven society, Americans are bombarded with an array of "super sized," high 
calorie fast food. In addition, low fat foods are aggressively, and deceptively marketed as 
a guilt-free alternative that can be consumed without consequences. The amenities of 
modern society have not only led to higher caloric intake, but have also facilitated 
decreased physical activity. Children in the US are spending increasing amounts of 
leisure time watching television or playing video games, activities that have been 
postulated to be partly responsible for the rise in childhood obesity (Robinson 2001). 
Furthermore, low physical activity and reduced energy expenditure have been found to be 
risk factors for weight gain (Ravussin et al. 1988; Rissanen et al. 1991). The above 
information supports an environmental basis for obesity, a hypothesis that has been 
further bolstered by studies of migrant populations. Among Asian Americans, the 
likelihood of overweight and obesity increases with the number of years spent in the US 
(Lauderdale and Rathouz 2000). Obesity is also more prevalent in American born than in 
foreign-born individuals, and increases markedly in second and third generation 
immigrants (Popkin andUdry 1998). 
An alternative theory for the etiology of obesity posits that weight is maintained 
by a precise physiological mechanism. Weight, whether normal or not, tends to remain 
stable in most adult humans and other mammals, implying the existence of a precise 
homeostatic circuit. Most adults gain a small amount of weight over the course of each 
decade, and calculations indicate that this trend requires that food intake and energy 
expenditure match one another within 0.17% over this period (Weigle 1994). 
Furthermore, when food intake is restricted to maintain a 10% reduction in body weight, 
energy expenditure decreases to offset this perturbation (Leibel et al. 1995). The inherent 
stability in body weight led to the 'set point' hypothesis, which proposes that food intake 
and energy expenditure are coordinately regulated to maintain a relatively constant body 
weight (Harris 1990; Friedman and Leibel 1992). This hypothesis suggests the presence 
of afferent signals indicating the level of energy stores, which are sensed and integrated, 
and then transduced into efferent signals controlling appetite and energy expenditure. 
Early physiology experiments indicated that the hypothalamus might be the central 
integrator, where afferent signals are sensed and efferent responses are generated, and 
that adipose tissue might be the source of the afferent signal (Kennedy 1950; Kennedy 
1953). In support of this theory, lesions of the ventromedial hypothalamus lead to 
hyperphagia and obesity, while lesions of the lateral hypothalamus result in increased 
energy expenditure, decreased food intake, and weight loss (Hetherington and Ranson 
1942; Powley and Keesey 1970). 
The above discussion supports the view that body weight is determined by 
environment and behavior, in conjunction with a precise homeostatic loop. Why then has 
this physiological system not countered the rise in body weight associated with the 
sedentary lifestyle and abundance of calories in modern society? According to the "thrifty 
genotype" hypothesis, in ancient hunter-gatherer societies, where food was scarce and 
obtaining nutrients required significant energy expenditure, the ability to efficiently store 
energy in the form of adipose tissue provided an adaptive advantage (Neel 1999). 
Individuals capable of most efficiently storing energy in adipose tissue would be most 
likely to survive frequent periods of food deprivation, and in turn, pass these genes on to 
their offspring. Now, thousands of years later, in an environment where calorically dense 
foods are plentiful and technology has permitted a sedentary existence, the ready storage 
of energy as adipose tissue no longer serves a beneficial purpose, and instead contributes 
to the obesity epidemic. This hypothesis explains the recent rise in obesity and further 
illustrates that this disorder is the result of an intricate connection between genes and 
environment. 
A genetic basis for obesity 
While body weight can be heavily influenced by environment, obesity has a 
definite genetic component. Twin studies, adoption studies, and patterns of familial 
aggregation all support a genetic basis for obesity. An analysis of identical twins either 
reared together or apart, found that the correlation in BMI was only slightly lower in 
twins raised apart, than in those raised together (Stunkard et al. 1990). Furthermore, when 
pairs of identical twins were subjected to periods of positive or negative energy balance, 
the rate and proportion of weight gain, as well as the site of fat deposition, were more 
similar within than between pairs (Bouchard et al. 1990). A large study of more than 
100,000 individuals from either biologic or adoptive relationships found a BMI 
correlation of 0.70 in monozygotic twins and 0.32 in dizygotic twins, which corresponds 
to a heritability of 50-90% (Maes et al. 1997). This heritability coefficient is equivalent to 
that for height and greater than those for many other traits considered to have genetic 
underpinnings (Friedman 2000a). In order to reconcile the disproportionate prevalence of 
overweight and obesity in westernized societies with this convincing genetic data, many 
researchers have proposed that susceptibility to obesity is under genetic control and that 
behavior and environment determine the phenotypic expression of these susceptibility 
genes (Barsh et al. 2000). 
Results 
1 
Obesity can thus be viewed as a Experiments 
complex, polygenic disease in which 
genetic modifiers interact with the 
environment to determine an individual's 
adiposity. However, rare, Mendelian 
single gene disorders giving rise to 
obesity in humans and rodents, have been 
invaluable in elucidating the 
physiological basis for body weight 
regulation. Recessive mutations in the 
mouse genes obese (ob) and diabetes (db) 
lead to an identical syndrome of marked 
nhe<:itv anH Hiahetes rpspmhlina human Figure 1.2 Coleman's parabiosis experiments. These studies 
ooesity ana aiaoetes, resemonng numan suggested that ob encoded a soluble factor and that db 
encoded its receptor (Taken from Coleman, 1978). 
morbid obesity (Coleman 1978). These 
mice weigh approximately three times more than normal littermates, with five times more 
body fat. Parabiosis experiments, in which the circulations of two mice are fused, 
suggested that the ob gene encodes a circulating factor regulating appetite and energy 
expenditure and that db encodes its receptor (Figure 1.2) (Coleman 1978). When the 
circulations of a wild-type and an ob/ob mouse are fused, the ob/ob mouse decreases its 
food intake and loses weight, indicating that a soluble factor exists in wild-type mice, 
which is absent in ob/ob mice (Figure 1.2, bottom panel). This factor also exists in db/db 
mice, as indicated by weight loss in ob/ob mice parabiosed to db/db mice (Figure 1.2 
middle panel). However, db/db mice are clearly resistant to this factor and overproduce it, 
Lean f insulinemia 
\ blood sugar 
Death by starvation 
Diabetes 
T body weight 
* adipose tissue mass 
Obese i body weight 
f adipose tissue mass 
\ insulinemia 
1 blood sugar 
Dealh by starvation 
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T body weight 
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Obese j food intalw 
f insulinemia 
1 blood sugar 
10 
because parabiosis of db/db and lean mice has no effect on db/db mice, but causes death 
by starvation in wild-type animals (Figure 1.2, top panel). 
A molecular basis for energy homeostasis 
Leptin and the regulation of body weight 
Coleman's hypothesis was validated with the positional cloning of the ob gene, 
which was shown to encode an adipose tissue-derived, 16 kilodalton circulating hormone, 
named leptin (Zhang et al. 1994; Friedman and Halaas 1998). Leptin is also expressed at 
lower levels in the placenta, skeletal muscle, and gastric epithelium (Masuzaki et al. 
1997; Bado 1998; Wang 1998). In the ob2j mutant, an Etn transposon is inserted into the 
first intron of the gene, generating hybrid RNAs, where the splice donor of the non-
coding first exon is joined to splice acceptors in the transposon, preventing the synthesis 
of mature RNA (Moon and Friedman 1997). In the more commonly studied oblj mutant, 
a nonsense mutation in the leptin gene leads to translation of a truncated protein that is 
not secreted into the circulation (Zhang et al. 1994). In this mutant, the levels of ob RNA 
are elevated, suggesting that leptin expression is under feedback control. 
The initial data indicated that leptin might be the afferent signal in a negative 
feedback loop regulating adiposity. Leptin is expressed in all adipose depots, and its 
expression is increased roughly 20-fold in mice with hypothalamic lesions or in db/db 
mutants (Maffei et al. 1995a). Plasma leptin levels are increased proportionately to body 
mass in obese mice and humans, and fall in both following weight loss (Maffei et al. 
1995b; Considine et al. 1996). 
11 
These results suggested that leptin 
was an indicator of nutritional excess, with 
high levels of circulating leptin signaling an 
animal to decrease food intake and increase 
energy expenditure. Administration of leptin 
by intraperitoneal injection or subcutaneous 
infusion leads to a dose-dependent decrease 
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Pelleymounter et al. 1995; Stephens et al. 
1995). In both ob/ob and wild-type mice, leptin-induced weight loss is specific to adipose 
tissue, with no affects on lean body mass (Halaas et al. 1995; Pelleymounter et al. 1995). 
Adenovirus-mediated leptin gene therapy also specifically depletes adipose tissue (Chen 
et al. 1996a). Furthermore, leptin treatment improves hyperglycemia, hyperinsulinemia, 
and hypercorticosteronemia in ob/ob mice (Halaas et al. 1995; Pelleymounter et al. 1995; 
Stephens et al. 1995). When wild-type mice are treated with leptin, the reduction in food 
intake only persists until the adipose tissue has been depleted, after which, food intake 
returns to normal, without any weight being regained (Halaas et al. 1997). The signal 
responsible for attenuating leptin's effects in wild-type mice remains unknown. 
An alternate view of leptin's role is as a signal of nutritional deprivation, with low 
leptin levels initiating an adaptive response to conserve energy, manifested by 
hyperphagia, decreased energy expenditure, and shutdown of the reproductive and other 
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endocrine axes, ob/ob mice, which lack circulating leptin, are hyperphagic and 
hypometabolic and exhibit other characteristics of starvation, such as decreased body 
temperature, impaired immune function, and infertility (Coleman 1978). Concurrent 
leptin administration largely corrects fasting induced changes in testosterone, luteinizing 
hormone, thyroxine, corticosterone, ACTH, and estrous (Ahima et al. 1996). Leptin also 
corrects the starvation induced fall in serum growth hormone and can reverse the 
immunosuppressive effects of starvation (LaPaglia et al. 1998; Lord 1998). Leptin 
administration can restore fertility in female ob/ob mice (Chehab et al. 1996). Leptin's 
effects on the reproductive axis are further evidenced by the early onset of puberty in 
leptin treated mice, and the delayed onset of puberty and cessation of ovulation in 
extremely thin, hypoleptinemic women (Ahima et al. 1997; Chehab et al. 1997). In 
addition, leptin injection into the third ventricle of ovariectomzied rats leads to a 
significant increase in plasma luteinizing hormone (Yu et al. 1997). 
The above findings indicate that leptin's role may be to signal nutritional 
deprivation to the endocrine system. However, leptin is also clearly important in 
preventing weight gain in periods of nutrient excess. A broader view holds that leptin 
dynamically regulates appetite, energy expenditure, and neuroendocrine function to 
maintain body weight within a narrow range. 
Leptin signaling 
A high-affinity leptin receptor (Ob-R) was identified from mouse choroid plexus 
by expression cloning (Tartaglia et al. 1995). Ob-R was found to be a membrane 
spanning receptor, related to the cytokine receptor family. Positional cloning of the 
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mouse db gene proved that it encodes Ob-R, which has five alternatively spliced 
isoforms, ObR (a-e) (Figure 1.4a) (Chen et al. 1996b; Chua et al. 1996; Lee et al. 1996). 
Strains of db/db and fa/fa rats have been characterized and found to contain different 
receptor defects (Philips et al. 1996; Lee et al. 1997; Li et al. 1998). C57B1/Ks db/db 
mice contain an insert leading to an alternatively spliced transcript with a premature stop 
codon, preventing the expression of Ob-Rb, 
Ob-Ra Ob-Rb Ob-Rc ObRd Ob-Re while other isoforms remain intact (Figure 
1.4b) (Chen et al. 1996b; Lee et al. 1996). Z] Z] ZJ l] ^ 
These mice have the same phenotype as 
other strains of db/db mice, lacking all Ob-
s — z \ — 3 — - r 
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mutations in rodent models of obesity (a) The structure of 
the five ObR splice variants and (b) the nature of different 
transducing Signals. It Signals through a ObR mutations (Taken from Friedman and Halaas. 1998V 
cytoplasmic tail with consensus Jak-Stat binding motifs and three tyrosine residues that 
are targets for phosphorylation by SH2 domain-containing proteins. Defective Stat 
signaling was observed in cells transfected with the mutant receptor found in db/db mice 
(Ghilardi et al. 1996). The role of the other isoforms is not presently known. Although 
Ob-Ra can mediate signal transduction in vitro, an in vivo activity has not been 
demonstrated (Bjorbaek et al. 1997). Ob-Ra and Ob-Rc are highly expressed in cerebral 
microvessels and have been suggested to be involved in leptin transport into the CNS 
(Banks et al. 1996; Hileman et al. 2002). Ob-Re is a soluble form of the receptor that 
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binds leptin in the plasma and appears to facilitate leptin action (Li et al. 1998; Huang et 
al. 2001). 
Ob-Rb is expressed at high levels in hypothalamic neurons and has also been 
detected in T cells, lymph nodes, vascular endothelium, and the jejunum (Chen et al. 
1996b; Ghilardi et al. 1996; Lee et al. 1996; Lord 1998; Morton et al. 1998; Sierra-
Honigmann et al. 1998). Ob-Rb appears to be expressed, albeit at low levels, in most 
other tissues (Ghilardi et al. 1996). In situ hybridization detected Ob-Rb in the arcuate 
nucleus, dorsomedial hypothalamic nucleus (DMH), paraventricular nucleus (PVN), 
ventromedial hypothalamus (VMH), and the lateral hypothalamus (LH), nuclei known to 
be involved in regulating appetite and body weight (Hetherington and Ranson 1942; 
Mercer et al. 1996b; Elmquist et al. 1997; Fei et al. 1997; Elmquist et al. 1998b). Leptin 
injection leads to a dose-dependent activation of Stat3 specifically in the hypothalamus of 
wild-type and ob/ob, but not db/db mice, detectable 15 minutes after administration 
(Vaisse et al. 1996). Leptin also induces the hypothalamic expression of fos, a Stat3 
target gene (Woods and Stock 1996). Leptin activates phosphatidylinositol-3-OH kinase 
(PI(3)K) in hypothalamic neurons, and intracerebroventricular (i.e.v.) infusion of 
inhibitors of this enzyme blocks leptin-induced anorexia (Niswender et al. 2001). 
A number of molecules are also involved in attenuating leptin signal transduction. 
Leptin receptor signaling requires Jak2 phosphorylation. Leptin binding induces tyrosine 
phosphorylation of SHP-2, a phosphatase that decreases Jak2 phosphorylation, thereby 
blunting leptin signal transduction (Carpenter et al. 1998; Li and Friedman 1998). 
Protein-tyrosine phosphatase PTP1B also dephosphorylates Jak2 and mice lacking 
PTP1B are hypersensitive to leptin, have increased levels of phosphorylated Stat3, and 
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are resistant to obesity (Elchebly et al. 1999; Cheng et al. 2002; Cook and Unger 2002; 
Zabolotny et al. 2002). Ob-R signaling is also negatively regulated by SOCS-3, a member 
of the suppressors-of-cytokine-signaling family of molecules (Bjorbaek et al. 1998). 
The high levels of Ob-Rb expression in the hypothalamus and the leptin resistance 
observed in rats with hypothalamic lesions indicate that leptin has direct effects on the 
brain (Satoh et al. 1997). I.C.V. administration of leptin reduces food intake at a dose that 
has no effect when delivered peripherally (Campfield et al. 1995; Stephens et al. 1995; 
Halaas et al. 1997). Complete depletion of adipose tissue in wild-type mice requires 
chronic i.c.v. infusion of only 3 ng/hr, whereas over 500 ng/hr are required when leptin is 
infused peripherally via a subcutaneous pump (Halaas et al. 1997). In addition, leptin has 
similar metabolic effects, whether delivered centrally or peripherally (Halaas et al. 1997; 
Kamohara et al. 1997). The leptin receptor, however, is broadly expressed and leptin has 
direct effects on some peripheral tissues. Leptin can modulate the immune system, 
angiogenesis, and bone metabolism (Lord 1998; Sierra-Honigmann et al. 1998; Ducy et 
al. 2000). Ob-Rb is expressed in a number of peripheral tissues and direct effects of leptin 
on T cells, macrophages, pancreatic 3-cells, muscle, and other cell types have been 
reported (Shimabukuro et al. 1997a; Lord 1998; Kim et al. 2000; O'Rourke et al. 2001; 
Minokoshi et al. 2002). Thus, the relative importance of leptin action on brain versus 
peripheral sites is untested. 
Neuronal circuitry regulating body weight 
Leptin action in the brain modulates an increasingly complex neuronal circuit, 
which regulates food intake and energy expenditure (Friedman and Halaas 1998; 
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Schwartz et al. 2000). Ob-Rb expressing neurons in the arcuate nucleus receive inputs 
from other hypothalamic nuclei as well as the cortex and amygdala (DeFalco et al. 2001). 
In addition, hypothalamic nuclei expressing Ob-Rb have efferents that interact with the 
cortex, sympathetic and parasympathetic nervous systems, and pituitary. 
The leptin receptor has been detected in a number of hypothalamic nuclei, such as 
the arcuate nucleus, VMH, DMH, and PVN, and these nuclei express neuropeptides 
which modulate food intake (Elmquist et al. 1997; Fei et al. 1997; Elmquist et al. 1998b). 
Key molecules in this neuronal circuit include neuropeptide Y (NPY) and agouti-related 
protein (AGRP), which stimulate food intake, and a-melanocyte stimulating hormone 
(a-MSH) and cocaine- and amphetamine-regulated transcript (CART), which suppress 
food intake. I.C.V. injection of NPY potently stimulates food intake, and NPY mRNA is 
upregulated in ob/ob mice and decreases following leptin treatment (Stanley et al. 1986; 
Stephens et al. 1995). ob/ob mice lacking NPY show an attenuation of obesity with 
decreased food intake and increased energy expenditure (Erickson et al. 1996). a-MSH is 
a cleavage product of the precursor pro-opiomelanocortin (POMC), whose cleavage also 
generates (3- and y-MSH, as well as adrenocorticotropin (ACTH) and (3-endorphin. a-
MSH acts on melanocortin receptors (MC-R), with effects on feeding through the MC-3 
and MC-4 receptors. Agonists of the MC-4 receptor inhibit feeding, while antagonists 
stimulate feeding (Fan et al. 1997). Furthermore, MC-4 receptor knockout mice are obese 
and leptin resistant, as are lethal yellow, agouti (Ay) mice, a mutant strain that ectopically 
expresses the agouti protein in brain, which acts as an MC-4 receptor antagonist (Lu et al. 
1994; Boston et al. 1997; Halaas et al. 1997; Huszar et al. 1997; Marsh et al. 1999). 
AGRP was cloned as an endogenous inhibitor of melanocortin signaling, and ob/ob mice 
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overexpress A G R P m R N A 8-fold (Ollmann et al. 1997; Shutter et al. 1997). In addition, 
transgenic mice overexpressing AGRP are obese (Graham et al. 1997). CART decreases 
food intake, and its expression is nearly undetectable in ob/ob mice, but can be induced 
by leptin (Kristensen et al. 1998). 
Leptin signals are transduced into a neuronal response, the general nature of 
which is beginning to emerge. In the hypothalamus, Ob-Rb is expressed in functionally 
distinct classes of neurons, the best characterized being neurons that co-express either 
NPY or a-MSH (Mercer et al. 1996a; Cheung et al. 1997). The orexigenic molecules 
NPY and AGRP co-localize in arcuate nucleus neurons (Broberger et al. 1998; Hahn et 
al. 1998). Furthermore, POMC and CART, both of which are anorexigenic, co-localize in 
a distinct subset of arcuate nucleus neurons (Elias et al. 1998). NPY/AGRP neurons are 
inhibited by leptin, while POMC/CART neurons are activated by leptin (Stephens et al. 
1995; Schwartz et al. 1997; Thornton et al. 1997; Broberger et al. 1998; Hahn et al. 
1998). These neurons are thought to innervate yet to be described higher order neurons 
coordinating energy homeostasis. 
The above model, however, is undoubtedly just one part of the higher order 
circuitry, as numerous additional molecules also impact feeding behavior. Melanin-
concentrating hormone, galanin, orexin, peptide YY, and noradrenaline all increase food 
intake, while cholecystokinin (CCK), corticotropin-releasing hormone (CRH), insulin, 
glucagon-like peptide-1 (GLP-1), bombesin, urocortin, and serotonin all decrease food 
intake (Friedman and Halaas 1998). 
18 
Efferent pathways modulated by leptin 
Early physiological studies demonstrated that lesions of the ventromedial 
hypothalamus lead to hyperphagia and obesity (Hetherington and Ranson 1942; Elmquist 
et al. 1999). When food intake in lesioned animals is restricted to the same levels as in 
controls, however, obesity still develops (Himms-Hagen 1989). Increased storage of 
calories in the setting of normal food intake, indicates that these animals have reduced 
energy expenditure. Thus, the brain serves a critical function in the coordination of 
energy homeostasis. The role of leptin in this process is confirmed by decreased energy 
expenditure in ob/ob mice (Boissonneault et al. 1978; Dauncey and Brown 1987). 
Therefore, the leptin modulated neuronal circuit, through still undescribed higher order 
neurons, is thought to regulate energy homeostasis. 
Energy expenditure can be divided into three main components: obligate energy 
expenditure required for basic cellular function, physical activity, and adaptive 
thermogeneis (Lowell and Spiegelman 2000). Adaptive or facultative thermogenesis, is 
defined as heat production in response to environmental temperature or diet. Energy 
expenditure is generally measured by oxygen consumption, which can then be used to 
caculate metabolic rate. Oxygen consumption or metabolic rate increases acutely 
following feeding, as well as after chronic overfeeding (Shibata and Bukowiecki 1987; 
Sims and Danforth 1987; Levine et al. 1999). Food restriction, on the other hand is 
associated with a decrease in metabolic rate (Leibel et al. 1995). These alterations, though 
counter-productive during dieting, serve to maintain weight within a narrow range. 
Leptin has clear effects on energy expenditure and is thought to exercise its 
effects, in part, through the autonomic nervous system. Treatment with ^-adrenergic 
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receptor agonists causes lipolysis and an increase in energy expenditure (Galton and Bray 
1967; Davies 1968; Landsberg et al. 1984). Brown adipose tissue and skeletal muscle 
play a major role in adaptive thermogenesis, and these tissues are highly innervated by 
the sympathetic nervous system. Decreased sympathetic output has been proposed to be 
responsible for the development of obesity (Bray and York 1998). Sympathetic outflow 
to brown adipose tissue is decreased in ob/ob mice (Young and Landsberg 1983). Leptin 
increases norepinephrine turnover in brown fat (Collins et al. 1996). The leptin-
dependent rise in sympathetic activity to brown adipose tissue increases the expression of 
the uncoupling protein, UCP1 (Scarpace et al. 1997; Scarpace and Matheny 1998). 
Uncoupling proteins disrupt the mitochondrial proton gradient causing energy to be 
dissipated in the form of heat, rather than channeled into the formation of ATP. The 
importance of brown adipose tissue to body weight homeostasis is indicated by the 
development of obesity in mice with genetic ablation of brown fat (Lowell et al. 1993). 
UCP1 knockout mice, however, are not obese, perhaps due to compensation by other 
UCP isoforms (Enerback et al. 1886). Ectopic overexpression of UCP1 in white adipose 
tissue, on the other hand, protects mice from obesity (Kopecky et al. 1995). While UCP1 
is expressed specifically in brown adipose tissue, UCP2 is expressed in most tissues, and 
UCP3 is expressed in muscle and brown adipose tissue (Boss et al. 1997; Fleury et al. 
1997; Gimeno et al. 1997; Gong et al. 1997; Vidal-Puig et al. 1997). 
Measurement of nerve activity following leptin treatment demonstrates dose-
dependent increases in sympathetic output to brown adipose tissue, kidney, hindlimb, and 
the adrenal gland in wild-type, but not in obese Zucker rats, which have a mutation in the 
leptin receptor (Haynes et al. 1997). Sympathetic output acts on P-adrenergic receptors, 
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of which there are three well characterized types, (31, |32, and 03. Activation of these 
receptors leads to intracellular activation of protein kinase A (PKA) and cyclic AMP 
(cAMP), and these molecules are involved in energy homeostasis (McKnight et al. 1998). 
Disruption of RII(3, one of the regulatory subunits of PKA, leads to an increase in free 
catalytic units of PKA, with greater avididity for cAMP. Despite normal food intake, 
these mice are lean, and show decreased triglyceride storage in white adipose tissue, 
elevated metabolic rate, and resistance to dietary obesity (Cummings et al. 1996). The 
P3-adrenergic receptor has been proposed to play a particularly important role in energy 
expenditure and body weight homeostasis, as its stimulation decreases adiposity and 
leptin expression (Collins and Surwit 1995; Mantzoros et al. 1996). The selective p3-
adrenergic agonist CL316243 is effective at treating obesity and diabetes in rodents (Sum 
et al. 1999). In addition, a knockout of the P3-adrenergic receptor leads to a mild increase 
in adiposity (Susulic et al. 1995). Confirmation of the importance of P-adrenergic 
receptors, as opposed to an unknown target, in the regulation of body weight was 
difficult, however, due to functional redundancy of the different receptor types. Triple 
mutant mice lacking all three P-adrenergic receptors have recently been generated and 
demonstrate reduced metabolic rate and massive obesity on a high-fat diet, indicating that 
these receptors are required for diet-induced thermogenesis (Bachman et al. 2002) 
Leptin also modulates energy expenditure through effects on the hypothalamic-
pituitary axis. Leptin regulates many aspects of hypothalamic-pituitary function, some of 
which are involved in energy homeostasis (Yu et al. 1997). Thyroid hormone modulates 
energy expenditure, with low levels associated with decreased metabolic rate and high 
levels associated with increased metabolic rate (al-Adsani et al. 1997). Leptin 
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administration can prevent fasting-induced suppression in thyroid hormone levels, by 
blunting the suppression in prothyrotropin releasing hormone RNA levels in the 
hypothalamic PVN (Ahima et al. 1996; Legradi et al. 1997). Elevated glucocorticoid 
levels, as in Cushing's syndrome, are associated with increased fat deposition. In fact, 
transgenic mice overexpressing lip hydroxysteroid dehydrogenase type 1 (lip HSD-1) 
have increased adipose tissue levels of corticosterone and develop visceral obesity and 
features of the metabolic syndrome (Masuzaki et al. 2001). Glucocorticoid levels are 
elevated in ob/ob and db/db mice, and obesity in these animals is improved by 
adrenalectomy or treatment with glucocorticoid antagonists (Naeser 1973; Freedman et 
al. 1986). Elevated glucocorticoid levels are unique to ob/ob and db/db mice, whereas 
other forms of rodent obesity are not associated with elevated corticosterone (Bray and 
York 1979). As further evidence for the role of leptin in modulating corticosterone levels, 
fatless A-ZIP/F-1 lipoatrophic mice, which are deficient in circulating leptin, also have 
hypercorticosteronemia (Haluzik et al. 2002). Leptin has been shown to lower 
glucocorticoids both by direct action on the adrenals and via the hypothalamic PVN 
(Bornstein et al. 1997; Huang et al. 1998; Cherradi et al. 2001). 
The growth hormone (GH) axis is also perturbed in obesity (Scacchi et al. 1999). 
In humans, plasma GH is inversely related to measures of adiposity, and in humans and 
rodents, obesity is also associated with reduced plasma insulin-like growth factor I (IGF-
I), which is downstream of GH (Rudman et al. 1981) (Copeland et al. 1990; Zhou et al. 
1998a). In obese Zucker rats, GH levels and pulsatility are severely decreased, due to 
decreased hypothalamic growth-hormone releasing factor (GRF) and an impaired 
pituitary response to GRF (Finkelstein et al. 1986; Tannenbaum et al. 1990). Transgenic 
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rats expressing a low level of human G H show suppression of endogenous G H secretion 
and pulsatility and develop massive obesity and insulin resistance (Ikeda et al. 1997). 
Double-labeling immunohistochemistry detected ObR in some hypothalamic neurons 
containing GH-releasing hormone (GHRH) (Hakansson et al. 1998). Administration of a 
leptin antiserum to rats leads to decreased GH secretion, suggesting that leptin, may, in 
part, regulate GH secretion (Carro et al. 1997). Furthermore, central leptin infusion 
stimulates spontaneous pulsatile GH secretion, as well as secretion in response to GHRH 
(Tannenbaum et al. 1998). 
Metabolic effects of leptin 
Differential actions of leptin and food restriction 
Leptin regulates energy expenditure by exerting specific and unique metabolic 
effects. These effects are likely due to modulation of sympathetic outflow and 
neuroendocrine activity, as well as direct actions of leptin on peripheral tissues. Rodents 
deficient in leptin (ob/ob) or resistant to its action (db/db, fa/fa) are markedly 
hyperphagic and morbidly obese. However, the effects of leptin deficiency are not purely 
the result of increased caloric intake, as food restricted ob/ob mice still develop obesity 
(Coleman 1978). Replacement of leptin in ob/ob mice leads to the specific depletion of 
fat mass, whereas food restriction depletes both fat and lean mass (Halaas et al. 1995; 
Pelleymounter et al. 1995; Halaas et al. 1997). ob/ob mice that have been food restricted 
to the level that leptin treated mice voluntarily consume (pair-fed) show smaller 
decreases in body weight and size of adipose depots (Levin et al. 1996). In addition, food 
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restriction is associated with a compensatory decrease in energy expenditure, which does 
not occur in response to leptin-induced hypophagia (Halaas et al. 1997). Finally, whereas 
food restriction leads to a rise in serum free fatty acids, leptin-mediated weight loss is not 
associated with a rise in free fatty acids or ketones, suggesting a unique mechanism of 
fatty acid oxidation (Chen et al. 1996a; Shimabukuro et al. 1997a). Taken together, these 
data confirm that leptin's effects on body weight are not due to its anorectic effects alone, 
but must also require actions on peripheral metabolism. 
Effects on lipid metabolism 
In the absence of effective leptin action, triglyceride not only accumulates in 
adipose tissue, but also in other peripheral sites such as liver, skeletal muscle, heart, and 
pancreatic islets. One dramatic manifestation can be seen in ob/ob liver, which is 
massively enlarged and steatotic, with numerous lipid-filled vacuoles apparent on 
histological examination (Figure 1.5). This build-up of lipid in non-adipose tissues causes 
lipotoxicity, which contributes to insulin resistance and organ dysfunction in the obese 
state (Unger 2002). Increased intracellular lipid in insulin-responsive tissues is 
increasingly appreciated as being critical to the development of insulin-resistance and 
diabetes (McGarry 1992; Shulman 2000). In addition, lipid accumulation in islets is 
involved in islet hypoplasia and destruction in advanced diabetes, via increased synthesis 
of the apoptotic mediators nitric oxide and ceramide, and reduced levels of Bcl-2, an 
inhibitor of apoptosis (Lee et al. 1994; Shimabukuro et al. 1997b; Shimabukuro et al. 
1998a; Shimabukuro et al. 1998b; Shimabukuro et al. 1998c). 
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Figure 1.5 Hepatomegaly and fatty liver in ob/ob mice. (A) Photographs of freshly 
dissected livers, wild-type on left and ob/ob on right. The ob/ob liver is 3-4x larger 
and has a shiny appearance, consistent with lipid accumulation. (B) Hematoxylin and 
eosin stained liver sections demonstrate vacuolation throughout ob/ob liver, suggestive 
of lipid accumulation and fatty liver disease. 
Given the deleterious consequences of lipid accumulation in peripheral tissues, 
evidence suggests a role for leptin in the control of lipid homeostasis in nonadipose 
tissues (Unger 2002). When caloric intake exceeds energy expenditure, leptin levels rise 
to prevent deposition of lipid in peripheral sites. In states of leptin deficiency or leptin 
resistance, however, this action is defective and lipotoxic disease develops. In support of 
this hypothesis, leptin treatment, significantly more so than pair-feeding, rapidly reduces 
lipid in non-adipose sites by decreasing triglyceride formation and increasing free fatty 
acid oxidation (Shimabukuro et al. 1997a). Islets isolated from hyperleptinemic rats, as 
compared to islets isolated from pair-fed or untreated rats, show a markedly increased 
ratio of fatty acid oxidation to esterification (Zhou et al. 1997). Relative to control and 
pair-fed samples, these islets demonstrate increased expression of acyl CoA oxidase 
(ACO) and carnitine palmitoyltransferase-I (CPT-I), enzymes involved in fatty acid 
oxidation, as well as increased expression of UCP-2. In addition, islets from both leptin 
treated and pair-fed rats show a comparable reduction in the expression of acetyl-CoA 
carboxylase (ACC) and glycerol-3-phospate acyltransferase (GPAT), enzymes involved 
in fatty acid biosynthesis and esterification (Zhou et al. 1997). Adipose tissue 
demonstrates a similar pattern of gene expression in hyperleptinemic animals, along with 
loss of expression of the adipocyte markers fatty acid binding protein-2 (aP2), tumor 
necrosis factor a, and leptin, and appearance of the preadipocyte marker Pref-1 (Zhou et 
al. 1999). 
The biochemical pathways mediating leptin's effects on fatty acid oxidation are 
beginning to be elucidated. The nuclear hormone receptor PPARa, which regulates many 
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of the enzymes of fatty acid oxidation, has been proposed to coordinate this 
transcriptional program (Aoyama et al. 1998). Hyperleptinemia in wild-type, but not fa/fa 
rats, induces the expression of PPARa, ACO, and CPT-I in peripheral tissues, genes 
which likely mediate the effects of leptin (Zhou et al. 1998b; Zhou et al. 1999). 
Administration of leptin to PPARa knockout mice leads to a smaller reduction in adipose 
depots and a smaller depletion in liver triglyceride, confirming that this pathway is 
required for the lipopenic effects of leptin (Lee et al. 2002). In muscle, leptin has been 
found to stimulate fatty acid oxidation, both directly and secondary to signaling in the 
brain. These actions are mediated through activation of a2 AMP-kinase, which 
phosphorylates and inhibits acetyl-CoA carboxylase (ACC) (Minokoshi et al. 2002). 
Inhibition of ACC leads to reduced levels of malonyl CoA, which is required for fatty 
acid biosynthesis and also inhibits the mitochondrial carnityl palmityl transferase system, 
the rate-limiting step in the import and oxidation of fatty acids in mitochondria (McGarry 
et al. 1977). Thus, malonyl CoA is considered to be a crucial metabolic control point, 
with reduced levels leading to decreased fatty acid biosynthesis and increased fatty acid 
oxidation (Ruderman et al. 1999). This mechanism also accounts for the lean phenotype 
and increased fatty acid oxidation in mice lacking acetyl-CoA carboxylase 2 (Abu-
Elheiga et al. 2001). However, activation of a2 AMP-kinase is not associated with 
increased leptin-mediated fatty acid oxidation in all tissues. While leptin stimulates fatty 
acid oxidation in liver and heart, a2 AMP-kinase is not activated, suggesting that 
alternative mechanisms can also explain leptin's lipopenic actions (Atkinson et al. 2002; 
Lee et al. 2002). 
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Leptin's effects on lipid metabolism are not solely the consequence of enhanced 
fatty acid oxidation, but are also due to decreased lipogenesis. ob/ob and db/db mice have 
enlarged steatotic livers (Yen et al. 1976; Koteish and Diehl 2001). The fatty liver is, in 
part, the result of an increased rate of hepatic lipogenesis, which is also thought to 
contribute to the development of obesity (Kaplan and Leveille 1981). Leptin treatment 
normalizes the hepatomegaly and associated elevations in hepatic lipid (Levin et al. 
1996). Analysis of ob/ob livers by 13C NMR after five days of leptin treatment reveals 
decreased de novo fatty acid synthesis, which is supported by biochemical assays 
showing decreased ACC and fatty acid synthase (FAS) activity (Cohen et al. 1998). 
Thus, by modulating gene expression and the pathways of fatty acid biosynthesis and 
oxidation, leptin confines storage of triglycerides to adipose tissue and prevents lipotoxic 
disease during states of overnutrition. 
More recently, leptin's metabolic effects have been shown to be important in 
lipodystrophies, a rare set of diseases characterized by complete or near-complete loss of 
adipose tissue (Garg 2000; Reitman et al. 2000). In the absence of adipose tissue, 
ingested nutrients are deposited as triglycerides in liver, muscle, and other peripheral 
tissues leading to severe insulin resistance and diabetes. Transgenic overexpression in 
white adipose tissue of either nuclear sterol regulatory element-binding protein-lc (aP2-
SREBP-Ic tg) or a dominant negative protein preventing the binding of certain bZIP 
transcription factors (A-ZIP) produces mice with a near complete absence of adipose 
tissue, along with marked hepatic steatosis, insulin resistance, and hyperglycemia (Moitra 
et al. 1998; Shimomura et al. 1998a). In the near-absence of adipose tissue, circulating 
levels of leptin and other adipose-derived factors are extremely low, and a deficiency in 
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one or more of these factors has been hypothesized to be responsible for disease. 
Treatment of aP2-SREBP-lc tg lipodystrophic mice with physiological doses of leptin 
for 12 days led to a complete normalization of hepatic steatosis and glucose and insulin 
levels, while pair-feeding had much more modest effects (Shimomura et al. 1999c). 
Originally, treatment of A-ZIP mice (which have a more severe phenotype) with leptin 
produced more modest effects on the diabetic phenotype (Gavrilova et al. 2000b). 
However, later studies showed that supraphysiological levels of leptin can correct the 
phenotype in these mice (Ebihara et al. 2001). In addition, surgical implantation of fat 
from wild-type mice, but not from ob/ob mice, can fully rescue the phenotype of A-ZIP 
mice (Gavrilova et al. 2000a; Colombo et al. 2002). While these findings do not rule out 
a role for other adipose factors, leptin clearly plays a crucial role in depleting peripheral 
triglyceride and correcting diabetes in these mice. Based on these findings, a leptin trial 
was initiated in lipodystrophic humans, resulting in marked reductions in appetite, 
hepatic steatosis, muscle triglyceride, diabetes, and hypertriglyceridemia (Oral et al. 
2002; Petersen et al. 2002). As lipodystrophy is a side effect of antiretroviral therapy for 
HIV, leptin therapy may become useful for this growing population of patients (Estrada 
et al. 2002). 
Effects on carbohydrate metabolism 
Leptin also has well-documented effects on glucose metabolism, ob/ob and db/db 
mice are hyperglycemic and hyperinsulinemic, with marked insulin resistance. The 
hyperglycemia and hyperinsulinemia of ob/ob mice are corrected with leptin 
administration, and leptin treatment leads to a greater reduction in glucose, insulin, and 
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hepatic glycogen than pair-feeding (Pelleymounter et al. 1995; Levin et al. 1996). 
Obesity is associated with hyperinsulinemia, which is the body's attempt to compensate 
for worsening insulin resistance. After a certain threshold, the capacity of the pancreatic 
islets is exceeded, at which point, hyperinsulinemia fails to compensate for insulin 
resistance, and hyperglycemia and diabetes become fully evident. Thus, the modulation 
of glucose metabolism by leptin is influenced by a complex interplay between obesity, 
leptin, and insulin. Leptin receptors are expressed in pancreatic P cells and treatment of 
islets inhibits insulin secretion by activating ATP-sensitive potassium channels (Kieffer 
et al. 1996; Harvey et al. 1997; Kieffer et al. 1997). As well as inhibiting insulin 
secretion, leptin counters hyperinsulinemia by decreasing the expression of preproinsulin 
mRNA in ob/ob islets (Seufert et al. 1999a). Leptin has similar effects on insulin 
secretion and gene expression in islets from human donors (Seufert et al. 1999b). As 
insulin, in turn, increases the expression of leptin mRNA, the existence of an adipoinsular 
axis has been proposed, where insulin stimulates leptin production, and leptin, in turn, 
inhibits insulin production (Saladin et al. 1995). Therefore, leptin's effects on glucose 
metabolism may, in large part, be mediated via its interactions with insulin. 
A number of studies, however, point to a more specific role for leptin in 
carbohydrate metabolism. When streptozotocin-induced, insulin-deficient diabetic rats 
were treated with leptin for 12-14 days and studied with a hyperinsulinemic-euglycemic 
clamp, leptin, independent of its effects on food intake, restored euglycemia and 
peripheral insulin sensitivity, and improved post-absorptive glucose metabolism 
(Chinookoswong et al. 1999). Transgenic overexpression of high levels of leptin leads to 
a complete disappearance of white fat and increased glucose metabolism and insulin 
30 
sensitivity (Ogawa et al. 1999). These mice are strikingly different from lipoatrophic 
mice, which also have no fat, but instead develop steatosis and severe diabetes (Moitra et 
al. 1998; Shimomura et al. 1998a). 
Acute treatment with leptin, either as a five hour intravenous or i.c.v infusion, or 
even as a single microinjection into the ventromedial hypothalamus, similarly increased 
glucose uptake and turnover in skeletal muscle and brown adipose tissue. Leptin 
stimulated glucose uptake was diminished in denervated muscle, pointing to centrally 
orchestrated sympathetic output as a mediator of these effects (Kamohara et al. 1997; 
Minokoshi et al. 1999). The increased glucose turnover and uptake occurred in the setting 
of decreasing hepatic glycogen and constant plasma insulin and glucose, suggesting that 
leptin acutely increases hepatic gluconeogenesis from glycogen to compensate for 
enhanced glucose turnover (Kamohara et al. 1997). An acute intravenous infusion of 
leptin in ob/ob mice also increased glucose uptake and turnover in brown adipose, heart, 
and brain, but not in white adipose or skeletal muscle. This protocol did not influence 
hepatic lipid metabolism, but did stimulate hepatic glucose production, and was 
associated with increased activity of glucose-6-phosphatase (G6Pase) and decreased 
activity of phosphoenolpuruvate carboxykinase (PEPCK) (Burcelin et al. 1999). 
An acute leptin infusion in lean rats clamped at physiological hyperinsulinemia, 
however, found no difference in glucose uptake and glycogen synthesis between leptin 
treated and control animals. In this study, leptin enhanced insulin suppression of hepatic 
glucose production and redistributed intrahepatic glucose fluxes such that the 
contribution from glycogenolysis was reduced and that from gluconeogenesis was 
enhanced, changes marked by decreased levels of glucokinase RNA and increased levels 
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of P E P C K R N A (Rossetti et al. 1997). This group reported the same findings with i.c.v. 
leptin, again indicating that leptin's effects on glucose metabolism are centrally mediated 
(Liu et al. 1998). A subsequent insulin clamp study compared the effects of 8 days of 
leptin and pair-feeding on glucose metabolism and showed that leptin enhanced insulin-
mediated inhibition of hepatic glucose production with a similar repartitioning of glucose 
fluxes, while also increasing insulin stimulated peripheral glucose uptake. Relative to 
food restriction, chronic administration of leptin also decreased expression of glucokinase 
and increased expression of G6Pase and PEPCK (Barzilai et al. 1997). While the insulin 
clamp experiments suggest that leptin mainly augments insulin action, the shift in glucose 
fluxes and the changes in gene expression in a direction counter to that induced by insulin 
alone, indicate that leptin has novel effects on glucose metabolism, independent of 
insulin. 13C NMR studies demonstrated that five days of leptin treatment in ob/ob mice 
increases hepatic gluconeogenesis and also increases the rate of hepatic glycogen 
synthesis, in part by increasing the activity of glycogen synthase (Cohen et al. 1998). 
Discrepancies exist in these studies, which may be due to the use of different assay 
techniques and rodent species, or due to different effects of leptin in lean and insulin-
resistant obese animals or following acute versus chronic administration 
Other mediators of energy homeostasis 
While leptin is critical in the regulation of energy homeostasis, a number of other 
circulating factors also act in endocrine pathways involved in energy metabolism. Insulin, 
which is secreted by pancreatic P cells, acts peripherally, as an anabolic hormone, 
stimulating glucose uptake and lipogenesis. However, insulin also crosses the blood-brain 
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barrier, and insulin receptors are expressed in brain regions involved in feeding (Baskin 
et al. 1988; Baura et al. 1993). High insulin levels reduce food intake and body weight, 
while low levels stimulate food intake (Woods et al. 1979; Sipols et al. 1995). Mice with 
a neuronal-specific knockout of the insulin receptor are hyperphagic and develop diet-
induced obesity (Bruning et al. 2000). Similarly, rats with decreased levels of 
hypothalamic insulin receptors are hyperphagic and insulin resistant (Obici et al. 2002). 
The recently identified hormone ghrelin, is synthesized by the stomach and the 
hypothalamus, and acts as a ligand for the growth hormone secretagogue receptor (GHS-
R) (Kojima et al. 1999). Ghrelin not only induces growth hormone secretion, but also 
stimulates food intake, with peripheral or central administration causing weight gain due 
to hyperphagia and reduced utilization of fat (Tschop et al. 2000; Wren et al. 2000; 
Nakazato et al. 2001; Wren et al. 2001). Interestingly, plasma ghrelin levels rise after 
dieting, but remain low following gastric bypass surgery, explaining the vastly different 
success rates of these two weight loss treatments (Cummings et al. 2002). 
A number of adipose-derived factors, in addition to leptin, have peripheral 
metabolic effects, challenging the traditional view of adipose tissue as a passive 
repository of triglyceride (Trayhurn and Beattie 2001). Levels of TNFa, a factor 
mediating cachexia, are increased in different rodent models of obesity, and 
neutralization of TNFa increases peripheral glucose uptake in response to insulin (Oliff 
et al. 1987; Hotamisligil et al. 1993). TNFa causes insulin resistance by inducing serine 
phosphorylation of insulin receptor substrate 1 (IRS-1), converting IRS-1 into an 
inhibitor of insulin receptor tyrosine kinase activity (Hotamisligil et al. 1996). This 
inhibitory form of IRS-1, which can attenuate signaling through the insulin receptor, was 
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observed in muscle and adipose tissue from obese fa/fa rats (Hotamisligil et al. 1996). 
Deletion of the TNFa gene or the two genes encoding its receptor improved insulin 
sensitivity in lean mice, diet-induced obese mice, gold-thioglucose injected mice, and 
ob/ob mice, further supporting the pivotal role of TNFa in obesity-associated insulin 
resistance (Uysal et al. 1997; Ventre et al. 1997). Others, however, have found that rather 
than contributing to insulin resistance, TNF receptors protect against obesity-related 
diabetes (Schreyer et al. 1998). 
Other factors include resistin, which is secreted from adipose tissue and circulates 
at increased levels in models of dietary and genetic obesity (Kim et al. 2001; Steppan et 
al. 2001). Treatment of mice with resistin leads to impaired glucose tolerance and insulin 
action, while administration of anti-resistin antibodies improves hyperglycemia and 
insulin resistance in diet-induced obese mice (Steppan et al. 2001). The specific 
physiological role of resistin, however, awaits the identification of its site of action and 
the generation of a knockout mouse. Acrp30 (adipocyte complement related protein of 
30kDa or adiponectin) is an abundant serum protein that can form large oligomers 
(Scherer et al. 1995). Treatment of mice with a proteolytic cleavage product of Acrp30 
induces fatty acid oxidation and weight loss (Fruebis et al. 2001). In addition, Acrp30 
inhibits hepatic glucose production, augments hepatic insulin action, and reverses insulin 
resistance due to lipoatrophy and obesity (Berg et al. 2001; Combs et al. 2001; Yamauchi 
et al. 2001). Obese type 2 diabetics have low adiponectin levels and adiponectin 
mutations have been associated with diabetes (Weyer et al. 2001; Kondo et al. 2002). 
Two separate groups have generated adiponectin null mice, and in one study, but not in 
the other, adiponectin deficiency leads to diet-induced insulin resistance (Ma et al. 2002; 
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Maeda et al. 2002). Thus, the precise function of Acrp30 remains to be elucidated. Other 
adipose-derived factors including angiotensinogen, adipsin, acylation-stimulating protein, 
haptoglobin, retinol-binding protein, interleukin 6, plasminogen activator inhibitor-1 and 
tissue factor also play important, but less well-defined roles in inflammation, metabolism, 
and energy homeostasis (Trayhurn and Beattie 2001). 
In addition to adipose tissue, other peripheral tissues such as liver, muscle, and 
pancreas may also secrete factors that modulate peripheral metabolism. Myostatin is 
secreted from skeletal muscle and negatively regulates muscle mass, as mice and cattle 
lacking myostatin display muscle hypertrophy and hyperplasia (Grobet et al. 1997; 
McPherron et al. 1997; McPherron and Lee 1997). In addition, myostatin null mice have 
reduced adiposity, in the setting of normal food intake, and double mutant ob/ob or Ay 
mice also lacking myostatin show a partial correction of obesity and diabetes (McPherron 
and Lee 2002). Systemic overexpression of myostatin, on the other hand, induces muscle 
and fat wasting, resembling cachexia (Zimmers et al. 2002). 
Leptin and body weight homeostasis in humans 
Human obesity mutations 
The scarcity of identified human mutations in the leptin circuit supports the 
premise that obesity is the result of a complex constellation of genetic and environmental 
factors, many of which have yet to be elucidated. While a number of genetic studies have 
identified linkages to loci contributing to obesity in humans, monogenic forms of obesity 
are rare (Barsh et al. 2000). However, study of these mutations illustrates a remarkable 
similarity to the homologous mouse mutants. Mutations in the human ob gene are thought 
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to be rare, as numerous studies in obese subjects have failed to detect any mutations 
(Maffei et al. 1996; Barsh et al. 2000). Thus far, two kindreds with homozygous loss-of-
function leptin mutations have been identified, displaying hyperphagia, morbid obesity, 
and hypogonadotropic hypogonadism (Montague et al. 1997; Strobel et al. 1998). One 
family has been identified with a mutation producing a truncated leptin receptor, and 
these patients have a similar phenotype to individuals lacking leptin, with the additional 
presence of growth retardation and central hypothyroidism (Clement et al. 1998). Unlike 
rodents with mutations in leptin or its receptor, cold intolerance, severe diabetes, and 
increased glucocorticoid production have not been reported in human mutants. Two 
children with a phenotype of obesity, adrenal insufficiency, and hypopigmentation have 
also been identified and shown to have loss-of-function POMC mutations (Krude et al. 
1998). Obese humans with dominant mutations in the MC-4 receptor have also been 
described, and this is the most commonly mutated gene in human obesity, with 3-5% of 
humans with BMI > 40 estimated to have mutations in this gene (Vaisse et al. 1998; Yeo 
et al. 1998; Hinney et al. 1999). 
The identification of humans with loss-of-function mutations in leptin or POMC 
suggests that hormone replacement therapy might be an effective treatment. One of the 
leptin-deficient probands has been treated with leptin for over a year with daily 
subcutaneous injections, with a notable decrease in body weight and appetite, along with 
pubertal progression (Farooqi et al. 1999). The successful use of leptin therapy in these 
children indicates that leptin is capable of enacting the same physiological response in 
humans as in mice. 
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Leptin and the pathogenesis of obesity 
Although specific mutations in the leptin loop are rare in humans, both obesity 
and other eating disorders are associated with perturbations in circulating leptin. 
Modulation of circulating leptin levels, in a manner that would have been adaptive in 
prehistoric times where nutrients were scarce, is now maladaptive and contributes to the 
high failure rate of dieting. Weight loss in overweight individuals is associated with a 
decrease in leptin levels, which consequently stimulates appetite and reduces energy 
expenditure, tending to restore body weight to its original value (Leibel et al. 1995; 
Maffei et al. 1995b; Considine et al. 1996). Low dose leptin administration during dieting 
can prevent these effects associated with falling leptin, and may help dieters maintain 
reduced body weight (Rosenbaum et al. 2002). Alterations in circulating leptin levels are 
also involved in the pathogenesis of anorexia nervosa. These patients have very low 
leptin levels, and the rapid rise in leptin following refeeding may play a role in this 
disorder by diminishing appetite before normal weight is reached (Casanueva et al. 1997; 
Mantzoros et al. 1997). 
Human obesity, though largely polygenic, is stll characterized by altered leptin 
physiology and can be broadly categorized as resulting from either inappropriately low 
leptin levels or leptin resistance. These two possibilities can be distinguished by 
measurement of plasma leptin. With the exception of ob/ob mice and rare human cases, 
leptin levels are high in most rodent and human obesity, illustrating the prevalence of 
leptin resistance in the pathogenesis of obesity (Maffei et al. 1995a; Maffei et al. 1995b; 
Considine et al. 1996). Rodent models have facilitated examination of leptin resistance on 
a molecular level. Peripheral and central administration of leptin to Ay, New Zealand 
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obese (NZO), and diet-induced obese (DIO) AKR/J mice confirmed their resistance to 
leptin (Halaas et al. 1997; Van Heek et al. 1997). Ay mice are totally resistant to high 
peripheral and i.c.v. doses of leptin, suggesting that signaling through the MC-4 receptor 
is necessary for the response to leptin and for maintenance of normal body weight 
(Halaas et al. 1997; Marsh et al. 1999). NZO mice are resistant to peripheral leptin, but 
respond normally to centrally delivered leptin, indicating that this polygenic form of 
obesity may be the result of impaired leptin transport into the CNS (Halaas et al. 1997). 
In obese, hyperleptinemic humans, a decreased cerebrospinal fluid to serum leptin ratio 
has been noted, supporting the existence of a saturable system for leptin transport into the 
brain, defects in which might account for leptin resistance (Caro et al. 1996; Schwartz et 
al. 1996). Although DIO mice respond to central leptin, they show peripheral resistance, 
requiring high doses to effect weight loss (Halaas et al. 1997; Van Heek et al. 1997). DIO 
mice are normally lean, but become obese when fed a high-fat diet, while other strains 
can maintain a stable weight on such a diet (West et al. 1992). Determining the 
mechanism whereby a high fat diet, on certain genetic backgrounds, contributes to 
obesity, would be highly relevant to human obesity, judging by the increased prevalence 
of obesity in populations consuming high fat, western diets. One proposed mechanism for 
diet-induced obesity holds that a palatable, high-fat diet causes a temporary weight gain, 
which is then normally lost. In susceptible individuals, however, the increased leptin 
levels associated with weight gain could desensitize the leptin response and bring about a 
new 'set-point' at a higher weight (Friedman and Halaas 1998). 
Decreased leptin synthesis or secretion could also lead to obesity. Although most 
obese humans are hyperleptinemic, 5-10% have relatively low leptin levels, pointing to 
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decreased leptin as being relevant in a subset of obesity (Maffei et al. 1995b; Considine et 
al. 1996). Relatively low leptin levels have been detected in Pima Indians, prior to the 
development of obesity (Ravussin et al. 1997). ob/ob mice carrying a human leptin 
transgene, expressing constitutively low levels of leptin, develop a marked obesity, which 
is not as severe as that in ob/ob mice, and which can be similarly corrected by leptin 
administration (Ioffe et al. 1998). In addition, humans with partial leptin deficiency also 
tend to develop increased adiposity (Farooqi et al. 2001). 
Molecular targets for the regulation of body weight 
Current and future obesity therapy 
Given the immense health burden of obesity, finding new, effective treatments is 
imperative. While the public would welcome a therapy that could eradicate obesity, 
studies indicate that even a 10% weight loss can decrease complications from obesity 
such as diabetes, hypertension, and hyperlipidemia, and increase longevity (Goldstein 
1992). Currently, the most widely used interventions are diet and exercise, weight loss 
drugs, and bariatric surgery (Yanovski and Yanovski 2002). 
Considering the overwhelming prevalence of weight regain following dieting and 
the risks of surgery, pharmacotherapy for obesity seems to be a reasonable approach. 
Both leptin and drugs targeting components of the leptin circuit are currently in clinical 
trials (Crowley et al. 2002). While leptin treatment of obese humans leads to a dose-
dependent weight loss, its effects are rather modest, which is to be expected since most 
obese humans are leptin resistant (Heymsfield et al. 1999). However, leptin appears to be 
far more effective in treating leptin-deficient obese and lipodystrophic patients, and may 
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also be useful in obese individuals with inappropriately low levels of leptin (Farooqi et al. 
1999; Farooqi et al. 2001; Oral et al. 2002). The development of novel therapies for 
obesity requires a fuller understanding of the physiological basis of body weight 
regulation. As leptin is a central mediator of energy homeostasis, further elucidation of its 
effects on appetite and metabolism will shed light on the biology of obesity. 
Specific aims 
This thesis aims to further define the molecular basis for leptin's metabolic 
effects. The effects of leptin on the liver are the focus here, due to this organ's critical 
role in coordinating peripheral metabolism. The physiological role of central versus 
peripheral sites of leptin action was examined using tissue-specific knockout mice 
(Chapter 3). These studies indicated that central action of leptin is critical for its effects 
on body weight and hepatic lipid metabolism. Next, transcriptional profiling was used to 
identify molecular targets of leptin's specific effects on peripheral metabolism (Chapter 
4). Using a novel computational approach, genes whose expression was specifically 
modulated during leptin-mediated weight loss were identified. One of these genes, 
stearoyl-CoA desaturase-1 (SCD-1) was shown to be required for leptin-mediated weight 
loss (Chapter 5). ob/ob mice lacking SCD-1 were resistant to obesity and showed a 
correction of the hypometabolic phenotype and hepatic steatosis characteristic of leptin-
deficiency. Mice lacking SCD-1 were also found to be resistant to alcoholic and 
nonalcoholic fatty liver disease (Chapter 6). Other leptin-regulated genes were also 
identified and studies on the role of insulin-like growth factor binding protein-2 (IGFBP-
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2) in leptin-mediated weight loss are presented (Chapter 7). Finally, a summary of the 
findings and directions for future research are discussed (Chapter 8). 
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Chapter 2: Materials and Methods 
Materials and Methods from Chapter 3 
ObR floxed mice. A 12 kb genomic clone containing the first coding exon of ObR was 
isolated. A single loxP element was PCR amplified from the plasmid pNeoTKLox. The 
oligonucleotide primers were engineered to introduce a BamHI-Ncol double restriction 
site at one end and a BamHI site at the other end. Following digestion with BamHI, the 
product was ligated into the BamHI site of the genomic clone, resulting in the clone 
BNLOXB with a single LoxP site upstream of the first exon. A loxP-Neo-HSV-TK-LoxP 
element was isolated by digesting pNeoTKLox with BstXI and Sail. The fragment was 
blunt-ended and cloned into Bgl-II digested blunt-ended BNLOXB. This clone, denoted 
ObR-lox-SSl-lox, was double digested with Aflll and Kpnl, blunt-ended, and re ligated to 
generate the targeting vector. The excised 500 bp Aflll-Kpnl fragment was used as Probe 
1. The targeting vector was linearized with Sail and electroporated into 129/SV ES cells. 
Cells were selected with G418 and surviving clones were screened for homologous 
recombination. Positive clones were transiently transfected with the Cre recombinase 
expressing plasmid, p0G231 (kindly provided by S. O'Gorman) (O'Gorman et al. 1997). 
Cells were then subjected to gancyclovir selection and surviving clones were checked by 
Southern blotting using Probe 2, which is within exon 2, to confirm the deletion of the 
Neo-HSV-TK cassette (Type II deletion). ES cells with the correct genotype (ObRflox/^) 
were injected into C57B1/6 blastocysts, and resulting chimeras were bred with C57B1/6 
mice to obtain germline transmission. ObRflox/+ mice were crossed to generate the line of 
ObR floxed mice, denoted ObRflox/flox. 
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ObR null mice. ObRflox/+ mice were crossed with transgenic adenovirus EIIA cre mice 
(kindly provided by H. Westphal) (Lasko et al. 1996). Since Cre is expressed early in 
embryogenesis in this line, progeny were screened by Southern blotting with Probe 2 for 
germline Cre-mediated deletion of the first coding exon (Type I deletion). These mice, 
with the genotype ObRA/+, were crossed to produce homozygous ObRA/A mice, designated 
ObR null mice. 
Conditional deletion of ObR. Neuron-specific deletion of ObR was achieved using 
synapsinl-Cre transgenic mice (Synl-Cre(+)) (kindly provided by J. Marth) (DeFalco et 
al. 2001; Zhu et al. 2001). Hepatocyte-specific deletion was achieved using albumin-cre 
transgenic mice (Alb-Cre(+)). The Alb-Cre transgene (Figure 3.5A) was constructed 
using plasmid NB, which contains 2 kb of the albumin promoter-enhancer (kindly 
provided by R. Palmiter) (Pinkert et al. 1987). A 2 kb fragment containing the Cre-
recombinase gene and a nuclear localization and polyadenylation signal was excised from 
a separate plasmid by digesting with Bglll and blunt-ending and then digesting with 
Kpnl. This fragment was cloned into KpnI-EcoRV digested plasmid NB downstream of 
the albumin promoter-enhancer. The resulting plasmid was digested with Notl and Kpnl 
to release the 4 kb transgene, which was gel purified and injected into fertilized eggs 
from C57/B16 x CBA (Fl) mice to produce transgenic mice. The presence of the 
transgene in both (Synl-Cre(+)) and (Alb-Cre(+)) mice was verified by PCR and 
Southern blotting. Tissue-specific knockout mice were generated by two successive 
crosses (Figure 3.2a). First, ObRA + mice were crossed with either synapsinl-Cre 
transgenic mice (Synl-Cre(+)) or albumin-cre transgenic mice (Alb-Cre(+)) to generate 
ObR^, Synl-Cre(+) mice or ObR^, Alb-Cre(+) mice. These mice were then mated to 
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0bRfiox/fiox mice tQ generate mice with the genotype O b R ^ A Synl-Cre(+) or O b R ^ A 
Alb-Cre(+), hereafter designated ObRSynIKO and ObRAlbKO respectively. Mice with the 
following genotypes were also generated: (1) ObR^A Synl-Cre(-) and ObR^0", Alb-
Cre(-) (heterozygotes), (2) ObRflox/+, Synl-Cre (+) and ObRflox/+, Alb-Cre (+) (referred to 
as wild type), and (3) ObRflox/+, Synl-Cre (-) and ObRflox/+, Alb-Cre (-) (referred to as 
wild type). All animals here, and those described in other chapters, were housed under 
controlled temperature (23° C) and lighting (12 hours of light, 0700-1900 hours; 12 hours 
of dark, 1900-0700) with free access to food and water, unless otherwise indicated. All 
procedures were in accordance with the guidelines of the Rockefeller University 
Laboratory Animal Research Center. 
Assay of Cre specificity. Genomic DNA was prepared from multiple tissues from 
0bRfW+ SynI.Cre (+) and obRflox/+ Alb-Cre (+) mice and 200 ng was PCR amplified 
using primers flanking the first coding exon of ObR. A schematic of the primer locations 
is shown in (Figure 3.2b). In tissues expressing Cre recombinase, exon 1 is excised and a 
single loxP site remains, generating an ObRA allele. While primers 1 and 3 can amplify a 
product from the ObRA allele, the primers are separated by too great a distance for 
amplification to occur in the ObR ox or ObR+ (wild-type) alleles. As a control, primers 1 
and 2 were used to amplify both the ObRflox and ObR+ alleles from all tissues. The ObR+ 
allele produces a slightly smaller product due to the absence of loxP sequence. The 
primer sequences are as follows: primer 1-5' GTCACCTAGGTTAATGTATTC 3', 
primer 2- 5' TCTAGCCCTCCAGCACTGGAC 3', primer 3- 5' GCAATTCATATC 
AAAACGCC 3'. 
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Assay of Cre efficiency. To determine the degree of Cre-mediated recombination, ObR 
expression levels from all ObRSynIKO and ObRAlbKO mice and a sample of mice with all 
other possible genotypes were quantitated using Taqman® real time PCR. Total RNA 
was isolated from ObRSynIKO and ObRAlbKO mice and reverse transcribed into cDNA 
using random hexamers with Reverse Transcription Reagents from Roche (Branchburg, 
NJ). Expression levels were determined using 25 ng of each cDNA sample assayed in 
duplicate and amplified with the ABI Prism 7700® Sequence Detection System (Perkin 
Elmer Applied Biosystems, Foster City, CA). The location of primers and fluorescent 
probes is indicated in Figure 3.3b. As amplification occurs, the probe is cleaved, resulting 
in a signal from a reporter dye that is directly related to the amount of amplicon. Primers 
were derived from sequences in the 5' untranslated region (forward) and the second 
coding exon (reverse). The fluorescent probe, labeled with the FAM dye, contains 
sequence located within the first coding exon. When this exon is deleted, the probe 
cannot be cleaved, and no signal is generated. As a control for input amount, each cDNA 
sample was also amplified using primers and a probe, labeled with the VIC dye, for 
cyclophilin. The sequences of the primers and probes are as follows: ObR- probe 5' AAA 
CCACATAGAATTTCTGACACATCATCTTTC 3', forward primer 5' AGGAATCGTT 
CTGCAAATCCA 3', reverse primer 5' TATGCCAGGTTAAGTGCAGCTATC 3'; 
cyclophilin- probe 5' ACACGCCATAATGGCACTGGTGG 3', forward primer 5' TGT 
GCCAGGGTGGTGACTT 3', reverse primer 5' TCAAATTTCTCTCCGTAGATGGA 
CTT 3'. Data were analyzed with the ABI Sequence Detector® software. Every set of 
reactions contained a set of four serial two-fold dilutions of the same liver cDNA source, 
which was used to generate a standard curve for both ObR and cyclophilin. Amounts of 
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each transcript were calculated from the standard curve and levels of ObR were corrected 
for levels of cyclophilin (ObR level/ cyclophilin level). 
Body composition analysis. Body composition was analyzed as previously described 
(Halaas et al. 1995). Carcasses were weighed and then oven dried in a 90° C oven until 
weight was constant. The total body water was calculated as the difference between the 
weights before and after drying. The carcass was then homogenized in a blender and 
duplicate aliquots were extracted with a soxhlet apparatus using a 3:1 mixture of 
chloroform:methanol. The extracted homogenate was dried overnight and weighed to 
calculate fat and lean mass. 
Neuropeptide expression levels. Neuropeptide levels were quantitated by Taqman® real 
time PCR from individual hypothalami. Expression levels were measured in the obese 
ObRSynIKO mice, heterozygote controls, and in female ObR null mice. Primers and 
probes were made for AGRP, NPY, MCH, POMC, and CART. The sequences of the 
primers and probes, labeled with 5' FAM and 3' TAMRA, are as follows: AGRP- probe 
5' TCCACAGAACCGCGAGTCTCGTTC 3', forward primer 5' CTTTGGCGGAGGTG 
CTAGA 3', reverse primer 5' GGACTCGTGCAGCCTTACACA 3'; NPY- probe 5' CA 
GAAAACGCCCCCAGAACAAGGC 3', forward primer 5' CACC AG AC AG AG AT AT 
GGC A AG A 3', reverse primer 5' TTTCATTTCCCATCACCACATG 3'; POMC- probe 
5' CAGTGCCAGGACCTCACCACGGA 3', forward primer 5' TGCTTCAGACCTCC 
ATAGATGTGT 3', reverse primer 5' GGATGCAAGCCAGCAGGTT 3'; CART- probe 
5' CACTGCGCACTGCTCCAGCG 3', forward primer 5' CGAG AAGA AGT ACGGCC 
AAGTC 3', reverse primer 5' CCGATCCTGGCCCCTTT 3'; MCH- probe 5' AGGTGT 
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A T G C T G G G A A G A G T C T A C C G A C C 3', forward primer 5' G G A A G G A G A G A T T T T 
GACATGCT 3', reverse primer 5' GCAGGTATCAGACTTGCCAACA 3'. 
Neuroendocrine function. After sacrifice, mice were exsanguinated and blood was 
collected on EDTA. Plasma was collected after centrifugation and used for all assays. 
Leptin levels were determined using an ELISA kit from R&D Systems (Minneapolis, 
MN). Insulin levels were determined using an ELISA kit from Alpco Diagnostics 
(Windham, NH). Glucose levels were determined using the Trinder reagent from Sigma 
(St. Louis, MO). Triglyceride levels were determined using an enzymatic kit from Wako 
Diagnostics (Richmond, VA). Corticosterone, estradiol, testosterone, and thyroxine levels 
were determined using RIA kits from ICN (Costa Mesa, CA). 
Liver triglyceride quantitation. 40-100 mg of liver from each mouse was homogenized in 
4 ml of chloroform-methanol (2:1). 0.8 ml of 50mM NaCl was added to each sample. 
Samples were then centrifuged for 5 minutes at 3000 rpm. The lower phase was removed 
and duplicate 50 jil aliquots were evaporated under N2 gas and then assayed for 
triglycerides using the Trinder reagent from Sigma (St. Louis, MO). Values are expressed 
as ug triglyceride / mg liver. 
Statistical analysis. Data here, and throughout this thesis, are expressed as means plus or 
minus standard error of the mean (SEM). Unless otherwise indicated, significance was 
evaluated using the unpaired Student's t test. Significance of correlation coefficients was 
evaluated using the t test for correlation. 
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Materials and Methods from Chapter 4 
Mice. Eight to ten week-old, female C57B1/6J ob/ob or lean littermate mice (ob/+ or +/+, 
referred to as wild-type) from the Jackson Laboratory (Bar Harbor, ME) were used for all 
expression studies and weight loss time courses. 
RNA isolation. All mice were sacrificed in the middle of the light cycle and livers were 
removed and rapidly frozen in liquid nitrogen. Total RNA was prepared from frozen 
livers using Trizol reagent (Invitrogen, Carlsbad, CA). 
Northern blotting. 10-20 (Xg of total RNA was separated by denaturing formaldehyde 
electrophoresis and transferred by capillary blot to positively charged nylon membranes 
as described (Ausubel et al. 1999). Blots were hybridized with a32-P labeled PCR 
amplified cDNA probes. To control for equal loading, 18S RNA was stained with 
ethidium bromide or blots were hybridized with a32-P labeled cyclophilin cDNA probes. 
Time course. The time course experiment has been previously described (Soukas et al. 
2000). All data presented in this thesis use material from this time course or an 
independent time course performed under identical conditions. Mice were individually 
caged and allowed to acclimate for a number of days prior to the start of the experiment. 
Alzet 2002 mini-osmotic pumps (Alza, Palo Alto, CA) were filled with PBS (free-fed and 
pair-fed groups) or 400 ng/ml leptin (Amgen, Thousand Oaks, CA), and implanted 
subcutaneously under anesthesia. RNA and plasma were isolated from ob/ob mice treated 
with subcutaneous leptin (infusion rate of 4.8 >ug/24 hours via an Alzet miniosmotic 
pump) for 2, 4, and 12 days, untreated ob/ob mice, and free-fed ob/ob mice that received 
saline. As an additional control, RNA and plasma were isolated from saline-treated ob/ob 
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mice that were pair-fed to the leptin treated group also for 2, 4, and 12 days of treatment. 
The pair-fed group was staggered one day behind the other two groups and fed an amount 
equal to the average amount of food consumed by the leptin treated group over the 
previous 24 hours. Body mass and food intake were measured each morning. The body 
weight and food intake of these groups of mice is shown in Figure 4.2. 
Liver histology and triglyceride quantitation. Liver histology was kindly performed by 
Dr. K. Sokol at the Rockefeller University Laboratory Animal Research Center. Livers 
were fixed in 4% paraformaldehyde, sectioned, and stained with hematoxylin and eosin. 
Liver triglyceride levels were determined by thin layer chromatography : gas 
chromatography (TLC:GC), as described below. 
Microarrays and data analysis. RNA from the livers of these animals was prepared and 
hybridized to Affymetrix murine 6500 Gene Chips according to established methods 
(Affymetrix, Santa Clara, CA). Data were analyzed using a AT-means clustering algorithm 
(Hartigan 1975; Kohonen 1997; Soukas et al. 2000). This computational method groups 
genes with similar patterns of expression over the time course experiment. For inclusion 
in the cluster analysis, a gene had to meet pre-established selection criteria, based on 
empirical observations from Northern blots. Specifically, genes were included that were 
given either an I (increased) or D (decreased) score by the Affymetrix GeneChip 3.1 
software and that met one of the following cutoffs in at least two samples: (i) fold change 
> 2.0 and average difference change > 250, (ii) fold change > 1.5 and average difference 
change > 500, (iii) fold change > ~1.5 and average difference change > 100. 
Western blotting. Nuclear SREBP protein levels were measured as previously described 
(Soukas et al. 2000). Following treatment with saline, leptin, or saline with pair-feeding, 
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as described above, fresh livers were rinsed in ice cold saline supplemented with I m M 
DTT and 0.5 mM PMSF. Livers were minced with a razor blade and homogenized with 
10 strokes of a dounce homogenizer in NDS buffer (10 mM Tris at pH 7.5, 10 mM NaCl, 
60 mM KCI, 0.15 mM spermine, 0.5 mM spermidine, 14 mM P-mercaptoethanol, 0.5 
mM EGTA, 2 mM EDTA, 0.5% NP-40, 1 mM DTT, and 0.1 mM PMSF) supplemented 
with complete protease inhibitors at 4° C (Roche, Indianapolis, IN). The NP-40 
concentration was raised to 1% and nuclei were pelleted by centrifugation at 700g for 5 
minutes. Nuclei were then washed once with NDS buffer (1% NP-40), pelleted at 500g 
for 5 minutes, resuspended in 1 volume of 1% citric acid, lysed (by the addition of 2.5 
volumes of 0.1 M Tris, 2.5% SDS, and 0.1 M DTT), sonicated, and heated to 90°C for 5 
min. Western blotting was performed using nuclear extract, according to previously 
established methods (Sambrook et al. 1989). SREBP was detected using 5g/ml rabbit 
anti-mouse SREBP-1 (kindly provided by M. Brown, University of Texas Southwestern 
Medical Center, Dallas, TX). Bound antibodies were detected using an HRP-conjugated 
anti-rabbit IgG secondary antibody (Organon Teknika, West Chester, PA) and visualized 
using enhanced chemiluminescence plus reagents (Amersham, Buckinghamshire, 
England). 
Statistical analysis. Data are expressed as means plus or minus SEM. Significance was 
evaluated using the unpaired Student's t test. 
Materials and Methods from Chapter 5 
Identifying and ranking leptin-regulated genes. In order to prioritize leptin-regulated 
genes for detailed functional analysis, we developed an algorithm to identify and rank 
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genes that are specifically repressed by leptin. This algorithm ranked genes based on the 
extent to which their expression was (1) increased in ob/ob liver compared to wild type 
(2) repressed by leptin treatment, and (3) different between leptin treatment and pair-
feeding. Specifically, we selected genes, which met the above criteria for cluster analysis, 
whose expression was increased in ob/ob relative to wild-type and corrected by leptin 
administration. The selected genes were then scored using the following two criteria: (1) 
the magnitude of the difference in expression between the untreated ob/ob sample and the 
day 12 leptin treated sample and (2) the magnitude of the distance between the leptin 
expression profile and the pair-fed expression profile. The above distance was defined to 
be the Euclidean distance between the normalized 3-dimensional vectors composed of the 
2, 4, and 12 day leptin-treated and pair-fed profiles. To combine the two scores, the genes 
were ranked according to both parameters and then the pair of ranks was averaged for 
each gene. This final average rank served as the score for each gene. Genes with the 
lowest scores are those most strongly leptin-regulated. 
Northern blotting. Membranes were hybridized with a32-P labeled cDNA probes made 
using the untranslated region of SCD-1, which specifically hybridizes to SCD-1 and not 
SCD-2 (Ntambi et al. 1988; Kaestner et al. 1989). To control for equal loading a cDNA 
probe for the small mitochondrial RNA pAL-15 was used. 
SCD activity assay. These assays measure the conversion of [1-14C] stearoyl-CoA to [1-
14C] oleate, as previously described (Miyazaki et al. 2000). Tissues were homogenized in 
10 volumes of buffer A (0.25 M sucrose, 1 mM EDTA, 10 mM Tris-HCl, 1 mM PMSF, 
pH 7.4). The microsomal fractions (100,00 x g) were isolated by sequential 
centrifugation. Reactions were performed at 37°C for 5 min with 100 |0.g protein 
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homogenate and 6 u M of [1-14C] stearoyl-CoA (60,000 rpm), 2 m m N A D H , 0.1 M Tris-
HCl, pH 7.2. After the reaction, fatty acids were extracted and methylated with 10% 
acetic chloride/methanol. Saturated and monounsaturated fatty acid methyl esters were 
separated by 10% AgN03-impregnated TLC using hexane:diethyl ether (9:1) as 
developing solution. The plates were sprayed with 0.2% 2',7'-dichloroflourescein in 95% 
ethanol, and the lipids were identified under UV light. Fractions were scraped off of the 
plate and radioactivity was measured using a liquid scintillation counter. 
Lipid Analysis. Total lipids were extracted from liver with Folch solvent 
(chloroform/methanol 2:1). At the start of the liver extraction, internal standards of C17:0 
triglyceride, cholesteryl ester, and phosphatidyl choline were added to quantitate each 
lipid class (Nu Check Prep, Elysian, MN and Sigma, St. Louis, MO). The lipid classes in 
the liver extract were separated by thin layer chromatography using silica gel G and a 
developing solvent of hexane/diethyl ether/acetic acid (60:40:1). The fatty acids in each 
lipid class were methylated with fresh 5% methanolic HCI and analyzed with a gas 
chromatograph (model 5890, Hewlett-Packard, Palo Alto, CA) equipped with a 100m x 
0.25mm SP2560 fused silica capillary column (Supelco, Bellefonte, PA). 
Mouse crosses. Asebia (abJ/abJ) mice were obtained from the Jackson Laboratory (Bar 
Harbor, ME). These mice have a spontaneous deletion of the first four exons of the SCD-
1 gene and express no SCD-1 RNA or protein (Gates and Karasek 1965; Zheng et al. 
1999). Double mutant abJ/abJ; ob/ob mice were generated by two successive crosses. 
First, abJ/abJ mice (mutation arose spontaneously in Balb/cJ mice) (more detailed 
background strain information is available on the internet at 
http://www.informatics.jax.org/external/ festing/mouse/docs/ABJ.shtml) were crossed to 
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ob/+ (C57B1/6 background). Then, progeny were intercrossed to generate the following 
groups of mice: (1) double mutant mice (abJ/abJ; ob/ob), (2) ob/ob controls (abJ/+; ob/ob 
and +/+; ob/ob), (3) asebia mice (abJ/abJ; ob/+ and abJ/abJ; +/+), and (4) controls 
(abJ/+; ob/+, abJ/+; +/+, +/+; ob/+, and +/+; +/+). ob genotypes were determined by 
PCR amplifying genomic DNA using the forward primer 5' GACTTCATTCCTGGG 
CTTCA 3' and the reverse primer 5' TCTGTGGAGTAGAGTGAGGC 3' and the 
following cycling conditions: 94°C 5 min, 40 x (94°C 1 min, 55°C 1 min, 68°C 2 min), 
68°C 7 min. The 247 bp PCR product was then digested with Ddel (a Ddel site is added 
by the ob mutation) and run on a 3% agarose gel. The wild-type allele shows a 152 bp 
and 32 bp band and the ob allele shows 105 bp, 47 bp, and 32 bp bands. For practical 
purposes only the 152 bp and 105 bp bands were used to determine genotypes, ab 
genotypes were determined by Southern blotting of Ncol digested genomic DNA. Blots 
were hybridized using an a32-P labeled SCD-1 exon 5 probe, PCR amplified from cDNA 
using the forward primer 5' TGTGCTTCATCCTGCCCACG 3' and the reverse primer 
5' GATTGAATGTTCTTGTCGTAGG 3' and the following cycling conditions: 94°C 5 
min, 35 x (94°C 30 sec, 60°C 30 sec, 72°C 1 min), 72°C 7 min. ab/ab, ab/+, and +/+ 
genotypes showed characteristic banding patterns. 
Carcass analysis. Carcass analysis was done as described above. 
Food intake. 12-18 week old were individually caged and allowed to acclimate for 1 
week. 24-hour food consumption was measured over 8 consecutive days, and these 
values were averaged for the mice in each group. Food intake for males and females was 
indistinguishable and was therefore pooled. 
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Oxygen consumption. 14-16 week old mice were placed in an Oxymax indirect 
calorimeter (Columbus Instruments, Columbus, OH) and allowed 2 hours to acclimate. 
The calorimeter was calibrated and operated according to the manufacturer's instructions. 
Measurements were taken for 5 hours during the middle of the light cycle. The first 
reading was discarded, and the total V02 was determined by averaging the other 19 
readings. The resting V02 is the average of all readings that are one standard deviation 
below the total V02, as these readings represent periods of inactivity. 
Plasma assays. Leptin levels were measured by ELISA (R&D Systems, Minneapolis, 
MN). P-hydroxybutyrate levels were measured using an enzymatic assay (Sigma, St. 
Louis, MO). 
Liver histology and triglyceride quantitation. Liver histology was kindly performed by 
Dr. T. Scase at the Bobst Hospital of the .Animal Medical Center (New York, NY). Livers 
were fixed in 4% paraformaldehyde, sectioned, and stained with hematoxylin and eosin. 
Liver triglyceride levels were determined as described above, with a monor modification: 
one drop of Triton X-100 was added to each aliquot prior to evaporating under N2 gas. 
VLDL production assay. Mice were fasted for five hours prior to injection with tyloxapol 
(Triton-1339) (Sigma, St. Louis, MO) as previously described (Merkel et al. 1998). Mice 
were injected via the tail vein with 0.5 mg/kg tyloxapol dissolved in saline at a 
concentration of 0.15 g/ml. Tail bleeds were done just before injection (tO) and 45 and 90 
minutes following injection. Plasma triglycerides were assayed using an enzymatic 
reagent (Sigma, St. Louis, MO). The slope of the line denotes the rate of VLDL 
production. 
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Fatty Acyl CoA Levels. Mice had their food removed at the beginning of the light cycle 
and were studied 6-10 hours later. Mice were anesthetized with an intraperitoneal 
injection of ketamine/xylazine. Livers were freeze-clamped in situ using tongs that had 
been cooled to -70°C and were stored at -80°C. Tissues were homogenized and long 
chain fatty acids were extracted and analyzed by LC/MS/MS analysis using a tandem 
mass spectrometer (Applied Biosytems, Foster City, CA) as previously described 
(Neschen et al. 2002). 
Statistical Analysis. Data are expressed as means plus or minus SEM. Significance was 
evaluated using the unpaired Student's t test. 
Materials and Methods from Chapter 6 
Alcohol Studies. Group housed, 5-7 week old male and female abJ/abJ and littermate 
control mice (abJ/+ or +/+) were acclimated to alcohol by the introduction of a 10% 
ethanol solution in addition to regular drinking water. After 1 week (time 0), regular 
drinking water was removed and mice were only given 10% ethanol to drink. Groups of 
mice were sacrificed after 3 and 5 weeks of ethanol consumption. As a control, non-
alcohol fed, age-matched abJ/abJ and littermate control mice (abJ/+ or +/+) were also 
studied. To measure food intake and alcohol consumption, 8-10 week old ab /ab and 
littermate control mice (abJ/+ or +/+) were individually caged, and food and alcohol 
intake were recorded weekly. Total caloric intake was based on a caloric value of 5.5251 
kcal/ml for pure ethanol and 4 kcal/g for mouse chow. 
Lipodystrophy Studies. Double mutant abJ/abJ;aP2-SREBP-lc transgenic mice were 
generated by two successive crosses. First, female abJ/abJ mice (strain information 
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described above) were crossed to male aP2-SREBP-lc transgenic mice obtained from the 
Jackson Laboratory (Bar Harbor, ME) (C57B16/J x SJL strain). Then abJ/+;aP2-SREBP-
1c transgenic male progeny were crossed to abJ/+ female progeny to generate the 
following groups of mice: (1) double mutant mice (abJ/abJ;aP2-SREBP-lc tg), (2) aP2-
SREBP-Ic tg controls (abJ/+;aP2-SREBP-Ic tg and +/+;aP2-SREBP-Ic tg), (3) asebia 
mice (abJ/abJ), and (4) controls (abJ/+ and +/+). Genotyping was performed by genomic 
PCR for the transgene and by Southern blotting for SCD-1. 
Liver histology and triglyceride quantitation. Liver histology was performed at the Bobst 
Hospital of the Animal Medical Center (New York, NY). Livers were fixed in 4% 
paraformaldehyde, sectioned, and stained with hematoxylin and eosin. Liver triglyceride 
levels were determined as described above, except for the additional step of adding one 
drop of Triton X-100 to each aliquot prior to evaporating under N2 gas. 
Statistical Analysis. Data are expressed as means plus or minus SE. Significance was 
evaluated using the unpaired Student's t test. 
Materials and Methods from Chapter 7 
Northern Blotting. C57B1/6J, ob/ob, db3J/db3J, dbKh/dbKh, NZO, Ay, and AKR/J mice 
were obtained from the Jackson Laboratory (Bar Harbor, ME). The AKR/J mice (strain is 
susceptible to dietary obesity) were not diet-induced, ob/ob tg mice were maintained at 
the Rockefeller University Laboratory Animal Research Center (Ioffe et al. 1998). All 
mice were 8-12 weeks old. Liver RNA was isolated from 2-3 animals of each genotype, 
sacrificed in the fed state or after a 48 hour fast. IGFBP-2 RNA levels were determined 
by Northern blotting, as described above, using an a32-P labeled PCR amplified IGFBP-2 
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c D N A probe. Equal loading was confirmed by ethidium bromide staining of 18S R N A or 
by hybridization with a cyclophilin probe. 
Mice. IGFBP-2";ob/ob mice were generated by two successive crosses. ob/+ mice 
(C57B1/6J strain) obtained from the Jackson Laboratory (Bar Harbor, ME) were crossed 
to IGFBP-2'- mice (129/ReJ x C57B16/J) generated and maintained at the Robert Wood 
Johnson Medical School / University of Medicine and Dentistry New Jersey (Piscataway, 
New Jersey) (Wood et al. 2000). IGFBP-2+/';ob/+ progeny were intercrossed to generate 
a line of IGFBP-2'/';ob/+ mice. These mice were intercrossed to generate IGFBP-2''' 
;ob/ob mice, ob/ob controls (C57B16/J strain) were obtained from the Jackson Laboratory 
(Bar Harbor, ME). 
Leptin Administration. Leptin treatment was performed as described above for Chapter 4. 
Mice were individually caged and allowed to acclimate for more than a week prior to the 
start of the experiment. Alzet 2002 mini-osmotic pumps (Alza, Palo Alto, CA) were filled 
with PBS (saline group) or 400 ng/ml leptin (Amgen, Thousand Oaks, CA), and 
implanted subcutaneously under anesthesia. Groups of ob/ob and IGFBP-2'''; ob/ob mice 
were treated with subcutaneous leptin (infusion rate of 4.8 (xg/24 hours via an Alzet 
miniosmotic pump) or PBS for 10 days. For ob/ob mice, n = 4 for saline (all males, age at 
start of experiment = 76 days) and n = 6 for leptin (4 females and 2 males, average age at 
start of experiment = 66 ± 3.2 days). For IGFBP-2'';ob/ob mice, n = 4 for saline (all 
females, average age at start of experiment = 103.8 ± 8.6 days) and n = 5 for leptin (all 
females, average age at start of experiment = 103.6 ± 8.3 days). 
Plasma Assays. Leptin levels were measured by ELISA (R&D Systems, Minneapolis, 
MN). Glucose levels were measured using an enzymatic assay (Sigma, St. Louis, MO). 
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Statistical Analysis. Data are expressed as means plus or minus SEM. Significance was 
evaluated using the unpaired Student's t test. 
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Chapter 3: Selective Deletion of Leptin Receptor in Neurons Leads to 
Obesity 
Introduction 
Leptin is an adipocyte hormone that functions as an afferent signal in a negative 
feedback loop that regulates energy balance (Zhang et al. 1994; Friedman and Halaas 
1998; Spiegelman and Flier 2001). Mice with mutations in leptin (ob/ob) or its receptor 
(db/db) are hyperphagic and severely obese (Tartaglia et al. 1995; Chen et al. 1996b; Lee 
et al. 1996). These mutant mice also manifest a large number of metabolic and endocrine 
abnormalities including diabetes, hypercortisolemia, infertility, and cold intolerance 
(Coleman 1978; Coleman 1982). ob/ob and db/db mice also have enlarged, steatotic 
livers (Yen et al. 1976; Koteish and Diehl 2001). The fatty liver is in part a result of an 
increased rate of hepatic lipogenesis, which is also thought to contribute to the 
development of obesity (Kaplan and Leveille 1981). 
Treatment of ob/ob mice with leptin reduces food intake and body weight and 
corrects the metabolic and endocrine defects associated with leptin deficiency. Leptin 
treatment also normalizes the hepatomegaly and associated elevations in hepatic 
glycogen and lipid (Levin et al. 1996). Infusions of leptin into wild type mice at 
physiological amounts results in a dose dependent reduction in food intake and body 
weight (Campfield et al. 1995; Halaas et al. 1995; Pelleymounter et al. 1995). This 
metabolic response to leptin in both ob/ob and wild type mice is novel and is not solely a 
consequence of its anorectic effects (Soukas et al. 2000). Intracerebroventricular leptin 
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has similar effects, but at much lower doses, suggesting that leptin has direct effects on 
brain (Campfield et al. 1995; Halaas et al. 1997). 
The leptin receptor, which has five splice variants (ObRa-e), is broadly expressed, 
however, and the relative importance of leptin's effects on brain vs. peripheral sites is 
unclear (Ghilardi et al. 1996; Fei et al. 1997). This distinction is of importance because 
leptin deficiency is associated with myriad abnormalities in many tissues including liver. 
While leptin has been suggested to act directly to deplete triglycerides, the contribution of 
these actions to body weight homeostasis, deposition of lipid in peripheral sites, and 
neuroendocrine function in vivo is untested (Shimabukuro et al. 1997a; Minokoshi et al. 
2002). In order to determine the role of leptin action in the central nervous system and the 
periphery, we are systematically deleting ObR in a tissue-specific fashion using the Cre-
loxP system. Here we present data from mice with either neuronal (ObRSynIKO) or 
hepatocyte-specific (ObRAlbKO) deletions of ObR. 
Among the ObRSynIKO mice, the extent of obesity was negatively correlated with 
the level of ObR in hypothalamus and those animals with the lowest levels of ObR 
exhibited an obese phenotype. The obese mice with low levels of hypothalamic ObR also 
show elevated plasma levels of leptin, glucose, insulin, and corticosterone. The 
hypothalamic levels of AGRP and NPY are increased in these mice. These data indicate 
that leptin has direct effects on neurons and that a significant proportion, or perhaps the 
majority, of its weight reducing effects are the result of its actions on brain. To explore 
possible direct effects of leptin on a peripheral tissue, we also characterized ObRAlbKO 
mice. These mice weigh the same as controls and have no alterations in body 
composition. Moreover, while db/db mice and ObRSynIKO mice have enlarged fatty 
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livers, ObRAlbKO mice do not. In summary, these data suggest that the brain is a direct 
target for the weight reducing and neuroendocrine effects of leptin and that the liver 
abnormalities of ob/ob and db/db mice are secondary to defective leptin signaling in the 
brain. 
Results 
Generation of tissue-specific knockout mice 
We have used the Cre-loxP system to generate mice with tissue specific deletions 
of ObR (Gu et al. 1994). The construction of the targeting plasmid is described in 
Chapter 2 (Materials and Methods) (Figure 3.1a). The first coding exon of ObR was 
flanked by loxP sites. This exon contains the signal sequence and deletion of it by Cre-
mediated recombination was predicted to inactivate all splice variants. Following 
transfection into mouse embryonic stem (ES) cells, 3/72 G418-resistant clones had 
undergone homologous recombination (Figure 3.1b). The targeting cassette was deleted 
by transiently transfecting one of the homologous recombinant ES cell lines with a 
plasmid expressing Cre recombinase and screening for clones with a type II deletion 
(Figure 3.1a). Clones with the correct genotype, ObRflox/+, were confirmed by Southern 
blotting and injected into C57B1/6 blastocysts (Figure 3.1c). Breeding of chimeras 
confirmed that animals with a germline insertion of loxP sites into ObR had been 
generated. Mice homozygous for the floxed allele, ObRflox/flox, were generated by 
crossing ObRflox/+ animals. 
ObRflox/flox mice were viable, fertile, and indistinguishable from wild-type or 
ObRflox/+ mice indicating that the insertion of loxP sites into the introns flanking the first 
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Figure 3.1 LoxP targeting of the O b R locus. Gene targeting was used to insert loxP sites on either side of 
the first coding exon of O b R (A) Restriction maps (from top to bottom) of the genomic locus, targeting 
vector, homologous recombinant, and the type II and type I deletion alleles Probe 1, located outside the 
targeting construct, was used to screen for homologous recombinants Probe 2, located in the second coding 
exon, distinguishes the endogenous allele, homologous recombinants, and type I (deletion of the first coding 
exon) and II (deletion of the targeting cassette leaving loxP sites on either side of the first coding exon) 
deletions A, Aflll, B, BamHI, Bg, Bglll; H, Hindlll; N, Ncol (B) Southern blot £in.alysis of Ncol-digested 
genomic D N A from ES cell clones using Probe 1. The endogenous allele (Wt) and homologous recombinants 
(HR) migrated at the predicted sizes. (C) Southern blot analysis of Hind-III digested genomic D N A using Probe 2 
The endogenous allele (Wt), homologous recombinant (HR) and Type II deletion were detected from ES cell D N A 
ObRtlov+ mice were generated from the Type II deletion and crossed to adenovirus EIIA-cre mice. The Type I 
deletion was detected in tail D N A from progeny derived from this cross. All alleles migrated at the predicted sizes. 
(D) Body weight at 8 weeks of age of O b R ^ and littermate control (ObR^4) mice. Data represent the mean 
+/- S E M of at least 9 animals of each genotype and gender. *, p < 0.02, **, p < 0.001 in an unpaired Student's t test. 
coding exon did not interfere with ObR function. To determine whether Cre-mediated 
deletion of the first coding exon results in a null allele, ObRflox/+ mice were crossed with 
transgenic mice expressing Cre at an early embryonic stage (Lasko et al. 1996). Mice 
with the genotype ObR +, heterozygous for a germline deletion of the first coding exon 
(Type I deletion), were generated and mated to produce homozygous ObRA/A mice, also 
referred to as ObR null mice (Figure 3.1c). ObR null mice are massively obese and 
indistinguishable from db3J/db3J mice, which are also null for all ObR isoforms (Figure 
3.1d) (Lee et al. 1997). These data confirm that the floxed allele is wild type and that the 
deleted allele is null, thus validating the targeting strategy. 
Neuron-specific ObR knockout 
Neuron-specific ObR knockout mice, designated ObRSynIKO were generated by 
two successive crosses (Figure 3.2a, and described in Materials and Methods). These 
mice carry one floxed and one null allele so that Cre-mediated inactivation of only one 
allele, rather than two, is sufficient to delete ObR in a given cell. The ObRSynIKO mice 
were compared to littermate controls with the genotype ObR^*10", Synl-Cre(-), also 
referred to as heterozygotes. These mice were used as controls because some phenotypic 
changes have been observed in db/+ mice (Coleman 1979). Data were also obtained from 
lean littermates with the genotypes ObRflox/+, Synl-Cre (+)or ObRflox/+, Synl-Cre (-), both 
of which are referred to as wild type. Genotypes of all mice were determined using PCR 
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Figure 3.2 Cre-mediated recombination specifically in the brain of ObRSynIKO mice. 
(A) The breeding strategy that was used to generate O b R A ' K O mice and littermate controls 
is shown. ObRAlbKO mice (described below) were generated using the same strategy. 
(B) Genomic D N A was prepared from several tissues from ObRflov", Synl-Cre(+) mice and 
P C R .amplified using primers flanking the first coding exon of ObR. The locations of the primers 
are shown on the schematic below the gel. In tissues expressing the Cre recombin.ase, exon 1 is 
excised and a single loxP site remains, generating an ObRA allele. While primers 1 and 3 can 
amplify a product from the ObRA allele, in the ObRtlox or ObR" (wild type) D N A , the primers 
are separated by a distance too great for amplification to occur. As a control, primers 1 and 2 were 
used to amplify both the ObRflox allele and the ObR+ alleles from all tissues. The ObR+ allele 
produces a slightly smaller product due to the absence of loxP sequences. 
In the synapsinl-Cre transgenic line, expression of Cre recombinase is controlled 
by the rat synapsin I promoter. This promoter has been shown to drive Cre expression 
specifically in neurons (Hoesche et al. 1993). Crossing Synl-Cre+ mice to LacZ indicator 
transgenic strains showed that Cre activity was first detectable at El2.5 and restricted to 
brain, spinal cord, and the dorsal root ganglion, and absent from astrocytes and glia (Zhu 
et al. 2001). To confirm the tissue specificity of Cre-mediated recombination, a 
qualitative PCR assay was developed that was capable of detecting recombination 
between the lox sites flanking the first coding exon of ObR in genomic DNA. In ObRflox/+ 
synapsinl-Cre (+) mice, Cre-mediated recombination was restricted to brain, 
hypothalamus and spinal cord (Figure 3.2b). As previously indicated by reporter gene 
expression in Synl-CAT transgenic mice, low level recombination was also seen in testis 
(data not shown). 
The weight of the ObRSynIKO mice was compared to that of heterozygous mice at 
four months of age. While the weights of ObRSynIKO mice, on average, were no different 
than heterozygotes, in both sexes a subset of the ObRSynIKO mice had an increased body 
weight (Figure 3.3a). The percent body fat of these mice (shown in yellow) was more 
than 3 standard deviations greater than the average percent body fat of heterozygotes 
(Figure 3.3a). This suggested the possibility that the extent of the knockout of ObR was 
variable and that the most obese ObRSynIKO animals had the lowest levels of ObR. In 
order to assess the efficiency of Cre-mediated recombination, real time PCR assays 
(Taqman®) were performed to quantitate ObR RNA using cDNA prepared from 
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Figure 3.3 O b R R N A levels. (A) The distribution of body weight and percent body fat for male 
and female ObRSynIKO mice at 16 weeks of age is shown. Those mice with less than 1 5 % of O b R 
R N A (as identified in Figure 3B) are shown in yellow. (B) Expression levels were determined using 
Taqman® real time P C R with the jABI Prism® 7700 Sequence Detection System. The locations of 
primers and fluorescent probe .are as indicated. Primers were derived from sequences in the 5' 
untranslated region and the second coding exon. The fluorescent probe is located within the first 
coding exon 1. W h e n this exon is deleted, no signal is generated. As a control for input amount, each 
c D N A sample was also amplified using primers and a probe for cyclophilin. Data were analyzed with 
ABI Sequence Detector® software and the levels of O b R were normalized to cyclophilin. Levels are 
represented as the percentage of the levels in ObRfloA Synl-Cre(+) .and ObRflra/+, Synl-Cre(-) wild 
type mice. Data represent the mean +/- SEM. At least 13 animals were analyzed for each genotype. 
p values for comparisons between genotypes are indicated. 
O b R is expressed at highest levels in hypothalamus and at much lower levels in other 
brain regions. This assay detected all forms of the leptin receptor. ObRflox/+, Synl-Cre(+) 
and ObR ° +, Synl-Cre(-) mice had equivalent levels of ObR expression, and thus both 
genotypes were designated as wild-type (Figure 3.3b). As expected, ObR^A Synl-Cre 
(-) mice, which have one allele inactivated in the germ line, have 50% as much RNA as 
wild type mice (p < 0.006). The average level of ObR RNA was significantly lower in 
ObRSynIKO mice than in ObR^A Synl-Cre (-) heterozygote littermates (30% vs. 50% of 
wild type respectively, p = 0.004). Moreover, while many of the ObRSynIKO mice had 
levels of ObR RNA that were indistinguishable from heterozygotes, a subset of the 
ObRSynIKO mice had markedly reduced levels of ObR. These results confirmed that Cre-
mediated recombination is variable, and indicated that in many animals there is no 
evident recombination. 
We next considered whether the most obese ObRSynIKO animals (i.e. percent 
body fat 2.5 standard deviations greater than heterozygotes) had lower levels of ObR 
RNA than the lighter ones. Analysis of the data indicated that percent body fat and body 
weight were significantly increased in each of six animals in which ObR RNA was less 
than 15% that of wild-type (shown in yellow in Figure 3.3a) (p < 0.005 for percent body 
fat, p < 0.05 at all ages greater than 5 weeks for body weight). This confirmed that a 
significant deletion of ObR is associated with an obese phenotype. Furthermore, in those 
cases where the deletion is most extreme, a severely obese phenotype is evident. Two 
ObRSynIKO females and one ObRSynIKO male had a greater than 97% reduction of ObR 
RNA and each weighed more than 50 grams at sacrifice, weights that approach, but do 
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not equal, that of db/db mice. In these studies, as well as studies of the ObRAlbKO mice 
(see below), there were no lean mice with hypothalamic ObR RNA levels less than 15% 
that of wild type, and there were no obese mice (obese defined as percent body fat > 2.5 
SD above heterozygotes: 30.5% for males, 47.8% for females) with RNA levels greater 
than 15%o that of wild type. These data suggest that a near normal body weight can be 
maintained until markedly reduced levels of ObR in hypothalamus are evident. In all 
following studies, the phenotype of the animals with <15% wild type levels of 
hypothalamic ObR RNA was compared to heterozygotes. These mice are referred to as 
obese ObRSynIKO mice. 
The weights of the obese ObRSynIKO mice were significantly increased relative to 
heterozygotes at all time points greater than 5 weeks of age (p < 0.05). At 5 months of 
age, males and females weighed 35% and 66% more than heterozygotes respectively. 
(Figure 3.4a). The increase in body weight was associated with increased adipose tissue 
mass and, as is also the case in ob/ob and db/db mice, decreased lean body mass (Table 
3.1). At sacrifice, the percent body fat of ObRSynIKO mice was 39% in males and 60% in 
females, compared to 15% in male heterozygotes and 26% in female heterozygotes. 
The obese ObRSynIKO mice were also analyzed with respect to a number of other 
abnormalities associated with the db/db mutation (Table 3.1). Plasma leptin 
concentrations were elevated 5.8-fold in obese ObRSynIKO males (p < 0.05) and 8.3-fold 
in obese ObRSynIKO females (p < 0.0001) and were highly correlated with percent body 
fat (r = 0.82, p < 0.01, t test for correlation). In addition, plasma insulin was increased 
6-fold in obese ObRSynIKO males (p < 0.05) and 16.1-fold in ObRSynIKO females. 
Glucose was increased 2.3-fold in ObRSynIKO females (p < 0.005), and was unchanged in 
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Figure 3.4 Obesity in a subset of ObRSynIKO mice. Significant obesity was evident in those 
ObRSynIKO mice that had 15% or less ObR R N A in the hypothalamus than wild type mice. 
(A) Weight curves of male and female ObRSynIKO mice (solid squares), heterozygote littermates 
(open squares), and ObR null mice (solid triangles). Mice were weighed weekly from 5 weeks of 
age. Data represent the mean +/- S E M of 4 male and 2 female ObRSynIKO mice and 7 male and 9 
female heterozygote littermates. For both sexes, ObRSynIKO vs. heterozygotes, p < 0.05 at all ages 
and ObRSynIKO vs. ObR null, p < 0.05 at all ages. (B) Expression levels of AGRP, NPY, P O M C , 
and C A R T were determined by Taqman ® and are expressed as normalized to cyclophilin. Levels 
were measured in ObRSynIKO, heterozygotes, and ObR nulls, n = 5 for heterozygotes, n = 6 for 
knockouts, and n = 3 for null mice. 
Body Composition and Neuroendocrine Function in ObR^'KO and ObRAlbKO Mice 
ObR^'KO ObR^'Het ObRAlbKO ObRAlbHet 
Percent Fat Mass 
Males 
Females 
Percent Lean Mass 
Males 
Females 
Percent Water Mass 
Males 
Females 




40.9 +/- 0.3 (4) 
27.2 +/- 0.3 (2) 
15.4+/-0.8 (8)A 
25.8+/-0.9(10)* 
25.7 +/- 0.2 (8)A 
22.6+/-0.3 (10)A 




30.2 +/- 0.8 (4) 
28.0 +/- 0.7 (4) 
55.8+/-1.3 (4) 
56.6 +/- 0.9 (4) 
13.2+/-0.5 (5) 
15.6+/-1.1 (5) 
30.2 +/- 0.8 (5) 
27.5 +/- 0.7 (5) 
56.6 +/- 0.6 (5) 















73.8 +/- 8.5 (4) 
125.0+/-0.7 (2) 




2.8 +/- 0.2 (8)B 
2.5 +/- 0.2 (8) 
158.3 +/- 9.3 (4) 165.3 +/- 4.9 (10) 
282.6 +/- 32.3 (2) 123.1 +/- 4.7 (8)4 
238.5+/-17.9 (4) 134.9+/-40.2 (3) 
469.4 +/- 32.7 (2) 195.9 +/-16.1 (8)B 





80.3 +/- 2.3 (7) 













^< 0.005 vs. knockout, BP< 0.05 vs. knockout, NDNot Determined 
Table 3.1 Body composition and neuroendocrine function in ObRSynIKO and ObRAlbKO mice. 
After sacrifice, the subset of significantly obese ObRSynIKO mice and the subset of O b R ^ K O mice 
with less than 3 0 % O b R R N A as well as heterozyogte littermates were exsanguinated and plasma was 
collected for the following assays. M l plasma was collected from mice sacrificed at 1200 hrs under free 
feeding conditions. Average ages for ObRSynIKO and O b R ^ K O mice sampled here are 26 weeks and 23 
weeks. All data represent the mean +/- S E M , with the sample size indicated in parentheses (A, p < 0.005, 
B, p < 0.05 in an unpaired Student's t test). 
ObRSynIKO males. Plasma corticosterone was elevated 1.8-fold in ObRSynIKO males and 
2.4-fold in ObRSynIKO females (p < 0.05). The elevation in plasma glucose and the 
greater elevation in corticosterone specific to females could be due to the fact that the 
females analyzed had a lower level of ObR RNA and were more obese. Of note, an 
increased plasma corticosterone is unique to ob/ob and db/db mice, whereas other forms 
of rodent obesity are not generally associated with elevated corticosterone (Bray and 
York 1979). Mutations in leptin or its receptor are also associated with infertility, and 
leptin has been shown to influence the hypothalamic-pituitary-gonadal axis (Chehab et al. 
1997). Consistent with this, obese female ObRSynIKO mice had 43% reductions in plasma 
estradiol. Male ObRSynIKO mice, however, did not have reduced levels of plasma 
testosterone. This sexual dimorphism is consistent with the fact that leptin deficiency has 
a more profound effect on female reproduction than male reproduction (Ewart-Toland et 
al. 1999). Finally, plasma thyroxine and triglycerides were not significantly different 
between mutant and control mice (data not shown). 
Despite the marked obesity in this subset of ObRSynIKO mice, these animals still 
weighed less than mice with germline deletions of ObR (Figure 3.4a, p < 0.05 at all ages). 
These data suggest either that the knockout was incomplete even in the most obese 
animals or that leptin also acts at peripheral sites to reduce weight. To further assess the 
extent of the knockout in brain, levels of a number of hypothalamic neuropeptides were 
examined using Taqman assays (Figure 3.4b). Defective leptin signaling is associated 
with increased levels of hypothalamic AGRP, NPY, and MCH RNA and reduced levels 
of POMC and CART RNA (Stephens et al. 1995; Qu et al. 1996; Ollmann et al. 1997; 
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Shutter et al. 1997; Thornton et al. 1997; Kristensen et al. 1998). Comparisons of 
heterozygotes to obese ObRSynIKO mice showed that AGRP and NPY levels were 
increased, while POMC and CART levels showed a trend towards being reduced. While 
the reduction in POMC and CART RNA levels is not significant, the levels of these 
RNAs are only modestly decreased in ob/ob and db/db hypothalamus. MCH levels were 
indistinguishable between heterozygous mice, ObRSynIKO mice, and ObR null mice. The 
reported 80% increase in MCH RNA in ob/ob mice is also more modest than the reported 
increases in AGRP and NPY RNA (Qu et al. 1996). While the levels of AGRP and NPY 
were increased in the obese ObRSynIKO mice, they were less elevated than in null mice. 
This suggests that, despite the low levels of ObR RNA in these mice, some ObR 
expressing neurons remained. 
Hepatocyte-specific ObR .knockout 
The data here indicate that leptin has direct effects on brain but leaves open the 
possibility that leptin also has direct effects on peripheral tissues. To assess a possible 
role of ObR in liver, a peripheral tissue that has been suggested to be a direct target of 
leptin action, mice with a hepatocyte-specific knockout of ObR were generated 
(ObRAlbKO). These mice were generated using the same breeding strategy as described 
for ObRSynIKO mice (Figure 3.2a). The albumin promoter was used to direct hepatocyte-
specific expression of Cre recombinase (Figure 3.5a) (Pinkert et al. 1987). Genomic PCR 
performed on multiple tissues from ObRflox/+ albumin-Cre (+) mice confirmed that cre-
mediated recombination was restricted to liver (Figure 3.5b). In contrast to ObR ynKO 
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Figure 3.5 Normal body weight and liver phenotype in ObRAlbKO mice. (A) Schematic of 
Albumm-Cre transgene. (B) Genomic D N A was prepared from several tissues from ObR""**, 
Alb-Cre(+) mice and P C R amplified using primers flanking the first coding exon of O b R as 
described in Figure 5.2B. (C) Weight curves of male and female ObRAJbKO mice (solid squares) 
and heterozygote littermates (open squares). Mice were weighed weekly from 5 weeks of age 
Data represent the mean +/- S E M of 9 male and 11 female O b R ^ K O mice and 23 male and 23 
female heterozygote littermates. For both sexes, O b R A l b K O vs. heterozygotes, p values were 
not significant at all ages (D) Photographs of freshly dissected livers from representative mice 
with the given genotypes. (E) Liver triglycerides (mg triglyceride ' gram liver) were determined 
for O b R ^ K O mice with < 3 0 % of wild type O b R RN.\ and heterozygote controls. Data represent 
the mean +/- S E M of 6 male and female Ob.RAlbKO mice, 5 male and 5 female heterozygote 
nsrtrols.. sad 6 siale and 3 female O b R null mice. For both sexes, p < 0.05 for O b R A l b K O and 
the levels of O b R R N A in liver (as measured using the aforementioned Taqman assay) 
were reduced to less than 30% wild type levels (9/12 males, 11/16 females analyzed) 
(Figure 3.5c). As the liver is composed of a number of different cell types, and 80% of 
the mass is accounted for by hepatocytes, this likely represents a near complete deletion 
in hepatocytes (Weibel et al. 1969; Gumucio et al. 1996). Inspection of the weight 
distributions showed that no ObRA KO mice manifested an increased weight. Body 
composition was analyzed to determine whether hepatocyte-specific deletion of ObR had 
a subtle effect on body partitioning in ObRAlbKO mice. Water mass, lean mass, and fat 
mass were all unchanged in these animals (Table 3.1). In both sexes, plasma leptin levels 
were within the normal range as were insulin, glucose, and corticosterone. While db/db 
and ObRSynKO mice have enlarged fatty livers characteristic of leptin deficient mice, the 
livers of ObRAlbKO mice were grossly normal (Figure 3.5d). Wet liver weight and liver 
weight as a percentage of body weight were also unchanged between ObRAlbKO mice 
and heterozygotes (data not shown). Quantitation of liver triglycerides showed no 
difference between ObRAlbKO mice and heterozygote controls, while levels in ObR null 
mice were significantly elevated relative to both of these groups (p < 0.05) (Figure 3.5e). 
These data indicate that ObR expressed in hepatocytes is not likely to play a significant 
role in body weight homeostasis or the hepatic steatosis associated with the db mutation, 
and that the liver abnormalities observed in ob/ob and db/db mice are secondary to 
defective leptin signaling in the brain. 
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Discussion 
In this study, two possible sites of leptin action were evaluated by analyzing the 
phenotype of mice with neuron and hepatocyte-specific knockouts of the leptin receptor. 
These data provide direct genetic evidence that leptin signals via direct effects on 
neurons. Separate data from studies of dbKls/dbKls mice indicate that the specific absence 
of the ObRb form of the receptor results in a phenotype indistinguishable from leptin 
deficiency, demonstrating that ObRb is absolutely required for the weight reducing 
effects of the hormone (Tartaglia et al. 1995; Chen et al. 1996b; Lee et al. 1996). ObRb is 
the only isoform that has all of the motifs necessary for signal transduction and is 
expressed at high levels in brain and a number of other tissues. 
These findings suggest that leptin exerts its weight reducing and some, or perhaps 
all, of its neuroendocrine effects via interactions with the ObRb form of the receptor in 
specific classes of neurons in brain. This is consistent with the high potency of leptin 
administered i.c.v. and the anatomic distribution of ObRb (see below) (Campfield et al. 
1995; Halaas et al. 1995). This conclusion is also consistent with data from experiments 
where an NSE-ObRb transgene was able to partially complement the phenotype of db/db 
mice (Kowalski et al. 2001). However, in this study ObRb was overexpressed 30-fold in 
all neurons, with some leakiness in peripheral tissues. 
The phenotype of the obese ObRSynKO, while significant, did not reach that of 
ObR null mice. However, in these animals, hypothalamic AGRP and NPY levies, while 
increased, were still not as high as in null mice suggesting that there were still some 
residual ObR expressing cells. This leaves open the possibility that a truly complete 
brain-specific knockout (i.e. deletion of ObR on every neuron) could recapitulate the 
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obese phenotype of ObR null mice. The generation of such a knockout might require the 
simultaneous use of multiple different neuron-specific cre expressing lines. 
In some studies, the expression of ObRb in brain was reported to be restricted to 
the hypothalamus, possibly implicating the hypothalamus as the principal target of 
leptin's weight reducing effects. In hypothalamus, ObRb is enriched in the arcuate, 
ventromedial, dorsomedial, and paraventricular hypothalamic nuclei, all of which are 
known, based on studies of animals with stereotactic lesions, to play a role in regulating 
food intake and body weight (Hetherington and Ranson 1942; Elmquist et al. 1997; Fei et 
al. 1997; Elmquist et al. 1998a). However, in other studies, ObRb expression has also 
been reported in other brain sites including the brainstem, thalamus, and cerebellum. The 
possibility that one or more of these extrahypothalamic brain sites play important roles in 
the regulation of body weight can be tested using region-specific or neuron-specific 
promoters to drive Cre expression in localized brain areas and specific cell types. In the 
hypothalamus, ObRb is expressed in functionally distinct classes of neurons, the best 
characterized being neurons that co-express either NPY or °=MSH (Mercer et al. 1996a; 
Cheung et al. 1997). Both of these neuropeptides exert potent effects on food intake and 
body weight. Experiments to test the effects of ObR deletion in these two types of 
neurons may allow an analysis of the functional importance of these two neuropeptides as 
downstream effectors of leptin signaling and could establish the extent to which these 
two cell types by themselves can fully account for the neural response to leptin. 
A number of studies have suggested that leptin also has direct effects on liver 
(Shimabukuro et al. 1997a; Kim et al. 2000). The data presented here indicate that 
hepatocyte-specific deletion does not have any observable effects on body weight or body 
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composition and does not result in any gross liver pathology. Furthermore ObRAlbKO 
mice have equivalent amounts of liver triglycerides as controls, indicating that the hepatic 
phenotype of db/db mice is secondary to defective leptin signaling in brain. However, 
hepatocyte-specific deletion may have less obvious effects on hepatic lipid and 
carbohydrate metabolism. In addition, these findings do not exclude the possibility that 
hepatocyte ObR by itself serves functions, such as modulating leptin turnover. 
While these findings suggest that neurons are required for leptin's effects on body 
weight, they do not exclude the possibility that leptin also directly acts on other 
peripheral targets. In addition to regulating food intake, body weight, and the 
neuroendocrine axis, leptin can also modulate the immune system, bone turnover, 
angiogenesis, and lipid metabolism (Lord 1998; Sierra-Honigmann et al. 1998; Ducy et 
al. 2000; Atkinson et al. 2002; Minokoshi et al. 2002). Indeed, ObRb is expressed in a 
number of peripheral tissues and direct effects of leptin on T cells, macrophages, 
pancreatic B-cells, skeletal muscle, heart, and other cell types have been reported 
(Shimabukuro et al. 1997a; Kim et al. 2000; O'Rourke et al. 2001; Atkinson et al. 2002; 
Minokoshi et al. 2002). Other forms of ObR (ObRa, c, d, e) may play a role in transport 
of leptin across the blood brain barrier and choroid plexus, sites that express high levels 
of ObR. The function of ObR at these and other sites can now be assessed by crossing 
ObR ox ox mice to transgenic lines that express Cre in a tissue-specific fashion. Such 
studies should allow an assessment of the relative role of direct effects of leptin on these 
tissues vs. indirect effects via signaling in brain. In conclusion, these findings indicate 
that the brain is a direct target for the weight reducing and neuroendocrine effects of 
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leptin and that the liver pathology of ob/ob and db/db mice is secondary to defective 
leptin signaling in neurons. 
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Chapter 4: Leptin-specific Programs of Gene Expression in Liver 
Introduction 
The adipocyte-derived hormone leptin functions as the afferent signal in an 
endocrine loop regulating energy homeostasis. Mice with mutations in leptin (ob/ob) or 
its receptor (db/db) exhibit marked obesity, hyperphagia, and endocrine abnormalities 
(Zhang et al. 1994; Tartaglia et al. 1995; Chen et al. 1996b; Lee et al. 1996). When 
administered to wild-type and ob/ob mice, leptin causes significant reductions in food 
intake and body weight (Campfield et al. 1995; Halaas et al. 1995; Pelleymounter et al. 
1995). These findings have implicated leptin as a key regulator of energy balance 
(Friedman and Halaas 1998). Current evidence indicates that the brain is a critical site of 
leptin action, suggesting that leptin modulates a neuronal circuit that controls food intake 
and peripheral metabolism (Chapter 3)(Cohen et al. 2001). At present, however, the 
components of this neuronal circuit and the nature of the efferent signals from the central 
nervous system that regulate metabolism in response to leptin are not well characterized. 
Leptin elicits a metabolic response that cannot be explained by its effects on food 
intake alone. When the food intake of an ob/ob mouse is restricted to the amount of food 
voluntarily consumed by a leptin-treated mouse (pair-fed), the pair-fed animal loses 
significantly less weight than a leptin treated counterpart (Levin et al. 1996). Animals 
treated with leptin also exhibit a number of physiological differences from food-restricted 
animals. While pair-feeding causes the breakdown of both lean and fat mass, leptin 
treatment selectively reduces fat mass (Halaas et al. 1995; Pelleymounter et al. 1995; 
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Halaas et al. 1997). In addition, leptin treatment does not produce an increase in 
circulating free fatty acids and ketone bodies typical of starvation (Chen et al. 1996a; 
Shimabukuro et al. 1997a). Leptin treatment also eliminates the compensatory drop in 
energy expenditure induced by starvation (Halaas et al. 1997). In aggregate, these 
findings suggest that leptin causes weight loss by enacting a novel metabolic program, 
distinct from food restriction on both a physiological and molecular basis. 
The mechanism underlying leptin's unique metabolic effects is likely to involve 
modulation of gene expression in metabolically active organs such as liver, adipose 
tissue, and muscle. In order to more fully characterize this metabolic response, data is 
presented here on leptin-specific programs of gene expression in liver. First, we 
examined the effects of total leptin deficiency on gene expression, by using 
oligonucleotide microarrays to compare ob/ob to wild-type liver. Next, gene expression 
was analyzed in ob/ob liver over a time course of leptin replacement and pair-feeding to 
identify unique profiles of gene expression characteristic of each state. Finally, the 
transcriptional regulation of clusters of genes with leptin-specific patterns of expression 
was examined. 
Results 
Comparison of gene expression in ob/ob and wild-type liver by oligonucleotide 
microarrays 
Initially, suppressive subtractive hybridization was used to compare gene 
expression in ob/ob and wild-type liver (Diatchenko et al. 1996). Although this method 
successfully identified a few clones with altered expression in ob/ob liver, high-density 
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microarrays permit a more comprehensive and high-throughput analysis of gene 
expression, allowing one to compare the RNA levels of thousands of genes 
simultaneously (Brown and Botstein 1999; Lockhart and Winzeler 2000). Using 
Affymetrix murine 6500 Gene Chips, we examined the expression of roughly 6500 genes 
in the livers of ob/ob and lean littermate control mice. Based on the GeneChip 3.1 
Software, 177 genes were upregulated and 98 genes were downregulated in ob/ob liver. 
Table 4.1 shows all genes with more than 3-fold altered expression in ob/ob liver. 
The gene most upregulated in ob/ob liver was apoliprotein A-IV (17.5-fold), which 
functions in HDL metabolism. Many of the other molecules overexpressed in ob/ob liver 
are involved in lipid and carbohydrate metabolism, which was expected since ob/ob mice 
demonstrate increased hepatic lipogenesis and gluconeogenesis (Yen et al. 1976; Kaplan 
and Leveille 1981; Yoon et al. 2001). The gene most downregulated in ob/ob liver was 
insulin-like growth factor binding protein-2 (27.7-fold), and studies on this gene are the 
subject of Chapter 7. Other molecules with decreased expression include 3 major urinary 
proteins, 2 proteasome components, and 2 DNA binding proteins (Statl and NF-kB). 
Interestingly, targeted knockout of aromatase, which is downregulated 3.2-fold, leads to 
obesity and other metabolic abnormalities (Murata et al. 2002). 
To assess the reliability of the microarray data, a number of Northern blots were 
performed on differentially expressed genes (Figure 4.1). All genes found to be 
differentially expressed by the microarrays were confirmed as being altered by Northern 
blotting. In fact, Northern blot analysis suggested that the GeneChip 3.1 Software might 
underestimate the true fold change values. Based on this analysis, any gene called I or D 
(increased or decreased) and called P (present) in at least one of the samples by the 
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A T P citrate lyase 
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insulin-like growth factor binding protein 2 
PACAP/VIP receptor (PACAPR-3) 
angiogenin precursor 
major urinary protein IV 
P311 
proteasome subunit Lmp2 
carboxy esterase 
G T P binding protein GTP2 
major urinary protein HI 
TDAG51 
angiogenin-related protein 
homologous to E R G 2 
statl 
alpha-2 macroglobulin receptor 
proteasome subunit Lmp7 
Ig gamma2a-b 
aromatase p450 
Via arginine vasopressin receptor 
NF-kappa-B D N A binding subunit 
polymeric immunoglobulin receptor 
complement component C2 
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Table 4.1 Genes with differential expression between ob/ob and wild-type liver. All genes with more than 
3-fold differential expression are shown. The average difference change is a software-derived quantitative measure 
of the difference in expression. ~ indicates that expression in the other sample is undetectable. Function 
apolipoprotein lectin L14 spotl4 Rne-la ThB apolipoprotein glucose-6-
A-IV C-II phosphatase 
wt ob wt ob wt ob wt ob wt ob wt ob wi ob 
L-Ll LU LU 111 I I 1 I IJ I IJ 
difference 4414 1367 6919 1572 77 2307 1355 
change 
fold change 17 5 9.7 6 3 3 8 -3 7 3 4 3 3 
18SRNA 
IGFBP-2 angiogenin carboxyesterase LRG-47 regucalcin corticosteroid 
precursor binding globulin 
wt ob wt ob wt ob wt ob wt ob wt ob 
III III I LI ill ill LLI 
difference -3160 -2343 -3055 -221 -3604 -1234 
change 
foldchange -277 -8 1 46 40 -24 -18 
18SRNA 
Figure 4.1 Northern blots of differentially expressed genes betweeen ob/ob and wild-type liver. Northern blots were 
performed to validate the microarray data using independently generated R N A . 10 g of total R N A was hybridized with a 
probe specific to the indicated genes. Equal loading was confirmed by ethidium bromide stained 18S R N A The average 
difference change and fold change for each gene is indicated. 
software, was considered to represent a reliable difference in R N A levels if the following 
criteria were also satisfied: (i) fold change > 2.0 and average difference change > 250, (ii) 
fold change > 1.5 and average difference change > 500, and (iii) fold change > -1.5 and 
average difference change > 100 (the average difference change is a computational value 
of the magnitude of difference in expression). These thresholds were chosen 
conservatively to minimize the inclusion of false-positives in subsequent analysis. Based 
on these conditions, 79 genes were increased and 56 genes were decreased in ob/ob liver. 
Leptin-specific patterns of gene expression 
While binary comparisons, as described above, are a useful starting point for 
analysis, making biological conclusions from this data is extremely difficult. The altered 
gene expression noted in ob/ob mice may result from obesity, hyperphagia, leptin 
deficiency, or hormonal perturbations. Monitoring gene expression over a dynamic 
process, such as a time course, can be more useful for dissecting the molecular basis of a 
complex physiological pathway (Soukas et al. 2000; Soukas et al. 2001). 
In order to better understand the basis for leptin's unique metabolic effects, we 
used microarrays to identify genes that are differentially regulated by leptin vs. pair-
feeding in liver. To this end, ob/ob mice were followed over a time course of weight loss 
induced by either leptin administration or pair-feeding, as previously described (Soukas 
et al. 2000). Liver RNA was isolated from groups of ob/ob mice treated with 
subcutaneous leptin (infusion rate of 4.8 ,ug/24 hours) for 2, 4, and 12 days and freely fed 
ob/ob mice that received saline. This dose of leptin has been shown to produce plasma 
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levels of the hormone comparable to those in wild-type mice (Shimomura et al. 1999c). 
RNA was also isolated from ob/ob mice that were pair-fed to the leptin treated group for 
2, 4, and 12 days of treatment. Adipose RNA was isolated from the same time course to 
analyze leptin-specific patterns of gene expression in this tissue (Soukas et al. 2000). The 
change in body weight and food intake of these groups of mice is shown in Figure 4.2 (a 
and b). As previously shown, leptin treated ob/ob mice lost significantly more weight 
than pair-fed mice indicating that leptin has metabolic actions that are not purely due to 
its effects on food intake (Levin et al. 1996). 
Leptin replacement preferentially corrected the liver pathology in ob/ob mice. 
Leptin reduced hepatomegaly, significantly more so than pair-feeding (p < 0.05 leptin vs. 
pair-fed at days 2, 4, and 12) (Figure 4.2c). Leptin also caused a significant decrease in 
liver triglyceride levels, with far greater potency than pair-feeding (Figure 4.2d). This 
was further evident in histological sections showing a greater reduction in hepatic 
vacuolation following 12 days of leptin treatment than after an equivalent period of food 
restriction (Figure 4.2e). 
RNA from the livers of these mice was hybridized to Affymetrix Murine 6500 
GeneChips. Data were analyzed using a AT-means clustering algorithm (Hartigan 1975; 
Kohonen 1997; Soukas et al. 2000). This computational method groups genes with 
similar patterns of expression over the time course experiment. For inclusion in the 
cluster analysis, a gene had to meet pre-established selection criteria, based on which 326 
genes were included in the analysis (See Materials and Methods, Chapter 2) (Soukas et 
al. 2000; Soukas et al. 2001). 
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Figure 4.2 Leptin treatment produces novel metabolic effects. (A) Percent change in body 
weight and (B) daily food intake in obob mice treated with leptin (green circles), PBS with 
pair-feeding (red triangles), and PBS with free-feeding (blue squares). Liver R N A was isolated 
from .animals sacrificed at days 2, 4, and 12 of the time course, n = 4 per group, error bars denote 
S E M , *, p < 0.05 pair-fed vs. leptin. At all time points, except tO, both pair-fed and leptin 
values were significantly different from pbs values (p < 0.01). (C) Liver weight and (D) liver 
triglyceride content at day 12 of treatment and in untreated wild-type liver. For (C) and (D), 
PBS is in blue, pair-fed is in red, and leptin is in green; error b.ars denote S E M . For (C) n =4, 
', p < 0.05 pair-fed vs. leptin, for (D) n =3, *, p < 0.05 leptin vs. pbs and *, p = 0.07 pair-fed vs. 
leptin. (E) Hematoxylin and eosin stained liver sections from representative mice sacrificed after 
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Figure 4.3 Leptin elicits a specific program of gene expression in ob/ob liver. K-means cluster analysis 
of genes from the time course. In the colorgram on the left, each row represents a gene and each column 
represents a group. The color denotes the expression level of each gene relative to wild type. The graphs on 
the right .are another means of representing the data. In these curves, the expression profile of the average 
gene in each cluster is depicted relative to untreated lean littermate controls for which expression is given a 
value of zero. The expression levels in leptin treated and pair-fed mice are shown in green -and blue 
respectively. 15 clusters of genes with distinct patterns of expression were identified, six of which correspond 
* ; î ~L :c--"y regulated by leptin relative to pair-feeding. 
15 clusters of genes with distinct patterns of expression were identified, six of 
which corresponded to genes specifically regulated by leptin, but not pair-feeding (Figure 
4.3). These clusters were likely to include genes that are either functional components or 
markers of leptin's metabolic effects. These six clusters were further subdivided into two 
classes: (a) genes that were overexpressed in ob/ob liver and specifically reduced by 
leptin (clusters 10, 11, 13, and 14) and (2) genes that were underexpressed in ob/ob liver 
and preferentially induced by leptin (clusters 7 and 12). In addition, several clusters of 
genes showed similar patterns of expression with both leptin treatment and pair-feeding, 
suggesting that these profiles represented a more general response to reduced food intake 
and weight loss or to experimental manipulation (Figure 4.3, clusters 2, 3, 5, 6, and 15). 
A complete list of the genes in all of the clusters can be found on the worldwide web 
(http://hal.rockefeller.edu/arrays/leptin/liver/). In aggregate, these data confirm that leptin 
elicits a novel program of gene expression in liver. As the genes in each of these clusters 
are specifically regulated by leptin (as compared to pair feeding), they could, in certain 
cases, mediate some of the effects of the hormone. 
Transcriptional control of leptin-regulated clusters of genes 
The leptin-regulated clusters, particularly those whose expression was specifically 
repressed by leptin (clusters 10, 11, 13, and 14), were enriched in genes involved in lipid 
and carbohydrate metabolism. Genes with roles in lipid metabolism included molecules 
involved in lipogenesis (SCD-1, SCD-2, malic enzyme, ATP citrate lyase, fatty acid 
synthase, spotl4, and glycerophosphate dehydrogenase), lipid transport (CD36, PMP70), 
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and apolipoprotein metabolism (plasma phospholipid transfer protein, apolipoprotien A-
IV, apolipoprotein C-II). Genes with functions in carbohydrate metabolism included the 
three rate-limiting enzymes of gluconeogenesis, glucose-6-phosphatase fructose 
bisphosphatase 1, and phosphoenolpyruvate carboxykinase 1 (PEPCK) (all members of 
cluster 10, Figure 4.3). The transcriptional regulation of lipogenesis and gluconeogenesis 
are both well characterized. Since leptin specifically repressed genes involved in these 
processes, we examined whether leptin regulated the transcription factors coordinating 
these metabolic pathways. 
Sterol regulatory element-binding proteins (SREBPs) are a family of basic helix-
loop-helix transcription factors that regulate the entire program of fatty acid and 
cholesterol biosynthesis (Horton et al. 2002). In their inactive form, SREBPs are bound to 
the endoplasmic reticulum membrane. In reponse to sterol depletion, SREBPs are 
proteolytically cleaved from the ER membrane and translocate to the nucleus, where they 
activate the transcription of genes containing sterol response elements (SREs)(Horton et 
al. 2002). Studies in transgenic mice have shown that SREBP-la and -lc primarily 
activate transcription of fatty acid biosynthetic molecules, while SREBP-2 preferentially 
activates cholesterol biosynthetic genes (Shimano et al. 1996; Shimano et al. 1997; 
Horton et al. 1998). SREBP-lc RNA levels and nuclear protein were shown to be 
increased in diabetic, leptin deficient ob/ob and aP2-SREBP-lc transgenic mice 
(Shimomura et al. 1999a; Shimomura et al. 2000). Microarray analysis of SREBP 
expression, however, found only a small, unreliable increase in SREBP RNA levels in 
ob/ob mice and no substantial alterations upon either leptin administration or pair-
feeding, a finding that was confirmed by Northern blot analysis (Figure 4.4a) and 
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Figure 4.4 Transcriptional regulation of leptin-specific cluster of gene 
expression. (A) Northern blot analysis (top) of SREBP-1 R N A levels using 
a probe that hybridizes with both SREBP-la and -lc. Ethidium bromide stained 
18S R N A was used to confirm equal loading. Western blot analysis (bottom) of 
68 k D nuclear S R E B P protein. The upper band likely represents an intermidate 
of proteioytic cleavage. Nuclear protein was prepared as described in Chapter 2. 
(B) Northern blot analysis of PGC-1 R N A levels using a probe that hybridizes 
to all three splice variants, indicated by an * The blot was hybridized with a 
cyclophilin probe to confirm equal loading. 
ribonuclease protection assays (data not shown). Furthermore, Western blotting detected 
no increase in nuclear SREBP-1 protein in ob/ob mice, and a minor, but equivalent 
repression following either leptin treatment or pair-feeding (Figure 4.4a). 
Gluconeogenic gene expression is regulated by a number of factors, including the 
transcriptional cofactor PGC-1. This molecule was originally identified as a cold-induced 
transcriptional coactivator of PPARy and thyroid hormone receptor in brown fat 
(Puigserver et al. 1998). Subsequent studies showed that the cAMP-regulated 
transcription factor CREB induced PGC-1, which in turn, coactivated HNF4cc and 
induced gluconeogenic gene expression (Herzig et al. 2001; Yoon et al. 2001). In 
addition, in animal models of hepatic insulin resistance, including ob/ob mice, which fail 
to downregulate hepatic gluconeogenesis in response to elevated insulin, liver PGC-1 
expression was elevated (Yoon et al. 2001). Northern blot analysis demonstrated leptin-
specific repression of the RNA levels of all three PGC-1 splice variants, with no 
alteration observed in response to pair-feeding (Figure 4.4b). The pattern of PGC-1 
expression in response to leptin treatment mirrored the expression profiles of glucose-6-
phosphatase, fructose bisphosphatase 1, and phosphoenolpyruvate carboxykinase 1 
(cluster 10, Figure 4.3). Thus, leptin-mediated repression of PGC-1 may be the 
mechanism by which leptin suppresses gluconeogenic gene expression. 
Discussion 
A number of reports have examined gene expression and its involvement in 
obesity and metabolic diseases. Differential display was done to identify alterations in 
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gene expression in ob/ob skeletal muscle, and global analysis of expression was 
performed in multiple tissues of ob/ob mice using the GeneCalling technology (Vicent et 
al. 1998; Renz et al. 2000). Oligonucleotide microarrays were used to characterize 
expression profiles in white adipose tissue in response to leptin treatment or over a 
gradient of increasing obesity and worsening diabetes (Nadler et al. 2000; Soukas et al. 
2000). Microarrays were also used to study gene expression in ob/ob liver in response to 
leptin therapy, with similar findings to those described here (Ferrante et al. 2001; Liang 
and Tall 2001). 
The liver is central to whole body metabolism and plays an important role in the 
determination to follow either an anabolic or catabolic fate. Lipogenic gene expression 
was elevated in ob/ob liver and was previously shown to be suppressed in ob/ob adipose 
tissue, an observation that was also noted in obese humans, and indicates that hepatic 
fatty acid biosynthesis may contribute substantially to the development and maintenance 
of obesity (Nadler et al. 2000; Soukas et al. 2000; Diraison et al. 2002). Livers of ob/ob 
mice are massively enlarged and steatotic, and contain elevated lipid and glycogen in 
keeping with an anabolic process. Weight loss and depletion of hepatic lipid require a 
shift to a catabolic program, which appears to be specifically modulated by leptin. 
Understanding the molecular basis for these programs could provide a marker for leptin's 
unique effects and could ultimately explain how body composition is determined. 
The effects of leptin cannot be accounted for by a reduction in food intake alone, 
as leptin treated ob/ob mice lose significantly more weight than pair-fed controls (Levin 
et al. 1996). In addition, leptin replacement completely corrects the hyperinsulinemia in 
ob/ob mice, which is likely associated with enhanced hepatic insulin sensitivity, whereas 
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pair-feeding only reduces insulin levels by 5 0 % (Levin et al. 1996). Thus, leptin-specific 
modulation of gene expression and the depletion of hepatic lipid may, in fact, be 
secondary to the correction of diabetes and neuroendocrine abnormalities of ob/ob mice. 
Leptin-deficient, lipodystrophic aP2-SREBP-lc transgenic mice also manifest 
hyperinsulinemia, diabetes, and hepatic steatosis, all of which can be corrected by leptin 
administration (Shimomura et al. 1999c). The alterations in gene expression and patterns 
of expression following leptin treatment of these mice demonstrate a striking similarity to 
those of ob/ob mice (E. Asilmaz, unpublished results). These findings suggest that leptin-
deficiency accounts for a significant component of the abnormalities in both of these 
animal models and that the leptin-specific programs of gene expression observed in ob/ob 
and aP2-SREBP-lc transgenic mice may be secondary to the correction of 
hyperinsulinemia and other endocrine defects. 
To study the effects of leptin, independent of its correction of the obese 
phenotype, gene expression was also analyzed in wild-type liver at several time points of 
leptin administration and pair-feeding. In wild-type mice, neither leptin treatment nor 
pair-feeding significantly affect insulin levels or other endocrine parameters (Levin et al. 
1996). Only a small number of genes were specifically modulated by leptin in wild-type 
liver, further indicating that the leptin-specific transcriptional signature in ob/ob mice 
might be largely secondary to correction of the obese condition (data not shown). These 
genes are more likely to be specifically modulated by quantitative changes in circulating 
leptin levels. 
Data presented earlier in this thesis (Chapter 3) suggested that a significant 
proportion of leptin's effects on hepatic gene expression were the result of central action. 
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In addition, i.c.v. leptin enacted a markedly similar program of gene expression to 
peripherally administered leptin in lipodystrophic mice (E. Asilmaz, unpublished results). 
The efferent pathways responsible for leptin's effects on gene expression and metabolism 
are not known, but are likely to involve the combined modulation of the autonomic 
nervous system and the hypothalamic-pituitary axis. Central administration of NPY 
stimulates peripheral lipogenic gene expression (Billington et al. 1991; Zarjevski et al. 
1993). Leptin decreases NPY levels in the hypothalamus, suggesting that the modulation 
of a neuronal circuit downstream of NPY may be responsible for leptin's effects on 
lipogenic gene expression (Stephens et al. 1995). Genetically modified pseudorabies 
viruses have been used to trace the leptin circuitry within the brain (DeFalco et al. 2001). 
Similar studies are in progress to identify the neuronal sites from which efferents project 
to peripheral metabolic organs such as adipose tissue and liver. 
Understanding the transcriptional mechanisms underlying leptin-specific patterns 
of gene expression may help identify the efferent signal(s) underlying leptin's peripheral 
effects. Based on the membership of leptin-regulated gene clusters, we examined whether 
leptin regulated the levels of known, candidate transcription factors. While previous 
reports indicated that levels of SREBP-lc RNA and nuclear protein were elevated in 
ob/ob mice, experiments performed here did not detect any alterations (Shimomura et al. 
1999a; Shimomura et al. 2000). SREBP expression and cleavage are stimulated by 
insulin, and the discrepancy between our results and those previously published may 
reflect differences in insulin levels (Foretz et al. 1999; Shimomura et al. 1999a; 
Shimomura et al. 1999b). Specifically, the previous studies used older mice in the middle 
of the dark cycle, when insulin levels should be at their peak, whereas we studied 
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younger mice in the middle of the light cycle, when insulin levels are likely to be at their 
nadir (Shimomura et al. 1999a; Shimomura et al. 2000). Leptin was found to regulate 
SREBP RNA levels and cleavage in adipose tissue (Soukas et al. 2000). However, in 
adipose tissue a far more comprehensive list of SREBP-target genes than identified here 
were found to co-cluster, perhaps indicating that the lipogenic genes regulated by leptin 
in the liver could be targets of another transcription factor. We did find that leptin 
specifically downregulated the RNA levels of PGC-1 a transcriptional cofactor, that 
regulates gluconeogenic gene expression (Herzig et al. 2001; Yoon et al. 2001). As ob/ob 
mice are diabetic and have elevated hepatic gluconeogenesis, leptin-specific modulation 
of PGC-1 might contribute to the correction of diabetes associated with leptin treatment. 
Further studies are required to determine the role of this molecule in the transcriptional 
response to leptin. In addition to these molecules, leptin may also regulate the levels 
and/or activity of PPARa, PPARy, ChREBP, HNFs, LXRs, or yet to be identified 
transcription factors (Bocher et al. 2002; Edwards et al. 2002; Schrem et al. 2002; Uyeda 
et al. 2002). 
In aggregate, these data demonstrate the induction of a novel, distinct 
transcriptional signature characteristic of the unique metabolic program of weight loss 
induced by leptin. These data distinguish leptin treatment from food restriction at a 
molecular level, and may ultimately provide new insight into the nature of the leptin-
stimulated efferent signals from the hypothalamus. A subset of these leptin-regulated 
genes may play a functional role in the obese phenotype and the unique metabolic actions 
of leptin. 
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Chapter 5: Role for Stearoyl-CoA Desaturase-1 in Leptin-Mediated Weight 
Loss 
Introduction 
Leptin regulates energy balance, metabolism, and the neuroendocrine response to 
altered nutrition (Zhang et al. 1994; Friedman 2000a). The metabolic program that leptin 
elicits is not explained by its effects on food intake alone (Levin et al. 1996; Kamohara et 
al. 1997). Leptin replacement in leptin-deficient (ob/ob) mice and humans leads to the 
depletion of lipid in adipose tissue, liver, and other tissues (Campfield et al. 1995; Halaas 
et al. 1995; Pelleymounter et al. 1995; Farooqi et al. 1999). Leptin treatment also 
improves insulin sensitivity and reduces fat content in lipodystrophic mice and humans 
(Shimomura et al. 1999c; Oral et al. 2002). 
To elucidate the mechanism whereby leptin reduces hepatic lipid content, we 
used microarrays to identify genes that were differentially regulated by leptin vs. pair-
feeding in liver. Leptin treated ob/ob mice lose significantly more weight than pair-fed 
mice, indicating that leptin stimulates energy expenditure (Figure 4.2). Liver R N A from 
these animals was hybridized to microarrays and the data were analyzed using a AT-means 
clustering algorithm (Soukas et al. 2000). 15 clusters of genes with distinct patterns of 
expression were identified, six of which correspond to genes specifically regulated by 
leptin, but not pair- feeding (Figure 4.3). 
W e used a more directed computational approach to identify genes that are 
particularly repressed during leptin-mediated weight loss. Leptin was found to 
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specifically repress R N A levels and enzymatic activity of hepatic stearoyl-CoA 
desaturase-1 (SCD-1), which catalyzes the biosynthesis of monounsaturated fatty acids. 
Mice lacking SCD-1 were lean and hypermetabolic. ob/ob mice with mutations in SCD-1 
were significantly less obese than ob/ob controls and had markedly increased energy 
expenditure, ob/ob mice with mutations in SCD-1 had histologically normal livers with 
significantly reduced triglyceride storage and VLDL production. These findings suggest 
that down-regulation of SCD-1 is an important component of leptin's metabolic actions. 
Results 
Identifying and ranking leptin-repressed genes. 
In order to prioritize leptin-regulated genes for detailed functional analysis, we 
developed an algorithm to identify and rank genes that are specifically repressed by 
leptin. This algorithm ranked genes based on the extent to which their expression was (1) 
increased in ob/ob liver compared to wild type (2) repressed by leptin treatment, and (3) 
different between leptin treatment and pair-feeding. Such genes are candidates as 
contributing to the obese phenotype. Specifically, we selected genes whose expression 
was increased in ob/ob relative to wild-type and corrected by leptin administration. Genes 
with the lowest scores are those most strongly leptin-regulated. The specific 
characteristics of this algorithm are described in more detail in Chapter 2. The results of 
this analysis are shown in Table 5.1. The gene encoding SCD-1 ranked the highest in this 
analysis. 
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glutathione S-transferase, alpha 1 
tubulin, beta 
glutathione S-transferase class mu 
glucose-6-phosphatase 
malate NADP oxidoreductase 
est, similar to human insulin induced protein 2 
spot 14 
ATP citrate lyase 
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fructose bisphosphatase 1 
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stearoyl-CoA desaturase-2 
glutathione peroxidase 4 
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protein tyrosine phosphatase, non-receptor type 16 
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Table 5.1 Leptin-repressed gene expression in ob/ob liver. In order to prioritize leptin-regulated 
genes for detailed functional analysis, an algorithm w a s developed to identify and rank genes that 
are specifically repressed b y leptin. This algorithm ranked genes based o n the extent to which then-
expression w a s (1) increased in ob/ob liver compared to wild type (2) repressed by leptin treatment, 
and (3) different between leptin treatment and pair-feeding. Such genes are candidates as contributing 
to the obese phenotype. G e n e s were selected w h o s e expression w a s increased in ob/ob relative to 
wild-type and corrected b y leptin administration. G e n e s with the lowest scores are m o s t strongly 
leptin-repressed. 
Leptin-specific regulation of SCD-1 
SCD-1 is a microsomal enzyme that is required for the biosynthesis of the 
monounsaturated fats palmitoleate and oleate from saturated fatty acids (Ntambi et al. 
1988; Ntambi 1999). SCD-1 RNA levels were highly elevated in untreated ob/ob liver 
(Figure 5.1a). SCD-1 RNA levels in leptin treated ob/ob mice were normalized at 2 days 
and by 4 days fell to levels below that of lean controls, a result consistent with previous 
studies (Ferrante et al. 2001; Liang and Tall 2001). Pair-fed mice showed a smaller and 
delayed decrease in SCD-1 gene expression. 
SCD enzymatic activity was elevated 7.2-fold in livers of untreated ob/ob mice 
relative to wild type (p < 0.0005) and remained significantly elevated in saline-treated, 
free-fed ob/ob controls (Figure 5.1b). Leptin treatment normalized SCD enzymatic 
activity, while pair-feeding reduced enzymatic activity to a lesser extent (p < 0.005 leptin 
vs. free fed, p < 0.02 leptin vs. pair-fed at each time point). Levels of hepatic 
monounsaturated 16:1 and 18:1 fatty acids, the products of SCD-1, were elevated in 
ob/ob mice and normalized by 12 days of leptin treatment, but not by pair-feeding (Table 
5.2). Leptin also preferentially normalized desaturation indices (ratio of 16:1/16:0 and 
18:1/18:0 levels), which are an indicator of SCD enzymatic activity. 
Reduced fat mass in mice lacking SCD-1 
To investigate whether SCD-1 might mediate some of leptin's metabolic effects, 
we studied asebia mice (abJ/ab ), which carry mutations in SCD-1 (Gates and Karasek 
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Figure 5.1 Leptin-specific down-regulation of S C D - 1 R N A levels and enzymatic 
activity. (A) Northern blot of liver R N A samples from an independent time course 
experiment probed with radioactively labeled c D N A probes specific for SCD-1 and 
the small mitochondrial R N A p A L - 1 5 (loading control). (B) S C D enzymatic activity 
assays measure the conversion of [1-14C] stearoyl-CoA to [l-l4C] oleate, as described in 
Chapter 2. Activity is expressed as nmol min"1 mg"1 protein. Error bars indicate the 
S E M , n =3 for each group. *, p < 0.05 vs. saline treated, *, p < 0.02 vs. p.air fed, 
" p < 0.0005 untreated lean vs. untreated ob/ob. (C) Ratios of 16:1/16:0 and 18:1/ 
18:0 triglycerides, as an indicator of S C D enzymatic activity. Values were determined 
from lipid composition analysis (Table 5.2). Error bars indicate the S E M , n =3 for each 
group.", p < 0.05 vs. saline treated, *, p < 0.05 vs. pair fed. 











































































































































































Table 5.2 Liver fatty acid composition. Liver lipid composition w a s determined 
in untreated lean and ob/ob liver and following 12 days of pbs, pair-feeding, or leptin. 
Total lipids were extracted from liver with Folch solvent (chloroform/methanol 2:1). 
A t the start of the liver extraction, internal standards of C 17:0 triglyceride, cholesteryl 
ester, and phosphatidyl choline were added to quantitate each lipid class. T h e lipid 
classes in the liver extract were separated by thin layer chromatography using silica gel 
G and a developing solvent of hexane/diethyl ether/acetic acid (60:40:1). T h e fatty acids 
in each lipid class were methylated with fresh 5 % methanolic H C I and analyzed with a 
gas chromatograph. N u m b e r s in the table are averaged from 3 mice per group. For clarity, 
S E M is not shown, but all error values were within acceptable limits. *, p < 0.05 lean vs. ob/ob 
or p < 0.05 pair-fed or leptin vs. saline, *, p < 0.05 leptin vs. p.air-fed. 
and express no SCD-1 R N A or protein, though expression of SCD-2 is not altered (Zheng 
et al. 1999). SCD-1 is highly expressed in the sebaceous glands of the skin and the 
harderian and meibomian glands of the eye. Consequently, abJ/abJ mice have cutaneous 
and ocular defects. The phenotype of these mice is identical to that of mice with an 
induced mutation in SCD-1 (Miyazaki et al. 2001). 
The weight of male abJ/abJ mice was indistinguishable from that of littermates 
U i„iJ and female ab /ab mice weighed significantly more than littermates (Figure 5.2a, p < 
0.005 at all ages after 6 weeks). However, abJ/abJ mice had significantly reduced fat 
mass relative to controls (from 12.7% to 8.3% in females, p < 0.005; from 13.5% to 6.9% 
in males, p < 0.0005, Figure 5.2b) and plasma leptin levels (females: 2.3±0.4 ng/ml vs. 
5.0±0.9 ng/ml, males: 2.7±0.5 ng/ml vs. 7.8±1.4 ng/ml, p < 0.01 for both sexes). 
To explore the effects of SCD-1 deficiency on the ob/ob phenotype, we 
intercrossed ob/+ and abJ/+ or abJ/ abJ mice. abJ/abJ; ob/ob mice showed a dramatic 
reduction in body weight at all ages compared to ob/ob littermate controls (Figure 5.2a, p 
< 0.0001 from 5 weeks of age). At 16 weeks of age, weight was reduced by 29% in 
females (p < IO"6) and 34% in males (p < IO"4). A photograph of a representative ob/ob 
and an abJ/abJ; ob/ob mouse is shown in Figure 5.2c. Fat mass in 16 week-old double 
mutant females was 32.1% vs. 51.0% in ob/ob (p < IO"4) and 28.1% in double mutant 
males vs. 49.9% in ob/ob (p < 10"5) (Figure 5.2b). abJ/abJ; ob/ob mice of both sexes also 
showed a significant increase in percent lean mass relative to ob/ob littermates (from 
15.3% to 18.5% in females, p < 0.005; from 15.3% to 20.1% in males, p < 0.05) 
indicating that double mutants do not suffer from a generalized growth defect. 
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Figure 5.2 Attenuation of the obese phenotype in mice with a mutation in SCD-1 (abJ/abJ). 
Weight curves of obob (blue squares), at/ 'at/; ob ob (green diamonds), at/ at/ (gold circles), 
and control (magenta tri,angles) mice. Error b.ars indicate the SEM, n > 9 for each group. 
*, p < 0.01 at/ at/ vs. control orp < 0.0001 at/ at/; ob ob vs. ob ob. (B) Carcass analysis of 
female and male ob ob (blue), at/ at/; ob ob (green), at/ at/ (gold), and control (magenta) mice 
was performed as in Chapter 2. Error bars indicate the SEM, n > 8 for each group. ', p < 0.005 vs. 
lean control, \ p < 0.05 vs. ob ob. (C) Photograph of a representative ob ob and at/ at/; ob ob 
mouse. 
Mechanism for reduced adiposity in mice lacking SCD-1 
To analyze energy balance, we measured food intake and energy expenditure in 
ob/ob and lean littermates with and without homozygous SCD-1 mutations, ob/ob mice 
were hyperphagic compared to lean controls (Figure 5.3a,b). Despite being significantly 
leaner, abJ/abJ; ob/ob mice consumed 35% more food than ob/ob littermates (9.0±0.9 
g/day vs. 6.6±0.4 g/day, p < 0.05) (Figure 5.3a,b). abJ/abJ mice consumed 53% more than 
lean controls (6.3±0.2 g/day vs. 4.2±0.2 g/day, p < IO"6) with an average food intake 
indistinguishable from that of ob/ob mice (Figure 5.3a,b). Relative to ob/ob controls, 
abJ/abJ; ob/ob mice showed increases of 96% (female) and 56% (male) in total V02 and 
increases of 174% (female) and 71% (male) in resting V02 (Figure 5.3c,d, p < 0.02). 
Total and resting oxygen consumption in female double mutants were indistinguishable 
from those of lean controls and in male double mutants they were even greater than those 
of lean controls (p < 0.05 for resting V02). Lean abJ/abJ mice expended more energy 
with increases of 30% and 46% in total oxygen consumption and increases of 43% and 
62% in resting oxygen consumption for females and males respectively (Figure 5.3c,d, p 
< 0.02). Double mutant abJ/abJ; ob/ob mice had increased plasma levels of ketone bodies 
(P-hydroxybutyrate) relative to ob/ob littermates, suggesting increased fatty acid 
oxidation (females: 6.6±1.2 mg/dl vs. 3.4±0.6 mg/dl, p < 0.05; males: 4.5±1.4 mg/dl vs. 
3.5±0.7mg/dl,NS). 
ob/ob mice have massively enlarged livers that are engorged with lipid. Gross 
inspection revealed that the hepatomegaly and the steatosis of ob/ob mice were 
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Figure 5 3 Increased energy expenditure, despite persistent hyperphagia, accounts for 
reduced adiposity in abJ/abJ;ob/ob and abJ/abJ mice. (A) Average daily food intake by group 
and (B) scatterplot of average daily food intake for individual mice in each group of oft ob (blue), 
abJ abJ; ob ob (green), abJ at/ (gold), and control (magenta) mice. Mice were acclimated m 
individual cages and 24 hour food consumption was measured for 8 consecutive days Food intake 
for each mouse w a s averaged over the 8 days and these values were averaged for the mice m each 
group. Mice were 12-18 weeks of age. Food intake for males and females was indistinguishable and 
has been pooled. Error bars indicate S E M , n > 4 for each group. * p < 0.05 vs. lean control,", p < 0 05 
vs. ob ob (C) Total and (D) resting oxygen consumption of female and male ob ob (blue), a f a f ; ob ob 
(green), abJ/abJ (gold), and control (magenta) mice. 14-16 week old mice were placed m an indirect 
calorimeter and allowed 2 hours to acclimate to the n e w environment Measurements were taken for 
5 hours during the middle of the light cycle The total V 0 2 is the average of these readmgs. The resting 
V 0 2 is the average of all readmgs that are one standard deviation below the total V 0 2 , as these readings 
represent periods of inactivity Error bars mdicate S E M , n > 3 for each group * p < 0.05 vs. lean control, 
*, p < 0.05 vs. ob ob 
lipid-filled vacuoles, while those of abJ/abJ; ob/ob mice showed little or no vacuolation 
and were indistinguishable from those of wild-type mice (Figure 5.4a). The levels of 
liver triglyceride were substantially increased in ob/ob mice (p < 0.005 vs. all other 
groups), whereas triglycerides in abJ/abJ; ob/ob mice were reduced to levels comparable 
to lean controls (Figure 5.4b). As previously shown, triglyceride levels in lean abJ/abJ 
mice were reduced below those of lean controls (Figure 5.4b) (Miyazaki et al. 2000). 
Palmitoleate and oleate in triglycerides and cholesterol esters are major 
constituents of very low density lipoprotein (VLDL) particles, which transport fatty acids 
from liver to adipose tissue and other sites. We assayed the rate of hepatic lipid export in 
mice injected with tyloxapol, an inhibitor of VLDL hydrolysis, permitting the 
measurement of VLDL production (Merkel et al. 1998). VLDL production was increased 
2.4-fold in ob/ob mice relative to lean controls (Figure 5.4c, p < 0.05). Compared to 
ob/ob controls, VLDL production was reduced 3.6-fold in abJ/abJ; ob/ob mice (8.2 
mg/dl/min vs. 2.3 mg/dl/min, p < 0.02) (Figure 5.4c). 
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Figure 5.4 Reduced hepatic lipid storage and V L D L production in af/af;ob/ob mice. (A) Hematoxylin 
and eosin ( H & E ) stained liver sections from representative obob .and a f a f ; ob ob mice. Images are 200x 
magnifications; scale bars denote 100 (im. (B) Liver triglyceride content ofob ob (blue), a f a f ; ob ob (green), 
a f a f (gold), .and control (magenta) mice. Levels were determined as described in Chapter 2. Error bars indicate 
S E M , n > 4 for each group. *, p < 0.0005 vs. obob. (C) V L D L production in ob ob (blue), a f a f ; ob ob (green), 
a f a f (gold), and control (magenta) mice. Mice fasted for 5 hours were injected with 0.5 mg/kg tyloxapol 
(Triton-1339) (Sigma, St. Louis, M O ) via the tail vein as described m Chapter 2. Tail bleeds were done at 0, 45, 
and 90 min .and plasma triglycerides were assayed using an enzymatic reagent. The slope of the line mdicates the 
rate of V L D L production. Error bars indicate S E M , n > 3 for each group. For a f a f ; ob ob and control, p < 0.05 
vs. ob/ob. For a f a f , p = 0.07 vs. obob. 
Discussion 
These data show that SCD-1 is required for the fully developed obese phenotype 
of ob/ob mice and suggest that a significant proportion of leptin's metabolic effects may 
result from inhibition of this enzyme. Mice with a targeted knockout of SCD-1 (SCD-A) 
have also been generated, and they resemble abJ/abJ mice in all respects (Miyazaki et al. 
2001). These mice also have reduced fat mass and are resistant to increased adiposity 
after long-term consumption of a high-fat diet (Ntambi et al. 2002). SCD-1"7" mice also 
have enhanced glucose and insulin tolerance. Microarray analysis of gene expression in 
these mice detected increased expression of genes involved in fatty acid oxidation and 
decreased expression of lipogenic genes in SCD-17" mice (Ntambi et al. 2002). 
The basis for the metabolic effects of SCD-1 deficiency is not known. One 
possibility is that in the absence of SCD-1, a reduced rate of triglyceride and VLDL 
synthesis increases the intracellular pool of saturated fatty acyl CoAs leading to an 
increase in fatty acid oxidation. Monounsaturated fats are necessary for normal rates of 
triglyceride and cholesterol ester synthesis, which are required for hepatic lipid storage 
and VLDL synthesis (Miyazaki et al. 2000). Saturated fatty acyl CoAs, but not 
monounsaturated fatty acyl CoAs, potently allosterically inhibit acetyl CoA carboxylase 
(ACC), reducing cellular levels of malonyl CoA (Volpe and Vagelos 1976; Lunzer et al. 
1977; Nikawa et al. 1979). Malonyl CoA is required for fatty acid biosynthesis and also 
inhibits the mitochondrial carnityl palmityl transferase shuttle system, the rate-limiting 
step in the import and oxidation of fatty acids in mitochondria (McGarry et al. 1977). 
Reduced activity of SCD-1 may decrease adiposity by decreasing cellular levels of 
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malonyl C o A thereby reducing fatty acid biosynthesis and de-repressing fatty acid 
oxidation. Figure 5.5a shows a schematic of this potential mechanism. Moreover, 
preliminary data indicates that levels of saturated fatty acyl CoAs are, in fact, increased 
3-fold or more in mice lacking SCD-1 (Figure 5.5b). Whether or not the increased 
saturated fatty acyl CoAs inhibit ACC and lead to reduced malonyl CoA and increased 
fatty acid oxidation remains to be tested. 
These findings are similar to those described in mice lacking acetyl-CoA 
carboxylase 2, which also have increased fatty acid oxidation in skeletal muscle and a 
lean phenotype (Abu-Elheiga et al. 2001). The mechanism by which leptin increases fatty 
acid oxidation in liver may be similar to that in skeletal muscle in that both may operate 
by reducing ACC activity. However, in skeletal muscle, leptin, acting directly and 
indirectly via the CNS, inhibits ACC via a2 AMP-kinase, which phosphorylates and 
inhibits ACC (Minokoshi et al. 2002). Recent studies have shown that leptin stimulated 
fatty acid oxidation in liver and heart does not activate oc2 AMP-kinase, indicating that 
other mechanisms may be involved, perhaps involving changes in SCD-1 activity 
(Atkinson et al. 2002; Lee et al. 2002). 
Alternative mechanisms could also account for the metabolic effects of SCD-1 
deficiency. Changes in SCD-1 activity could alter the levels of ligands for PPARa, 
PPARy, or other nuclear hormone receptors. Changes in the ratio of saturated:unsaturated 
fatty acids in phospholipids can also alter membrane fluidity, which could affect signal 
transduction. The observed increase in energy expenditure associated with SCD-1 
deficiency also suggests that uncoupling activity and/or futile cycles are induced. 
Reactive oxygen species are a byproduct of elevated oxidative metabolism and can 
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Figure 5.5 Basis for increased energy expenditure in mice lacking SCD-1. (A) Hypothetical 
mechanism for the metabolic effects of SCD-1 deficency In the absence of SCD-1, synthesis 
of triglycerides and V L D L is blocked, leading to decreased hepatic lipid storage and export. 
A lack of SCD-1 causes an increase in the pool of saturated fatty acyl CoAs, which allosterically 
inhibit acetyl C o A carboxylase (ACC). Inhibition of A C C reduces levels of malonyl CoA, a 
metabolite which normally inhibits the mitochondrial carnityl palmitoyl shuttle system, the 
rate-limiting step in the import and oxidation of fatty acids in mitochondria. Decreased malonyl 
C o A thus de-represses fatty acid oxidation, leadmg to mcreased burning of fat. (B) Liver fatty 
acyl C o A levels were measured as decribed in Chapter 2 in ob ob (blue), atr atr: ob ob (green), 
atr atr (gold), .and control (magenta) mice. Mice were scanficed in the mid-light cycle after a 
6-10 hour fast. Error bars indicate S E M , n > 3 for each group, except control n= 2. p < 0.05 
atr atr vs. lean control or atr atr; ob ob vs. ob ob control. 
increase cellular oxidative stress, thereby increasing the risk of cancer, atherosclerosis, 
and other diseases (Droge 2002). Future studies are necessary to determine whether 
increased oxidative stress is an unwanted side effect of SCD-1 deficiency. 
The effects of leptin on SCD-1 in liver are likely to require central action, as mice 
lacking the leptin receptor in brain have enlarged, fatty livers, while livers of mice with a 
liver-specific knockout of the leptin receptor appear normal (Cohen et al. 2001). Leptin 
also reduces hepatic SCD-1 activity when administered intracerebroventricularly, at a 
dose that has no effect when delivered peripherally (E. Asilmaz, unpublished results). 
The CNS signals that modulate liver metabolism in response to leptin are unknown. 
SCD-1 deficiency also appears to modulate CNS pathways that regulate food intake, 
perhaps secondary to the increased oxygen consumption. 
Leptin may also modulate the production of monounsaturated fatty acids in 
tissues other than liver. Down-regulation of SCD enzyme activity by leptin in other 
tissues, including brain, could contribute to some of the observed metabolic effects. 
Although SCD-1 is the only isoform normally expressed in liver, both SCD-1 and SCD-
2, a similar enzyme, are expressed in most other tissues. While both enzymes catalyze the 
same reaction, their cellular distribution and substrate preferences may be different. 
In summary, a deficiency of SCD-1 ameliorates the obesity of ob/ob mice and 
completely corrects the hypometabolic phenotype of leptin deficiency. These findings 
suggest that leptin-specific down regulation of SCD-1 is an important component of the 
novel metabolic response to leptin and suggests that inhibition of SCD-1 could be of 
benefit for the treatment of obesity, hepatic steatosis, and other metabolic disorders. 
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Chapter 6: Role for Stearoyl-CoA Desaturase-1 in Fatty Liver Disease 
Introduction 
Hepatic steatosis, or fatty liver, is the earliest manifestation of both alcoholic and 
nonalcoholic liver disease. Both types of fatty liver disease are marked by the histological 
presence of steatosis and a mixed inflammatory cell infiltrate, and as disease worsens, by 
the appearance of hepatocyte necrosis and fibrosis (Angulo 2002). In fact, the two types 
of disease are histologically indistinguishable, and the differential diagnosis is largely 
based on the presence or absence of alcohol abuse (Yu and Keeffe 2002). Fatty livers are 
particularly susceptible to endotoxin-mediated damage, which in turn, accelerates the 
progression of disease to steatohepatitis, fibrosis, cirrhosis, and end-stage liver disease. 
(Yang et al. 1997; Diehl 2001; Yang et al. 2001). Nonalcoholic fatty liver disease 
(NFLD) is now recognized as the most common form of liver disease in the United 
States, and alcoholic fatty liver disease is a major cause of morbidity and mortality 
(Menon et al. 2001; McCullough 2002). Furthermore, both forms of disease are largely 
untreatable. Thus, understanding the molecular basis for fatty liver disease is required to 
develop effective treatments. 
While alcoholic fatty liver disease is, by definition, a result of chronic alcohol 
abuse, NFLD has a diverse set of etiologies. Both obesity and type 2 diabetes mellitus 
markedly increase the risk and severity of NFLD (Silverman et al. 1990; Wanless and 
Lentz 1990; Bellentani et al. 2000). While NFLD is estimated to affect 10-24% of the 
population, the prevalence among obese individuals has been estimated to be as high as 
74% (Angulo 2002). Both types of disease are characterized, in their early stages, by the 
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presence of hepatic steatosis. Lipid can accumulate in hepatocytes due to either increased 
fatty acid uptake or biosynthesis or decreased fatty acid export or oxidation (Koteish and 
Diehl 2001). 
Alcoholic fatty liver was originally thought to result from the generation of 
NADH during ethanol oxidation, which then inhibits NAD+-dependent enzymes of the 
citric acid cycle and ft-oxidation, thereby inhibiting hepatic fatty acid oxidation (Grunnet 
and Kondrup 1986; Crabb 1993). However, increased lipogenesis is being increasingly 
appreciated as underlying alcoholic fatty liver (Lieber et al. 1966; Muramatsu et al. 1981; 
Carrasco et al. 2001). A number of studies have demonstrated increased RNA levels and 
enzymatic activity of lipogenic enzymes in ethanol fed rodent models (Joly et al. 1973; 
Arakawa et al. 1975; Muramatsu et al. 1981; You et al. 2002). 
Increased rates of hepatic lipogenesis have also been demonstrated in obese rodents and 
humans, who are more prone to NFLD (Godbole and Yotk 1978; Kaplan and Leveille 
1981; Diraisonetal. 2002). 
Stearoyl-CoA desaturase-1 (SCD-1) is the rate-limiting enzyme in the conversion 
of saturated to monounsaturated fatty acids (Ntambi 1995). SCD-1 is required for normal 
rates of hepatic triglyceride and cholesterol ester biosynthesis (Miyazaki et al. 2000). 
SCD-1 RNA levels and enzymatic activity are increased in ob/ob mice, and SCD-1 plays 
a role in leptin-mediated weight loss, as ob/ob mice lacking SCD-1 (abJ/abJ; ob/ob) 
demonstrate a significant correction of obesity (Chapter 5)(Cohen et al. 2002). abJ/abJ; 
ob/ob mice also have a dramatic correction in the hepatic steatosis typical of ob/ob mice. 
This suggested that SCD-1 may play a more general role in fatty liver disease. Here, we 
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examine the role of SCD-1 in alcoholic fatty liver disease and in N F L D secondary to 
lipodystrophy. 
Results 
SCD-1 and alcoholic fatty liver disease 
To explore the role of SCD-1 in alcohol-induced fatty liver, we studied asebia 
mice (abJ/abJ), an inbred, naturally occurring mutant with a mutation in SCD-1 (Gates 
and Karasek 1965; Zheng et al. 1999). After an acclimation period, abJ/abJ and littermate 
control mice (abJ/+ or +/+) were given a 10% ethanol solution as their sole source of 
fluid. Mice will consume alcohol at this concentration, and this treatment induces fatty 
liver in a number of mouse models (Furuno et al. 1975; Wood 1976; Watabiki et al. 
2000). 
abJ/abJ and littermate controls were sacrificed after 3 and 5 weeks of alcohol 
consumption. As an additional control, age-matched mice of each genotype that were not 
exposed to alcohol were also studied. After 3 weeks of alcohol intake, livers from both 
abJ/abJ and control mice appeared grossly normal. In addition, liver triglyceride content 
was equivalent to that of untreated control mice (Fig. 6.1a). After 5 weeks of ethanol, 
however, littermate controls developed grossly steatotic livers, while livers from abJ/abJ 
mice appeared normal. Quantitation of liver triglycerides revealed a 2-fold increase in 
littermate controls mice relative to abJ/abJ (17.4 mg/g vs. 8.6 mg/g, p = 0.0009) (Figure 
6.1a). Furthermore, even after five weeks of alcohol consumption, triglyceride levels in 
abJ/abJ mice remained indistinguishable from mice not given alcohol. 
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In order to confirm that the absence of fatty liver disease in abJ/ab mice was not 
due to reduced alcohol consumption, we measured alcohol intake. Surprisingly, abJ/abJ 
mice actually consumed more alcohol than littermate controls. To quantitate alcohol 
consumption more exactly, 5 male abJ/abJ and 5 littermate controls were individually 
caged, and food and alcohol intake were recorded weekly. abJ/abJ mice consumed more 
food than littermate controls, at all time points (Figure 6.2b). While they also consumed 
more alcohol within the first few weeks, alcohol intake was comparable between the two 
groups thereafter (Figure 6.2b). Thus, despite consuming more food and an equivalent 
amount of alcohol abJ/abJ mice remained resistant to the development of alcoholic fatty 
liver. 
SCD-1 and nonalcoholic fatty liver disease secondary to lipodystrophy 
Transgenic overexpression of nuclear sterol regulatory element-binding protein-
ic (aP2-SREBP-lc tg) in white adipose tissue produces mice with a near complete 
absence of adipose tissue, along with marked hepatic steatosis, insulin resistance, and 
hyperglycemia (Shimomura et al. 1998a). The livers in these mice closely resemble those 
of ob/ob mice, and in both cases, treatment with physiological doses of leptin for 12 days 
corrects the hepatic steatosis, along with the hyperglycemia and hyperinsulinemia 
(Chapter 4) (Shimomura et al. 1999c). A number of human lipodystrophy syndromes 
have also been described, and treatment of these patients with leptin also reverses hepatic 
steatosis and insulin resistance (Oral et al. 2002; Petersen et al. 2002). 
To study the role of SCD-1 in the fatty liver disease of lipodystrophy, abJ/abJ 
mice were crossed to aP2-SREBP-lc tg mice to generate lipodystrophic mice lacking 
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Figure 6.1 Resistance to alcoholic fatty liver in mice lacking SCD-1. (A) 5-7 week 
old, male and female a f a f (gold) and littermate control mice (magenta) were offered 
a 1 0 % EtOH solution for one week. After this acclimation period (time 0), mice were 
provided with 1 0 % EtOH as the only liquid source. Groups of animals were sacrificed 
after 3 .and 5 weeks of alcohol consumption. As a control, similarly aged mice, that were 
not exposed to alcohol were also studied (untreated). Error bars indicate SEM, n > 3 for 
each group. *, p = 0.0009. (B) 8-10 week old a f a f and littermate control mice were 
individually caged and given a few days to acclimate to a 1 0 % EtOh solution. Then, 
regular drinking water was removed (time 0) and weekly food and alcohol intake were 
recorded. Error bars indicate SEM, n = 5 for each group. *, p < 0.05 a f a f vs. control. 
SCD-1 (abJ/abJ;aP2-SREBP-lc tg). Analysis of these mice confirmed that aP2-SREBP-
lc tg mice had massively enlarged steatotic livers. Livers from abJ/abJ;aP2-SREBP-lc tg 
mice, on the other hand, remained enlarged, but were no longer grossly steatotic (Figure 
6.2a). Histological sections showed hepatic vacuolation consistent with fatty liver disease 
in aP2-SREBP-lc tg mice, while abJ/abJ;aP2-SREBP-lc tg sections showed a nearly 
normal histological appearance (Figure 6.2b). Measurement of liver triglyceride levels 
revealed a 4-fold increase in triglyceride levels in aP2-SREBP-Ic tg livers relative to 
double mutant livers (34.0 ± 8.9 mg/g vs. 8.2 ± 1.2 mg/g, p = 0.02) (Figure 6.2c). 
Triglyceride levels in abJ/abJ;aP2-SREBP-lc tg livers were comparable to those in wild-
type littermate controls. 
Discussion 
The data presented here indicate that the absence of SCD-1 can not only correct 
the fatty liver of obesity (Chapter 5), but can also block the development of alcoholic 
fatty liver disease and nonalcoholic fatty liver disease associated with lipodystrophy. 
Elevated lipogenesis has been postulated to cause both types of fatty liver disease, and 
mice lacking SCD-1 have decreased rates of hepatic triglyceride production (Miyazaki et 
al. 2000). Reduced hepatic fatty acid oxidation can also contribute to fatty liver disease. 
Evidence suggests that the absence of SCD-1 indirectly leads to increased liver fatty acid 
oxidation (Cohen et al. 2002; Ntambi et al. 2002). Enhanced fatty acid oxidation could 
also underlie the resistance to hepatic steatosis in mice lacking SCD-1. Elevated fatty 
acid oxidation can be associated with increased levels of reactive oxygen species (Droge 
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Figure 6.2 Resistance to fatty liver associated with lipodystrophy in mice lacking 
SCD-1. (A) Photograph of freshly dissected livers from mice with the genotypes 
+/+;nontg (ctrl), a f +;aP2-SREBP-lc tg (tg), and a f af;aP2-SREBP-lc tg (ab;tg). 
(B) Hematoxylin and eosin stained liver sections from a representative aP2-SREBP-lc tg 
.and an a f af;aP2-SREBP-lc tg mouse. Images are 200x magnifications; scale bars 
denote 100 (im. (C) Liver triglyceride content of control (+ +;nontg and a f -;nontg) 
(magenta) a f af;aP2-SREBP-lc tg (green), and transgenic {af +;aP2-SREBP-lc tg 
and +/+;aP2-SREBP-lc tg) (blue). Error bars indicate S E M , n > 4 for each group. 
*, p < 0.05 vs transgenic. 
2002). Since increased (ROS) contribute to fatty liver disease as well as to other disease 
processes, it will be important to test whether this is a sequella of SCD-1 deficiency 
(Pessayre et al. 2002). 
Increased lipogenesis is a recognized feature of alcoholic fatty liver (Lieber et al. 
1966; Muramatsu et al. 1981; Carrasco et al. 2001). Expression analysis of liver RNA 
from alcohol fed mice found a 3-fold increase in SCD-1 RNA levels (data not shown). 
Real-time quantitative PCR confirmed this increase in SCD-1 expression (data not 
shown). A number of studies have demonstrated increased RNA levels and enzymatic 
activity of lipogenic enzymes in ethanol fed rodent models (Joly et al. 1973; Arakawa et 
al. 1975; Muramatsu et al. 1981). A recent study showed that the levels of SREBP target 
genes, including SCD-1, are upregulated in alcoholic fatty liver, due to increased levels 
of cleaved, nuclear SREBP (You et al. 2002). In addition, ethanol-fed rodents have a 
dramatic increase in hepatic levels of palmitoleic and oleic acid, the products of SCD-1 
(Tsukamoto et al. 1984). Further study is required to determine whether abJ/abJmice 
remain resistant to alcoholic fatty liver disease after more chronic ethanol administration. 
In addition, longer exposure to alcohol is associated with a progression to hepatitis, 
fibrosis, and ultimately cirrhosis, and it will be interesting to see whether mice lacking 
SCD-1 are also resistant to further liver damage. 
Lipodystrophic mice also demonstrate increased hepatic lipogenesis, due to 
increased expression of fatty acid biosynthetic enzymes, including SCD-1 (Shimomura et 
al. 1998a). Leptin administration corrects diabetes and hepatic steatosis, and is associated 
with a normalization in the expression of SCD-1 and other lipogenic molecules (E. 
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Asilmaz, unpublished results) (Shimomura et al. 1999c). Since these mice lack adipose 
tissue, they also deposit triglyceride in a number of other peripheral tissues, such as 
muscle, heart, kidney, and spleen (Garg 2000; Reitman et al. 2000). abJ/abJ;aP2-SREBP-
Ic tg mice appear to be resistant to triglyceride accumulation in these tissues as well (data 
not shown). While hepatic steatosis was prevented, livers remain grossly enlarged in 
double mutant animals, and the cause for this remains unknown. In addition, it is not yet 
clear whether abJ/abJ;aP2-SREBP-lc tg mice have any improvement in insulin resistance 
or hyperglycemia. 
Mice with transgenic overexpression of nuclear sterol regulatory element-binding 
protein-la (PEPCK-SREBP-la tg) in liver also have massively enlarged livers, engorged 
with lipid (Shimano et al. 1996). These mice have increased expression of genes involved 
in the entire program of monounsaturated fatty acid biosynthesis (Shimomura et al. 
1998b). In addition, Ay mice, which develop severe adult onset obesity, also have 
increased hepatic lipogenesis and NFLD (Yen et al. 1976). Both of these mutants have 
been crossed to abJ/abJ mice, and studies are underway to examine whether the absence 
of SCD-1 can prevent fatty liver disease in these models. 
In the absence of SCD-1, two different forms of fatty liver disease could be 
largely prevented. The incidence of NFLD has been steadily rising in parallel with the 
rise in obesity and diabetes. At present, there is no effective treatment other than 
correction of the underlying condition (Angulo 2002). Based on these results, the 
inhibition of SCD-1 may be of benefit in treating fatty liver disease. 
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Chapter 7: Role for Insulin-like Growth Factor Binding Protein-2 in Leptin-
mediated Weight Loss 
Introduction 
Leptin has metabolic actions that are distinct from its effects on food intake 
(Levin et al. 1996). Transcriptional profiling of ob/ob liver during a time course of weight 
reduction demonstrated a program of gene expression that is specific to leptin-mediated 
weight loss (Chapter 4). Cluster analysis identified several groups of genes whose 
expression was uniquely modulated by leptin as compared to pair-feeding. These clusters 
were broadly divided into two classes: (i) genes with increased expression that were 
preferentially reduced with leptin treatment and (ii) genes with decreased expression that 
were preferentially induced with leptin treatment. 
To prioritize the first class of genes for functional study, an algorithm was 
developed to identify and rank genes in ob/ob liver that were specifically reduced by 
leptin administration. This list served as a molecular signature of leptin action and could 
contain genes that are functionally important in energy homeostasis. SCD-1, the gene that 
ranked at the top of this list, was found to play an important role in obesity and fatty liver 
disease (Chapters 5 and 6)(Cohen et al. 2002; Ntambi et al. 2002). 
While ob/ob mice lacking SCD-1 showed a marked improvement in adiposity and 
other components of the obese phenotype, the absence of this gene alone did not 
completely correct the abnormalities of ob/ob mice. This suggested that other alterations 
in gene expression, typical of ob/ob mice, remained and contributed to the residual 
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phenotype in these mice. To identify additional genes involved in leptin's metabolic 
effects, we used an algorithm to prioritize the second class of genes, those that were 
reduced in ob/ob liver and specifically induced by leptin. Insulin-like growth factor 
binding protein-2 (IGFBP-2) ranked at the top of this list and studies on the role of this 
molecule in leptin-mediated weight loss are presented here. 
Results 
Modulation of IGFBP-2 R N A levels 
The algorithm described in Chapter 5 (and more fully in Chapter 2) was modified 
to rank genes based on the extent to which their expression was (1) decreased in ob/ob 
liver compared to wild type (2) induced by leptin treatment, and (3) different between 
leptin treatment and pair feeding. Genes with the lowest scores are those most strongly 
leptin-regulated. Such genes may be functionally involved in the metabolic effects of 
leptin. The results of this analysis are shown in Table 7.1. 
The list of leptin-induced genes included a diverse number of functional 
categories. Unlike the list of leptin repressed genes (Table 5.1), the majority of which 
function in lipid and carbohydrate metabolism, nearly half of the leptin-induced genes are 
secreted. The identification of such factors may reflect a normalization of impaired liver 
function, secondary to leptin-deficiency, insulin resistance, and hepatic steatosis. 
Alternatively, some of these genes could also be directly involved in the unique program 
of leptin-mediated weight loss. 
The genes in Table 7.1 included a number of molecules that are components of 
the growth hormone (GH) / insulin-like growth factor (IGF) pathway. Growth hormone is 
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Table 7.1 Leptin-induced gene expression in ob/ob Liver. G e n e s were ranked based 
o n the extent to w h i c h their expression w a s (1) decreased in ob/ob liver c o m p a r e d to 
wild-type, (2) induced b y leptin treatment, and (3) maximally different between leptin 
treatment and pair-feeding. G e n e s with the lowest scores are m o s t strongly leptin-induced. 
secreted into the bloodstream by the pituitary gland and stimulates the production of IGF-
I, particularly from the liver. IGF-I then circulates in a complex with any of a number of 
binding proteins, known as insulin-like growth factor binding proteins (IGFBPs), which 
modulate IGF-I action. IGF-I has pleiotropic actions on multiple target tissues, generally 
stimulating cell growth and division (Le Roith et al. 2001). The list of leptin-induced 
genes included prepro-IGF-Ia itself, insulin-like growth factor binding protein-2 (IGFBP-
2) and acid labile subunit (ALS), which bind IGF-I in the circulation, and three different 
major urinary proteins, the levels of which are positively regulated by GH (Knopf et al. 
1983; Clemmons 1998). 
One of the three genes sharing the top rank for being most strongly leptin-induced 
was IGFBP-2, a member of a family of IGF binding proteins, which has endocrine 
functions by modulating serum IGF half-life and transport, as well as autocrine and 
paracrine functions by blocking or enhancing the availability of IGFs to bind their 
receptors (Binkert et al. 1989; Schuller et al. 1994; Ranke and Elmlinger 1997). Northern 
blot analysis showed that IGFBP-2 RNA levels were undetectable in ob/ob mice, and 
were induced to wild-type levels with leptin replacement (Figure 7.1a). Pair-feeding, on 
the other hand, had a negligible effect on IGFBP-2 expression. Leptin also specifically 
induced ALS, which circulates as a ternary complex with IGFs and IGFBP-3, stabilizing 
this complex and thereby increasing the half-life of IGFs (Boisclair et al. 1996). With the 
exception of IGFBP-2 and ALS, based on microarray analysis, the other known IGFBPs 
were not found to be leptin-induced. 
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To gain further insight into the role of IGFBP-2, its R N A levels were also 
measured in a number of other rodent models of obesity (Figure 7.1b). IGFBP-2 was 
expressed at equivalent levels in livers of C57B1/6J and AKR/J, two inbred strains of 
wild-type mice. IGFBP-2 was markedly suppressed in mice lacking leptin or totally 
resistant to its actions (ob/ob, dbKls/dbKls, and db3J/db3J). In addition, IGFBP-2 expression 
was drastically decreased in moderately obese transgenic mice, constitutively expressing 
a low level of leptin (ob/ob tg)(Ioffe et al. 1998). Interestingly, IGFBP-2 levels were 
reduced far less in Ay and New Zealand obese (NZO) mice, which manifest partial leptin 
resistance (Halaas et al. 1997). IGFBP-2 expression was also measured in each of these 
models following a 48 hour fast (Figure 7.1b). In every case, fasting led to a marked 
upregulation in IGFBP-2, confirming previous studies in wild-type rodents (Tseng et al. 
1992). The modulation of IGFBP-2 levels by leptin, its alteration in numerous rodent 
obesity models, and its regulation by fasting support a role for this molecule in energy 
homeostasis. 
Attenuated response to leptin in ob/ob mice lacking IGFBP-2 
In order to examine the functional role of IGFBP-2 induction by leptin, we 
studied IGFBP-2 knockout mice. Aside from reduced spleen size and increased liver size, 
IGFBP-2 null mice have no obvious abnormalities, possibly due to redundancy within the 
IGFBP family (Wood et al. 1993; Pintar et al. 1995; Wood et al. 2000). To test whether 
IGFBP-2 induction is important in leptin-mediated weight loss, we crossed IGFBP-2''' 
mice to ob/ob mice to generate double mutant animals. These mice were then treated with 
leptin, and their response was compared to that of ob/ob mice. We hypothesized that if 
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Figure 7.1 Regulation of IGFBP-2 R N A levels by leptin and nutritional status. 
Northern blots of 10 (ig of liver R N A were hybridized with radioactively labeled probes 
specific for IGFBP-2, 18S R N A , or P-actin. IGFBP-2 R N A levels in (A) time course 
experiment and (B) different mouse models of obesity in either the fed state or after a 
48 hour fast. 
IGFBP-2 is involved in leptin's metabolic effects, then ob/ob mice lacking IGFBP-2 
might have a diminished response to leptin. 
After ten days of subcutaneous leptin administration, IGFBP-2''';ob/ob and ob/ob 
mice showed marked differences in the amount of weight loss (Figure 7.2a). ob/ob mice 
lost nearly twice as much weight as IGFBP-2'';ob/ob mice (28% vs. 15% weight loss, p 
= 0.008), with significant differences between these mice detectable as early as five days 
after initiating leptin treatment. This is consistent with the time course of IGFBP-2 
induction in leptin-treated ob/ob mice (Figure 7.1a). Leptin also had a significantly more 
potent anorectic effect in ob/ob than on IGFBP-2'';ob/ob mice (Figure 7.2b). 
These data suggest that leptin can reach higher circulating levels and/or produce 
more potent effects in obese mice capable of inducing IGFBP-2. While leptin levels in 
both groups of mice were close to the physiological range, levels in ob/ob mice were 50% 
greater than those in IGFBP-2'1';ob/ob mice (17.2 ng/ml vs. 11.9 ng/ml, p = 0.04) (Figure 
7.2d). In addition, as shown before, leptin completely corrected hyperglycemia in ob/ob 
mice (glucose: 91.5 mg/dl) (Halaas et al. 1995; Pelleymounter et al. 1995). IGFBP-2''' 
;ob/ob mice, on the other hand, showed a more modest reduction in hyperglycemia, 
though glucose levels were substantially higher in these mice than in ob/ob controls 













Figure 7.2 Attenuated response to leptin in IGFBPZ;ob/ob mice, obob and 
IGFBP2~~;ob/ob mice were treated with subcutaneous pbs or leptin (4.8 |j.g/day) for 
10 days. (A) percent change in body weight, *, p < 0.05 ofob vs. IGFBP2';obob 
leptin treated. (B) daily food intake averaged over days 3-10 of treatment. *, p < 10"5 
pbs vs. leptin;", p < IO"5 ob/ob vs. IGFBP2";ob/ob (C) plasma glucose levels, 
*, p < IO"5 pbs vs. leptin; *, p < 10"5 ofob vs. IGFBP2"";o6'ob and (D) plasma leptin, 
', p < 0.05 ob/ob vs. IGFBP2';ob/ob. n > 4 for each group, error bars indicate S E M . 
Discussion 
The data presented here indicate that IGFBP-2 is necessary for the full 
complement of leptin's metabolic effects. Double mutant mice lost significantly less body 
weight than ob/ob counterparts. IGFBP-2''';ob/ob mice were also observed to be leptin 
resistant in a separate time course experiment (data not shown). Although the IGFBP-2''' 
;ob/ob mice were older than the ob/ob mice studied here, in seaprate experiments older 
ob/ob mice also lost approximately 30% of their body weight following leptin therapy (as 
opposed to 15% in IGFBP-2'';ob/ob mice). In addition, IGFBP-2'';ob/ob mice have less 
marked reductions in hyperglycemia. This could point to a specific function of IGFBP-2, 
or may simply be due to the more modest weight loss in these mice. Further study, in 
inbred mice is required to determine whether double mutant mice have other phenotypic 
alterations relative to ob/ob mice. 
Despite the lack of any dramatic phenotype in IGFBP-2 knockout mice, perhaps 
due to functional redundancy, data from transgenic mice and obese humans support a role 
for this molecule in body weight physiology (Wood et al. 1993; Pintar et al. 1995; Wood 
et al. 2000). Transgenic mice expressing IGFBP-2 under the control of the CMV 
promoter expressed IGFBP-2 in every tissue, but liver, and had a 3-fold increase in serum 
IGFBP-2 levels (Hoeflich et al. 1999). These mice developed normally, but from 
weaning onward showed a significant reduction in body weight (approximately 10%) at 
all ages (Hoeflich et al. 1999) (Schneider et al. 2000). In addition, transgenic mice had 
reduced glucose levels relative to non-transgenic controls. When outbred mice were 
selectively bred to generate lines of mice with either low or high body weight, low body 
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weight was associated with elevated hepatic IGFBP-2 expression, while high body 
weight was associated with reduced hepatic IGFBP-2 expression (Hoeflich et al. 1998). 
IGFBP-2 levels were also suppressed in obese humans, and this suppression was 
accentuated by the concomitant presence of diabetes (Nam et al. 1997; Frystyk et al. 
1999). 
The findings in leptin treated IGFBP-2'1' ;ob/ob mice are highly similar to those in 
pair-fed ob/ob mice. Since ob/ob mice have undetectable IGFBP-2 expression, which is 
not induced at all by pair-feeding, the induction of IGFBP-2 upon leptin treatment could 
be responsible for many of the differences observed between leptin treated and pair-fed 
mice. Pair-fed mice also lose significantly less weight than leptin-treated ob/ob mice and 
show a less dramatic correction of the diabetic phenotype (Levin et al. 1996). Since pair-
fed mice lose both fat mass and lean mass, whereas leptin treated mice only lose fat mass, 
body composition analysis of leptin treated IGFBP-2''';ob/ob mice is necessary to 
determine which body compartments contribute to their weight loss (Halaas et al. 1995; 
Pelleymounter et al. 1995). 
The mechanism by which IGFBP-2 contributes to leptin-mediated weight loss is 
currently unknown. Numerous studies have shown that the growth hormone (GH) axis is 
perturbed in human obesity (Scacchi et al. 1999). In humans, plasma GH is inversely 
related to measures of adiposity, and obesity is associated with reduced plasma IGF-I, 
which is downstream of GH (Rudman et al. 1981) (Copeland et al. 1990). Treatment of 
patients with growth hormone results in increased lean mass and decreased adiposity 
(Rudman et al. 1990). In rodents, central leptin infusion stimulates spontaneous pulsatile 
GH secretion, as well as secretion in response to GHRH (Tannenbaum et al. 1998). In 
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addition, leptin reverses the starvation-induced fall in serum G H (LaPaglia et al. 1998). 
Thus, the leptin-specific induction of IGFBP-2 expression may be related to the 
normalization of the GH/IGF axis, and could thereby account for the role of IGFBP-2 in 
leptin-mediated weight loss. 
Alternatively, the effects of IGFBP-2 may be independent of its role in the 
GH/IGF pathway. Recent reports have shown that IGFBP-s can also mediate actions 
independent of IGF, initiating signal transduction and acting as growth factors on their 
own (Mohan and Baylink 2002). IGFBP-s may also bind other circulating molecules, 
perhaps stabilizing them and increasing their half-life. IGFBP-4 can bind circulating 
leptin as part of a macromolecular complex (Sui and Wilson 2000). Since the IGFBP-s 
share a high degree of structural homology, IGFBP-2 could also bind leptin and stabilize 
it in the plasma, a possibility that is being explored. This would explain the higher leptin 
levels achieved in ob/ob mice capable of inducing IGFBP-2, and could ultimately 
account for the greater potency of leptin in these mice relative to IGFBP-2'1';ob/ob mice. 
IGFBP-2 is part of a complex endocrine system with multiple levels of regulation. 
Its activity can be modulated by proteolysis, phosphorylation, and adherence to the cell 
membrane or extracellular matrix (Clemmons 1998). IGFBP-2 also has a specific pattern 
of temporal and tissue-type expression (Schneider et al. 2000). Finally, IGFBP-2 levels 
are altered in numerous disease states including obesity, diabetes, glioma, prostate cancer 
(Cohen et al. 1993; Nam et al. 1997; Frystyk et al. 1999; Zhang et al. 2002). Thus, further 
studies of animal models with tissue-specific deletion and overexpression of IGFBP-2 are 
necessary to dissect its pleiotropic physiological roles. 
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While the mechanism is not yet known, the data presented here indicate that 
IGFBP-2 induction plays an important role in leptin-mediated weight loss. While IGFBP-
2 expression is completely suppressed in ob/ob and db/db mice, it is only partially 
suppressed in Ay and NZO mice, models of severe and moderate leptin resitance 
respectively. The presence of tonic IGFBP-2 expression in these mice may underlie their 
partial response to leptin therapy and suggests that co-administration of leptin and 
IGFBP-2 may augment their weight loss response. Leptin resistance appears to be a 
feature of the majority of human obesity, and obese humans also have suppressed levels 
of IGFBP-2 levels (Nam et al. 1997; Frystyk et al. 1999). These findings suggest that 
IGFBP-2 could be useful as a leptin adjuvant in the therapy of obesity and metabolic 
diseases. 
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Chapter 8: Conclusion 
S u m m a r y of findings 
The studies in this thesis explore the molecular basis for the metabolic effects of 
leptin. We specifically studied the effects of leptin on the liver, due to its prominent role 
in carbohydrate and lipid metabolism. Leptin-deficient ob/ob mice manifest a mixed form 
of hepatic insulin sensitivity and resistance, resulting in increased lipogenesis along with 
elevated gluconeogenesis, which contributes to both obesity and diabetes (Shimomura et 
al. 2000). In the absence of effective leptin action, triglyceride is deposited in peripheral 
sites such as liver, skeletal muscle, heart, and pancreatic islets. This build-up of lipid in 
non-adipose tissues causes lipotoxicity, which contributes to insulin resistance and organ 
dysfunction in the obese state (Unger 2002) (McGarry 1992; Shulman 2000). Leptin 
replacement in leptin-deficient (ob/ob) mice and humans leads to the specific depletion of 
lipid in adipose tissue, liver, and other tissues (Campfield et al. 1995; Halaas et al. 1995; 
Pelleymounter et al. 1995; Farooqi et al. 1999). The metabolic program that leptin elicits 
is not explained by its effects on food intake alone (Levin et al. 1996; Kamohara et al. 
1997; Shimomura et al. 1999c). Leptin, with significantly greater potency than pair-
feeding, rapidly reduces lipid in non-adipose tissues by decreasing triglyceride formation 
and increasing free fatty acid oxidation (Shimabukuro et al. 1997a). The goal of this 
thesis was to dissect the molecular basis for leptin's effects on hepatic metabolism in 
order to better understand the unique program of leptin-mediated weight loss. 
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As an entry point to this question, we first examined whether leptin's effects on 
liver were the result of direct action on heptocytes or secondary to action on the brain 
(Chapter 3). While data from intracerebroventricular administration of leptin suggested 
that it has direct effects on brain, the leptin receptor is broadly expressed, and leptin has 
also been shown to act directly to deplete triglycerides (Campfield et al. 1995; Ghilardi et 
al. 1996; Fei et al. 1997; Halaas et al. 1997; Shimabukuro et al. 1997a; Minokoshi et al. 
2002). The relative importance of leptin's effects on brain vs. peripheral sites was 
untested as was the contribution of these actions to body weight homeostasis, deposition 
of lipid in peripheral sites, and neuroendocrine function. Therefore, we generated and 
studied mice with either neuronal (ObRSynIKO) or hepatocyte-specific (ObRAlbKO) 
deletions of ObR (Cohen et al. 2001). Among the ObRSynIKO mice, animals with the 
lowest levels of ObR exhibited an obese phenotype with elevated plasma levels of leptin, 
glucose, insulin, and corticosterone. These data demonstrated that leptin has direct effects 
on neurons and that a significant proportion, or perhaps the majority, of its weight 
reducing and neuroendocrine effects result from its actions on the brain. ObRA bKO mice, 
on the other hand, weighed the same as controls with no alterations in body composition. 
Moreover, while db/db and ObRSynIKO mice had enlarged fatty livers, ObRAlbKO mice 
did not. While these findings do not exclude a functional role for the hepatic leptin 
receptor, they do indicate that the severe liver abnormalities of ob/ob and db/db mice are 
secondary to defective leptin signaling in the brain. 
The demonstration that the brain is a critical site of leptin action suggested that 
leptin modulates a neuronal circuit regulating peripheral metabolism. The components of 
this neuronal circuit and the nature of the efferent signals from the central nervous system 
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that regulate metabolism in response to leptin are unknown. Since leptin elicits a 
metabolic response that cannot be explained by its effects on food intake alone, we 
hypothesized that leptin causes weight loss via a novel program, distinct from food 
restriction on both a physiological and molecular basis (Levin et al. 1996). This program 
was presumed to involve modulation of gene expression in metabolically active organs 
such as liver, adipose tissue, and muscle, associated with the depletion of peripheral lipid 
(Soukas et al. 2000). In order to more fully characterize this metabolic response, we 
examined leptin-specific gene expression in liver (Chapter 4). We identified a novel, 
distinct transcriptional signature characteristic of the unique metabolic program of weight 
loss induced by leptin. These data distinguish leptin treatment from food restriction at a 
molecular level, and may ultimately provide new insight into the nature of the leptin-
stimulated efferent signals from the brain. 
We also presumed that a subset of these leptin-regulated genes might play a 
functional role in the obese phenotype and the unique metabolic actions of leptin. To 
prioritize such genes for further analysis, we developed an algorithm to identify genes 
that were repressed during leptin-mediated weight loss (Chapter 5). Leptin was shown to 
specifically repress RNA levels and enzymatic activity of hepatic stearoyl-CoA 
desaturase-1 (SCD-1), which catalyzes the biosynthesis of monounsaturated fatty acids. 
Mice lacking SCD-1 were hypermetabolic and lean, ob/ob mice with mutations in SCD-1 
(abJ/abJ; ob/ob) were significantly less obese than ob/ob controls and demonstrated 
markedly increased energy expenditure, ob/ob mice with mutations in SCD-1 had 
histologically normal livers with significantly reduced triglyceride storage and VLDL 
production. These data suggested that down-regulation of SCD-1 is an important 
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component of leptin's metabolic actions and that inhibition of this enzyme may be 
beneficial for the treatment of obesity and other metabolic diseases. 
SCD-1 is required for normal rates of hepatic triglyceride and cholesterol ester 
biosynthesis and ob/ob mice lacking SCD-1 (abJ/abJ; ob/ob) displayed a dramatic 
correction in the hepatic steatosis typical of ob/ob mice (Miyazaki et al. 2000). Therefore, 
we examined whether SCD-1 plays a more general role in fatty liver disease (Chapter 6). 
Hepatic steatosis is the earliest sign of both alcoholic and nonalcoholic fatty liver disease. 
SCD-1 expression is elevated in livers of mice with alcoholic fatty liver and in mice with 
nonalcoholic fatty liver disease (NFLD) secondary to lipodystrophy. Mice lacking SCD-1 
(abJ/abJ) were resistant to the development of alcoholic steatosis, while littermate 
controls accumulated significant amounts of liver triglyceride. In addition, lipodystrophic 
mice lacking SCD-1 (abJ/abJ;aP2-SREBP-lc tg) showed a marked correction in the 
NFLD associated with this condition. Millions of people worldwide are affected by 
alcoholic fatty liver disease or NFLD and no effective treatment is currently available. 
Our findings suggest that targeted inhibition of SCD-1 may be therapeutically useful for 
these disorders. 
The important role demonstrated for SCD-1 suggested that other leptin-regulated 
genes might also be functionally involved in leptin's unique metabolic effects. While 
ob/ob mice lacking SCD-1 showed a marked correction of obesity and other components 
of the obese phenotype, the absence of this gene alone did not completely eliminate the 
abnormalities of ob/ob mice. We therefore assumed that other alterations in gene 
expression, typical of ob/ob mice, persisted and contributed to the residual phenotype in 
these mice. Using a computational approach, we identified a group of genes that were 
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reduced in ob/ob liver and specifically induced by leptin. W e reasoned that the induction 
of some of these genes might be required for leptin's metabolic effects. Insulin-like 
growth factor binding protein-2 (IGFBP-2) expression was uniquely induced by leptin 
administration and not by pair-feeding, ob/ob mice lacking IGFBP-2 (IGFBP-2''';ob/ob) 
showed markedly attenuated weight loss following leptin treatment. 
Directions for future research 
The findings presented here have generated a number of questions which remain 
to be answered. With regard to leptin's central vs. peripheral action, more detailed studies 
using metabolic tracers may yet uncover a role for the hepatic leptin receptor in 
modulating lipid metabolism. Furthermore, hepatic ObR may only be functionally 
relevant in altered physiological states such as genetic or dietary obesity or marked hypo-
or hyperleptinemia, possibilities that are currently being evaluated. However, the 
enlarged fatty liver in ObRSynIKO mice and the absence of steatosis in ObRAlbKO mice, 
clearly indicates that defective central leptin action is responsible for the liver pathology 
of ob/ob and db/db mice. Therefore, it will be important to define the neuronal circuit and 
to determine the nature of the efferent signal from the CNS that modulates the metabolic 
effects of leptin in liver. Given that most obese humans are leptin resistant and that likely 
sites of resistance are in the transport across the blood-brain-barrier and downstream CNS 
pathways, identifying the efferent signal(s) emanating from the brain in response to leptin 
could have great therapeutic benefits (Maffei et al. 1995b; Caro et al. 1996; Considine et 
al. 1996). 
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The efferent signal is part of a homeostatic pathway, in which elevated leptin 
levels signal nutritional abundance to the brain, which then activates thermogenesis to 
increase energy expenditure and maintain stable body weight (Lowell and Spiegelman 
2000). The CNS efferent is likely to involve the autonomic system and/or the 
hypothalamic pituitary axis. The presence of obesity in mice lacking all three 
P-adrenergic receptors (P-less mice) indicates that the sympathetic nervous system is a 
critical component of the CNS efferent pathway activated by leptin (Bachman et al. 
2002). Testing the response of these mice to leptin should allow the contribution of this 
limb of the CNS efferent pathway enacted by leptin to be evaluated. 
The leptin-specific programs of liver gene expression identified in Chapter 4 may 
be valuable for further dissecting the CNS efferent pathways activated by leptin. 
Regardless of their functional role, these patterns of expression can be used as a 
molecular marker of leptin action. In addition to treating P-less mice with leptin, these 
mice can be also be bred on to the ob/ob background and treated with leptin (Bachman et 
al. 2002). Comparison of liver gene expression between these mice (P-less; ob/ob) and 
ob/ob mice might show that certain clusters of genes with leptin-specific patterns of 
expression in ob/ob liver were no longer modulated in a leptin-dependent manner. These 
clusters would likely contain genes that are regulated by leptin-dependent sympathetic 
activation. In theory, the role of any candidate efferent signal could be similarly tested in 
genetic models or determined by treating ob/ob mice with an agonist or antagonist of that 
pathway and monitoring leptin-specific gene expression. 
Further understanding of the transcriptional regulation of leptin-specific patterns 
of gene expression can also be used to trace backwards to identify the efferent signal 
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emanating from the C N S . If a leptin-regulated transcription factor were identified, the 
next goal would be to determine the mechanism by which leptin modulates this factor. 
Such studies could elucidate post-translational modifications, signal transduction 
pathways, and even extracellular signals that are stimulated or repressed by leptin. It 
should be noted that in this discussion, the term leptin-regulated is used rather loosely. 
The transcriptional machinery regulating metabolism is highly complex and could be 
modulated by a multitude of factors. In addition, leptin may only regulate this pathway 
secondary to its effects on other hormones, such as insulin. In any case, the identification 
of such a factor would help elucidate the mechanism for leptin's novel metabolic actions. 
A number of transcription factors regulate metabolic gene expression, and 
whether or not these factors are regulated by leptin remains untested. In addition, clusters 
of gene expression can also be used to computationally study transcriptional regulation. 
With the completion of the human and murine genomes, in prinicipal, the transcriptional 
start sites and upstream promoter sequence of every clustered gene can be obtained. 
Computational methods can then query these sequences and determine whether either 
known or novel promoter motifs are enriched in particular clusters. This could lead to the 
identification of a "leptin-regulated element" which could then be used to biochemically 
purify the transcription factor which binds it. Such an approach has been successfully 
applied to identify a novel circadian regulated transcription factor in mice (Ueda et al. 
2002). 
The more detailed characterization of leptin-specific regulation of SCD-1 and 
IGFBP-2 suggests that these genes may be useful for studying the transcriptional control 
of leptin-repressed and leptin-induced gene expression, respectively. Of interest, both of 
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the R N A levels of both of these genes also appear to regulated by leptin administration in 
wild-type mice (data not shown). As discussed in Chapter 4, very few genes were 
specifically modulated by leptin in wild-type liver, and these genes are more likely to be 
specifically modulated by quantitative changes in circulating leptin levels. Prior to 
beginning these studies, nuclear run-on assays will be performed to test whether 
regulation of these genes is at the level of transcription and not at the level of RNA 
stability. If regulation does prove to be transcriptional, constructs fusing different 
portions of the promoter to a CAT or luciferase indicator will be made. The human SCD-
1 promoter has been cloned and a number of different luciferase-promoter constructs 
have already been studied in vitro (Bene et al. 2001). Generation of transgenic mice 
harboring these constructs will allow in vivo analysis of leptin-dependent regulation of 
gene expression. These studies will permit the delineation of promoter regions required 
for leptin-dependent gene expression. The identification of these sequences will be a 
useful reagent for studying the signal transduction pathways and transcription factors that 
regulate these genes. 
The data presented suggests one possible mechanism by which leptin regulates 
SCD-1 expression. The transcriptional modulation of SCD-1 is complex, with a number 
of factors known to stimulate and repress transcription (Ntambi 1995). Polyunsaturated 
fatty acids (PUFAs) repress SCD-1 transcription through a defined promoter element, 
independent of their reported ability to inhibit SREBP cleavage and nuclear translocation 
(Yahagi et al. 1999; Bene et al. 2001; Ntambi and Bene 2001). Fatty acid composition of 
ob/ob livers demonstrated that leptin-specifically increased the levels of PUF As, which 
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are otherwise repressed in ob/ob liver (Table 5.2). These increased PUF A levels could, in 
turn, account for the leptin-dependent suppression of SCD-1 RNA levels. 
As well as being used as molecular markers of leptin's effects, SCD-1 and 
IGFBP-2 have functional roles in metabolism and energy homeostasis. With regard to 
SCD-1, future studies on inbred abJ/abJ;ob/ob mice will determine whether other 
metabolic abnormalities of the obese phenotype such as insulin resistance and diabetes 
are corrected in the absence of SCD-1. Neuroendocrine, thermoregulatory, immune, and 
reproductive function will also be examined. In addition, the phenotype of these mice 
will be characterized at an older age to determine whether there are any undesirable side 
effects of eliminating SCD-1. 
Understanding the mechanism underlying the effects of SCD-1 deficiency will 
also be a focus of future studies. Figure 5.5a proposed one possible mechanism by which 
the absence of SCD-1 could lead to increased fatty acid oxidation and increased energy 
expenditure. While Figure 5.5b presented preliminary data illustrating that abJ/abJ and 
ab'/ab"r;ob/ob mice have elevated saturated fatty acyl CoAs, other elements of this 
hypothesis require further testing. Measurement of malonyl CoA levels is necessary to 
confirm whether these saturated fatty acyl CoAs might inhibit ACC. In addition, abJ/abJ 
and abJ/abJ;ob/ob mice will be treated with etomoxir, an inhibitor of CPT-1, to determine 
whether the increased oxygen consumption is blunted when fatty acid translocation into 
the mitochondria and subsequent oxidation is blocked (Esser et al. 1993). Finally, 
measurement of tissue-specific fatty acid oxidation in these mice is necessary to 
determine whether increased fatty acid oxidation, or another mechanism altogether, is 
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responsible for the increased energy expenditure and resistance to obesity in mice lacking 
SCD-1. 
These same studies will also be performed in alcohol fed abJ/abJ mice and in 
ab /ab ;aP2-SREBP-lc tg mice to see if similar mechanisms are operative in their 
apparent resistance to fatty liver disease. In addition, abJ/abJ mice have been bred to 
other mouse models of fatty liver disease including mice with transgenic overexpression 
of nuclear sterol regulatory element-binding protein-la (PEPCK-SREBP-la tg) and Ay 
mice (Yen et al. 1976; Shimano et al. 1996). In addition to assessing resistance to hepatic 
steatosis, all of these models will be followed over time to see if they are similarly 
resistant to fibrosis and other advanced pathology of fatty liver disease. Furthermore, 
mice lacking SCD-1 will be treated with carbon tetrachloride and thioacetamide, inducers 
of hepatic fibrosis, to determine whether their resistance to hepatic lipid accumulation 
renders them resistant to more severe liver pathology as well (Friedman 2000b). 
Future studies will also explore whether SCD-1 and SCD-2 expression, activity, 
and enzymatic products, are modulated by leptin in tissues other than liver. While the 
effects of SCD-1 deficiency described are attributable to an increased rate of energy 
expenditure, the full complement of tissues contributing to this increased energy 
expenditure are as yet unknown, ob/ob mice were followed over a time course of leptin 
administration, saline with pair-feeding, and saline with free-feeding (identical to the 
experiment described in Chapter 4) and liver, fast and slow twitch skeletal muscle, white 
and brown adipose tissue, heart, hypothalamus, and other tissues were harvested for this 
analysis. Leptin was recently shown to activate fatty acid oxidation in heart, independent 
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of a 2 AMP-kinase activation, suggesting that another pathway, potentially involving 
regulation of SCD-1 could be relevant (Atkinson et al. 2002). 
In addition, analysis of SCD-1 regulation in hypothalamus and other brain regions 
will be important to determine whether there is a direct role for SCD-1 and its products in 
the neuronal pathways controlling feeding. Central administration of C75, an inhibitor of 
fatty acid synthase, has indicated that alterations in hypothalamic malonyl CoA levels are 
associated with reduced levels of NPY, leading to reduced food intake and weight loss 
(Loftus et al. 2000). ab /ab ;ob/ob mice are hyperphagic relative to ob/ob mice, perhaps 
secondary to increased energy expenditure or possibly due to a compensatory increase in 
SCD-2 expression and/or activity in the brain. Understanding the mechanism for the 
hyperphagia in abJ/abJ;ob/ob mice and its consequent blunting, could lead to an even 
greater correction of the obese phenotype in these animals. To explore whether there is a 
compensatory increase in other SCD isoforms in mice lacking SCD-1, SCD-2 and SCD-3 
expression, SCD activity, and enzymatic products will also be measured in multiple 
tissues from abJ/abJ;ob/ob mice. Data generated thus far indicates that there is no 
compensation by other SCD isoforms in the liver, as SCD activity in abJ/abJ and 
abJ/abJ;ob/ob mice could not be detected. Similar studies are underway in other tissues, 
including the hypothalamus. 
Generation of mice with tissue-specific overexpression of different SCD isoforms 
is another means to dissect the role of this molecule in individual tissues. Constructs 
directing hepatocyte-specific overexpression of SCD-1 and SCD-2 are currently being 
generated. The demonstration of markedly elevated hepatic SCD-1 expression and 
activity in the hyperlipidemic, hyplip mutant mouse suggests that hypertriglyceridemia 
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and hypercholesterolemia could be one consequence of hepatic overexpression of SCD-1 
(Attie et al. 2002; Bodnar et al. 2002). Based on the analysis of leptin-specific SCD 
regulation in other tissues, described above, transgenic overexpression could also be 
targeted to other relevant sites. 
The data demonstrating a role for IGFBP-2 in leptin-mediated weight loss are 
more preliminary than that for SCD-1, and therefore require further experimentation. The 
data presented here suggest that IGFBP-2''";ob/ob mice have a more severe phenotype 
than ob/ob controls. A complete analysis of the metabolic and other alterations 
characteristic of the obese phenotype need to be performed in inbred IGFBP-2''';ob/ob 
mice. As IGFBP-2 is widely expressed, further studies are necessary to determine 
whether leptin-dependent induction of IGFBP-2 RNA is unique to liver or whether other 
tissues are also involved. To further dissect the effects of liver-specific induction of 
IGFBP-2, transgenic mice overexpressing IGFBP-2 exclusively in heptocytes and an 
adenovirus producing IGFBP-2 are currently being generated. 
The mechanism for the apparent leptin resistance in IGFBP-2''';ob/ob mice and 
the role for IGFBP-2 induction in leptin-mediated weight loss are unknown. 
Administration of recombinant IGFBP-2 and infection of mice with an IGFBP-2 
adenovirus (currently being made) will allow for further study of the effects of increased 
levels of this molecule. The findings presented here could be due to an indispensable role 
for IGFBP-2 in the induction of the GH / IGF axis or could be due to an IGF independent 
role of IGFBP-2. Future experiments will be necessary to assay the effects of leptin on 
other components of the GH / IGF axis in ob/ob mice with and without IGFBP-2. One 
possible IGF-independent role for IGFBP-2 may be to stabilize circulating leptin, thereby 
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increasing its half-life and potentiating its actions. This possibility can be tested by 
comparing the leptin dose-response curves of ob/ob and IGFBP-2''';ob/ob mice. 
Alternatively, this hypothesis could be explored by treating mice with different doses of 
recombinant IGFBP-2 and leptin or by co-infecting mice with different titers of IGFBP-2 
and leptin adenoviruses. If the observed effects of IGFBP-2 are, in fact, independent of 
IGF, then the role for this molecule may be further dissected by analyzing gene 
expression in mice following IGFBP-2 administration or adenoviral infection. Perhaps, 
IGFBP-2 initiates a signaling pathway that represses anabolic gene expression and / or 
induces catabolic gene expression. 
A common biochemical pathway determining nutrient partitioning 
Analysis of leptin-specific gene expression in the liver has identified two 
molecules, SCD-1 and IGFBP-2 with functions in energy metabolism. SCD-1, and 
perhaps IGFBP-2 as well, is involved in determining whether calories are partitioned into 
fat or burned. Based on the findings in abJ/abJ;ob/ob mice, SCD-1 joins a list of other 
genes, that when either deleted or overexpressed confer leanness. Thus far, approximately 
50 such genes have been described and the mechanisms underlying their effects have 
been divided into eight major categories: (1) peripherally driven increased energy 
expenditure in muscle, (2) peripherally driven increased energy expenditure via adipose 
tisse, (3) increased energy expenditure via multiple or unknown tissues, (4) CNS-
mediated, (5) peripherally decreased energy availability, (6) abnormal adipocyte 
biochemistry, (7) white fat ablation, and (8) unknown (Reitman 2002). SCD-1 could be 
145 
placed in the third grouping, pending elucidation of the tissue(s) driving increased energy 
expenditure in mice lacking this gene. 
Further analysis of genetic alterations conferring leanness indicates that a number 
of other molecules in the same biochemical pathway as SCD-1 are also involved in 
energy partitioning (Figure 8.1). Deletion of acetyl-CoA carboxylase 2 produces a lean 
phenotype, secondary to decreased malonyl CoA and increased fatty acid oxidation (Abu-
Elheiga et al. 2001). Inhibition of fatty acid synthase by the compound C75 also leads to 
reduced adiposity (Loftus et al. 2000). This molecule was originally thought to act 
centrally to decrease food intake, but has been subsequently found to increase energy 
expenditure and peripheral fatty acid oxidation (Thupari et al. 2002). The finding of 
increased fat oxidation in the setting of elevated malonyl CoA was paradoxical. However, 
studies have suggested that C75 competes with malonyl CoA, thereby disinhibiting its 
actions on CPT-1 (Thupari et al. 2002). As described in this work, in the absence of 
SCD-1, animals demonstrate resistance to obesity and increased energy expenditure, 
perhaps also due to effects on malonyl CoA and fatty acid oxidation (Chapter 5)(Cohen et 
al. 2002). Furthermore, mice with a targeted deletion of acyl CoA:diacylglycerol 
transferase (DGAT), which catalyzes the final step in triglyceride biosynthesis, have 
increased energy expenditure and are protected from obesity (Smith et al. 2000). DGAT 
null mice also have sebaceous gland defects very similar to those in asebia mice (Chen et 
al. 2002). Interestingly, a promoter polymorphism in this gene leading to decreased 
expression is associated with reduced BMI in Turkish women (Ludwig et al. 2002). 
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Figure 8.1 SCD-1 is part of a biochemical pathway regulating energy partitioning 
and adiposity. A s described in the text, modulation of the gene targets in bold print 
affect body weight. In all cases (except for Apo-Cl, which exerts its effects when over-
expressed), inhibition of the gene target protects mice from obesity. A C C : acetyl-CoA 
carboxylase 2, FAS: fatty acid synthase, SCD-1: stearoyl C o A desaturase-1, D G A T : 
acyl CoA:diacylglycerol transferase, VLDLr: very low density lipoprotein receptor, 
LPL: lipoprotein lipase, APO-C1: apolipoprotein Cl. 
that proposed for SCD-1 in Figure 5.5a. Therefore, it will be important to determine the 
common and unique features of each of these models. 
In the liver, the triglycerides formed through this pathway can be packaged in 
VLDL and exported to adipose tissue and other sites. A number of genetic alterations, 
inhibiting hydrolysis and consequently delivery of VLDL triglyceride, also lead to 
reduced adiposity (Figure 8.1). Mice lacking the VLDL receptor are lean, and breeding of 
this mutation on to the ob/ob background leads to a marked correction in obesity 
(Frykman et al. 1995; Goudriann et al. 2001). In addition, ob/ob mice lacking adipose 
tissue lipoprotein lipase (LPL), an enzyme required for triglyceride hydrolysis, also show 
diminished weight and fat mass (Weinstock et al. 1997). Finally, ob/ob mice 
overexpressing of apolipoprotein Cl (apo-Cl), which has been proposed to inhibit 
hydrolysis of VLDL triglyceride, demonstrate a nearly total correction in obesity (Jong et 
al. 2001). 
Analysis of other leptin-regulated genes in Table 5.1 and Table 7.1 may identify 
other molecules that can protect from obesity, operating through the aforementioned 
pathway or through an entirely different mechanism. One such gene may already exist in 
corticosteroid binding globulin (CBG), which is reduced in ob/ob liver and specifically 
induced by leptin (Figure 4.1, Table 7.1). Obese Zucker rats have reduced levels of CBG, 
which binds corticosterone in the circulation and limits its tissue availability (Grasa et al. 
2001). Increased tissue corticosterone levels lead to visceral obesity and metabolic 
defects in mice (Masuzaki et al. 2001). In addition, an obese human proband has been 
identified with total genetic deficiency in CBG (Roitman et al. 1984). 
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The continued study of SCD-1, IGFBP-2, and other leptin-regulated genes in liver 
should help further elucidate the mechanism for leptin's effects on metabolism and the 
means by which these genes modulate body weight. In addition, microarray analysis of 
liver gene expression in abJ/abJ;ob/ob mice should also be of value in determining which 
expression alterations in ob/ob mice are corrected and which remain dysregulated. 
Functional study of both groups of genes may identify other molecules involved in 
energy homeostasis. 
Conclusion 
Overweight and obesity are a pressing public health problem. With increased 
prosperity and development, obesity is gradually replacing starvation and malnutrition as 
the world's most common metabolic disease. The discovery of leptin confirmed that body 
weight and appetite are under molecular control. Identification of other molecules 
involved in leptin's endocrine loop has demonstrated other control points for body 
weight, some of which may be amenable to pharmacologic manipulation. The polygenic 
nature of obesity and the complex interplay of genes and environment in this disorder 
make it unlikely that a single gene product or drug will be found to cure all human 
obesity. However, targeted manipulation of numerous points in the molecular machinery 
regulating energy homeostasis may alleviate this condition. Therefore, the complete 
elucidation of leptin's circuit and the identification of the full complement of molecules 
involved in its unique metabolic effects may provide novel therapeutic targets. The use of 
oligonucleotide microarrays to identify such genes coupled with functional analysis of 
these molecules should contribute to this effort. 
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